CN112236515A - 新型发热伴血小板减少综合征病毒 - Google Patents

新型发热伴血小板减少综合征病毒 Download PDF

Info

Publication number
CN112236515A
CN112236515A CN201980037023.0A CN201980037023A CN112236515A CN 112236515 A CN112236515 A CN 112236515A CN 201980037023 A CN201980037023 A CN 201980037023A CN 112236515 A CN112236515 A CN 112236515A
Authority
CN
China
Prior art keywords
leu
ser
gly
glu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980037023.0A
Other languages
English (en)
Inventor
崔汝祯
朴须蔯
金荣镒
俞旼我
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Appraisal Biology Co ltd
Original Assignee
Appraisal Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Appraisal Biology Co ltd filed Critical Appraisal Biology Co ltd
Publication of CN112236515A publication Critical patent/CN112236515A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
    • C12N2760/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/175—Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)

Abstract

本发明涉及新型基因型发热伴血小板减少综合征病毒及其免疫原性组合物的用途，本发明的病毒中的发热伴血小板减少综合征病毒与以往的血小板减少综合征病毒具有遗传性区别，是在系统学上从B基因型细化为三个的新型病毒，因此，在仅通过某个特定基因型的病毒产生限制性防御能力的疫苗的特性上，可将本发明的新型病毒有用地利用为针对发热伴血小板减少综合征病毒具有优秀的交叉免疫原性的疫苗。

Description

新型发热伴血小板减少综合征病毒
技术领域
本发明涉及新型基因型发热伴血小板减少综合征病毒及其免疫原性组合物的用途。
背景技术
发热伴血小板减少综合征(Severe fever with thrombocytopenia syndrome，SFTS)是一种伴随着如高烧、呕吐、腹泻、血小板减少、白细胞减少及多发性器官功能衰竭等症状，死亡率高达6～30％的严重的疾病(Yu XJ et al.，N.Engl.J.Med.2011；364:1523-32；Ding F et al Clin Infect Dis 2013；56:1682-3)。
发热伴血小板减少综合征的原因病原体为发热伴血小板减少综合征病毒(severefever thrombocytopenia syndrome virus，SFTSV)，属于布尼亚病毒科(Bunyaviridae)。布尼亚病毒科为包含三个节段的负链(negative-strand)RNA病毒，由包括正布尼病毒(Orthobunyavirus)，汉他病毒(Hantavirus)，内罗病毒(Nairovirus)，白蛉病毒(Phlebovirus)，番茄斑萎病毒(Tospovirus)的五个属(genus)形成。发热伴血小板减少综合征病毒属于白蛉病毒属(Phlebovirus genus)，裂谷热病毒(Rift valley fever virus)等就属于这种病毒属中。2011年在中国首次报道过发热伴血小板减少综合征病毒(Yu XJet al.ibid)，这种病毒为在除了中国之外的韩国和日本持续发病的新变种病毒。发热伴血小板减少综合征病毒为直径为80～100nm的球形病毒。此病毒具有作为单链负股RNA节段(single-stranded negative sense RNA segment)的大节段(large(L)segment)、中节段(medium(M)segment)及小节段(small(S)segment；NP，NS)等三个基因。
发热伴血小板减少综合征病毒以长角血蜱(Haemaphysalis longicornis)作为媒介，上述蜱也遍布于韩国(Chae JS et al.J Vet Sci 2008；9:285-93；Kim CM et al.ApplEnviron Microbiol 2006；72:5766-76)。发热伴血小板减少综合征病毒的血清转换及病毒血症被发现于山羊、羊、猪及狗等饲养动物中，而这种动物也在发热伴血小板减少综合征病毒分布的地区中作用为中间媒介(Zhao L et al.Emerg Infect Dis 2013；18:963-5；NiuG et al.Emerg Infect Dis 2013；19:756-63)。在患者的血液中检测到发热伴血小板减少综合征病毒，尤其在重症患者的血液中的发热伴血小板减少综合征病毒的浓度非常高，因此，人与人之间可通过血液传播(Tang X，Wu W，Wang H，et al.J Infect Dis 2013；207:736-739.)。
由于尚未开发出针对发热伴血小板减少综合征病毒的抗病毒剂，对于发热伴血小板减少综合征的治疗，主要使用输血、肾替代疗法等针对器官功能衰竭的保守疗法。在中国，从2012年开始将利巴韦林静脉注射导入了治疗方针上，在最近发表的治疗结果中，利巴韦林给药组和非给药组之间的死亡率并不存在差异。因此，需要针对发热伴血小板减少综合征病毒的疫苗，但至今还未开发出疫苗。
发明内容
技术问题
本发明的目的在于，提供新型基因型发热伴血小板减少综合征病毒及利用其的免疫原性组合物。
技术方案
为了实现上述目的，本发明提供新型发热伴血小板减少综合征病毒。
并且，本发明提供用于预防或治疗发热伴血小板减少综合征的免疫原性组合物。
并且，本发明提供针对发热伴血小板减少综合征病毒或其抗原的抗体。
并且，本发明提供发热伴血小板减少综合征病毒的诊断试剂盒。
并且，本发明提供发热伴血小板减少综合征病毒抗体的检测方法。
并且，本发明提供生产针对发热伴血小板减少综合征病毒的抗血清的方法。
同时，本发明提供与发热伴血小板减少综合征的诊断有关的信息的提供方法。
有益效果
本发明的发热伴血小板减少综合征病毒与以往的血小板减少综合征病毒具有遗传性区别，是在系统学上从B基因型细化的新型病毒，因此，在仅通过某个特定基因型的病毒产生限制性防御能力的疫苗的特性上，可将本发明的新型病毒有用地利用为针对发热伴血小板减少综合征病毒具有优秀的交叉免疫原性的疫苗。
附图说明
图1为示出本发明的三种新型病毒和在本发明的三种新型病毒分离的发热伴血小板减少综合征病毒L基因的系统树图的图。
图2为示出本发明的三种新型病毒和在本发明的三种新型病毒分离的发热伴血小板减少综合征病毒M基因的系统树图的图。
图3为示出本发明的三种新型病毒和在本发明的三种新型病毒分离的发热伴血小板减少综合征病毒S(NP)基因的系统树图的图。
图4为示出本发明的三种新型病毒和在本发明的三种新型病毒分离的发热伴血小板减少综合征病毒S(NS)基因的系统树图的图。
图5为示出本发明的B-1(CB3/2016)、B-2(CB7/2017)及B-3(CB6/2016)基因型的三种新型病毒的L基因及M基因中的氨基酸变异部位的图。
图6为确认本发明的B-1(CB3/2016)、B-2(CB7/2017)及B-3(CB6/2016)基因型的三种新型病毒的疫苗效果的图。
最优实施方式
以下，参照附图通过本发明的实例更加详细地说明。但是，以下实例为了例示本发明而揭示，当本领域的普通技术人员判断主旨显要的描述或对结构的具体说明不必要地混淆本发明的要旨时，可省略其详细说明，而本发明并不限定于此。本发明在发明要求保护范围的记载及由此解释的同等范畴内可进行多种变形及应用。
并且，在本说明书中所使用的术语(terminology)是为了适当表述本发明的优选实施例而使用的术语，其可根据使用人员、操作人员的意图或本发明所属技术领域的惯例等而不同。因此，应以本说明书整个内容为基础对本术语下定义。在整个说明书中，当某个部分“包括”某个结构要素时，除非另有特别相反的记载，否则其意指还包括其他结构要素，而并不意味着排除其他结构要素。
在一实施方式中，本发明涉及发热伴血小板减少综合征病毒，其中，在L基因的ORF(6255bp)中表达的蛋白质的第1447位氨基酸为缬氨酸或第1913位氨基酸为赖氨酸，在M基因的ORF(3222bp)中表达的蛋白质的第83位氨基酸为酪氨酸、第404位氨基酸为苏氨酸或第904位氨基酸为缬氨酸。本发明的一实施例中，将上述病毒命名为B-1(CB3)。
在一实例中，上述发热伴血小板减少综合征病毒属于基因型B-1，可以为在分类为以往的基因型B的病毒的L基因的ORF(6255bp)中表达的蛋白质的作为第1447位氨基酸的异亮氨酸被缬氨酸取代、作为第1913位氨基酸的精氨酸被赖氨酸取代(序列13)、M基因的作为第904位氨基酸的异亮氨酸被缬氨酸取代的(序列14)病毒。
在一实例中，上述发热伴血小板减少综合征病毒可包括S基因，上述S基因包括包含序列1的碱基序列的L基因、包含序列2的碱基序列的M基因、包含序列3的碱基序列NP基因以及包含序列4的碱基序列的NS基因。
在一实例中，上述发热伴血小板减少综合征病毒可包含在L基因的ORF(6255bp)中表达的序列13的氨基酸序列、在M基因的ORF(3222bp)中表达的序列14的氨基酸序列、在NP基因的ORF中表达的序列15的氨基酸序列以及在NS基因的ORF中表达的序列16的氨基酸序列。
在一实施方式中，本发明涉及发热伴血小板减少综合征病毒，其中，在L基因的ORF(6255bp)中表达的蛋白质的第1447位氨基酸为异亮氨酸或第1913位氨基酸为精氨酸，在M基因的ORF(3222bp)中表达的蛋白质的第83位氨基酸为苯丙氨酸、第404位氨基酸为苏氨酸或第904位氨基酸为异亮氨酸。在本发明的一实施例中，将上述病毒命名为B-2(CB4)。
在一实例中，上述发热伴血小板减少综合征病毒属于基因型B-2，可以为分类为以往的基因型B的病毒的M基因的作为第83位氨基酸的酪氨酸被苯丙氨酸取代的病毒。
在一实例中，上述发热伴血小板减少综合征病毒可包括S基因，上述S基因包括包含序列5的碱基序列的L基因、包含序列6的碱基序列的M基因、包含序列7的碱基序列NP基因以及包含序列8的碱基序列的NS基因。
在一实例中，上述发热伴血小板减少综合征病毒可包含在L基因的ORF中表达的序列17的氨基酸序列、在M基因的ORF中表达的序列18的氨基酸序列、在NP基因的ORF中表达的序列19的氨基酸序列以及在NS基因的ORF中表达的序列20的氨基酸序列。
在一实施方式中，本发明涉及发热伴血小板减少综合征病毒，其中，在L基因的ORF(6255bp)中表达的蛋白质的第1447位氨基酸为异亮氨酸或第1913位氨基酸为精氨酸，在M基因的ORF(3222bp)中表达的蛋白质的第83位氨基酸为酪氨酸、第404位氨基酸为丙氨酸或第904位氨基酸为异亮氨酸。在本发明的一实施例中，将上述病毒命名为B-3(CB1)。
在一实例中，上述发热伴血小板减少综合征病毒属于基因型B-3，可以为分类为以往的基因型B的病毒的M基因的作为第404位氨基酸的苏氨酸被丙氨酸取代的病毒。
在一实例中，上述发热伴血小板减少综合征病毒可包括S基因，上述S基因包括包含序列9的碱基序列的L基因、包含序列10的碱基序列的M基因、包含序列11的碱基序列NP基因以及包含序列12的碱基序列的NS基因。
在一实例中，上述发热伴血小板减少综合征病毒可包含在L基因的ORF中表达的序列21的氨基酸序列、在M基因的ORF中表达的序列22的氨基酸序列、在NP基因的ORF中表达的序列23的氨基酸序列以及在NS基因的ORF中表达的序列24的氨基酸序列。
在本发明的一实施例中所分离的发热伴血小板减少综合征病毒的基因分析结果，它们的基因序列与公知的发热伴血小板减少综合征病毒的基因不同，通过对它们的系统学分类结果可知，每个基因为细化为至少三个的基因型，而并不是公知的一个B基因型组。
在本说明书中所使用的术语“取代”是指一个以上氨基酸或核苷酸分别被其他氨基酸或核苷酸代替。
本发明的发热伴血小板减少综合征病毒为负单链RNA病毒，其属于布尼亚病毒科(Bunyaviridae)、白蛉病毒属(phlebovirus)。并且，这种病毒为直径为80～100nm的球形病毒，以长角血蜱作为媒介，基因组由大(large(L))节段、中(medium(M))节段及小(small(S))节段组成，用于编码RNA依赖性RNA聚合酶(RNA dependent RNA polymerase，RdRp)、糖蛋白前体(glycoprotein precursor，M)，糖蛋白N(glycoprotein N，Gn)、糖蛋白C(glycoprotein C，Gc)、核衣壳蛋白(nucleocapsid protein，NP)及非结构蛋白(non-structural protein，NSs)等六个蛋白质。负链或反义链(针对用于编码病毒蛋白的正义链或正链的反义)以反义编码蛋白质或基因，为了表达至基因的蛋白质，生成正义链或正链RNA后，由此进行翻译来生成蛋白质。
在一实施方式中，本发明涉及包含发热伴血小板减少综合征病毒或其抗原作为有效成分的用于预防或治疗发热伴血小板减少综合征的免疫原性组合物。
在一实例中，本发明的免疫原性组合物可包含灭活的发热伴血小板减少综合征病毒和药剂学上可接受的载体(carrier)或佐剂(adjuvant)。
在一实例中，上述免疫原性组合物可以为疫苗组合物，其形态可选自由活疫苗、灭活疫苗、使用弱毒化发热伴血小板减少综合征病毒的基因生产的亚单位疫苗、载体疫苗、嵌合疫苗、DNA疫苗及RNA疫苗组成的组中。
在一实例中，上述免疫原性组合物可包含如下的发热伴血小板减少综合征病毒或它们的抗原作为有效成分：包括包含序列1的碱基序列的L基因、包含序列2的碱基序列的M基因以及包含序列3的碱基序列的S基因的发热伴血小板减少综合征病毒；包括包含序列4的碱基序列的L基因、包含序列5的碱基序列的M基因以及包含序列6的碱基序列的S基因的发热伴血小板减少综合征病毒；以及包括包含序列7的碱基序列的L基因、包含序列8的碱基序列的M基因以及包含序列9的碱基序列的S基因的发热伴血小板减少综合征病毒。
为了制备本发明的免疫原性组合物(即，疫苗)，本发明的病毒或其抗原可转化为生理学上可接受的形态。这可以基于对于流感的疫苗接种中所使用的疫苗的制备经验来实施(由Stickl，H.等公开。Dtsch.med.Wschr.99，2386-2392)。为了制备疫苗注射剂，例如，在安瓿瓶中，优选地，在玻璃安瓿瓶中在存在1％的人白蛋白及2％的蛋白胨的条件下的100ml的磷酸缓冲盐溶液(PBS)中进行冷冻干燥。不同地，疫苗注射剂在制剂化过程中通过对病毒依次进行冷冻-干燥来生成。这种制剂可含有如甘露醇、葡聚糖、糖类、甘氨酸、乳糖或聚乙烯吡咯烷酮等附加添加剂或者如抗氧化剂或非活性气体、稳定剂或适于向生物体内给药的重组蛋白(例如，人血清白蛋白)等其他辅助剂。接着，密封玻璃安瓿瓶并可在4℃至室温下储藏几个月。但是，除非另有其他要求，否则上述安瓿瓶可优选在小于-20℃的温度下储藏。
为了预防接种或治疗，冷冻干燥物溶解于0.1ml至0.5ml的水溶液中，优选地，溶解于生理盐水或tris缓冲液中，并能够以全身或局部，即，胃肠外、皮下、肌肉内或本领域的普通技术人员公知的任意其他给药途径给药。给药形态、服用量及给药次数可由本领域的普通技术人员通过公知的方式进行优化。但是，通常，患者接受第一次疫苗接种约一个月至六周后，接受第二次疫苗接种。
在本发明中，术语“预防”是指通过给药本发明的免疫原性组合物来抑制或延缓发热伴血小板减少综合征的发生、扩散及复发的所有行为。
在本说明书中所使用的术语“治疗”是指通过给药本发明的免疫原性组合物来使发热伴血小板减少综合征及由此引起的并发症的症状得到好转或改善的所有行为。只要是本发明所属技术领域的普通技术人员，通过参照韩国大韩韩医学会等中提供的材料来确认本发明的组合物为具有效果的疾病的正确标准，可判断改善、好转及治疗程度。
在本发明中结合有效成分来使用的术语“治疗有效量”是指针对由移植排斥反应引起的疾病的预防或治疗有效的量，本发明的组合物的治疗有效可根据如给药方法、目标部位、患者的状态等各种因素而不同。因此，对人体使用时，需要一起考虑安全性及效率性决定适当量的给药量。也可以从通过动物实验决定的有效量推断对人类使用的量。例如，在决定有效量时需要考虑的事项记载于Hardman and Limbird，eds.，Goodman and Gilman'sThe Pharmacological Basis of Therapeutics，10th ed.(2001)，Pergamon Press；以及E.W.Martin ed.，Remington's Pharmaceutical Sciences，18th ed.(1990)，MackPublishingCo.中。
以药学有效量给药本发明的药学组合物。在本发明中所使用的术语“药学有效量”是指以可适用于医学治疗的合理的利益/风险比充分治疗疾病且不引起副作用程度的量，有效剂量水平可根据包括患者的健康状态、饮食种类、重症度、药物的活性、对药物的敏感度、给药方法、给药时间、给药途径及排泄比例、疗程、配合或同时使用的药物在内的因素及其他医学领域中公知的因素来决定。本发明的组合物可作为单独的治疗剂给药或者可与其他治疗剂联用来给药，可与以往的治疗剂依次或者同时给药，可进行单次给药或多次给药。考虑到上述全部因素，优选地，给药在没有副作用的情况下可得到最大效果的量，这可由本领域的普通技术人员容易决定。
本发明的药学组合物可包含通常使用于生物学制剂中的载体、稀释剂、赋形剂或它们中两种以上的组合。在本发明中所使用的术语“药学上可接受”是指对于暴露在上述组合物中的细胞或人类没有毒性的特性。上述载体只要是将组合物适于传递至生物体内的载就不受特别限制，例如，可将在Merck Index，13th ed.，Merck&Co.Inc.中记载的化合物、生理盐水、无菌水、林格氏液、缓冲生理盐水、葡萄糖溶液、麦芽糊精溶液、丙三醇、乙醇及这些成分中的一种成分以上混合来利用，根据需要，可添加抗氧化剂、缓冲液、细胞抑制剂等其他常规的添加剂。并且，进一步添加稀释剂、分散剂、表面活性剂、结合剂及润滑剂来制剂化为如水溶液、悬浊液、乳浊液等注入用剂型、丸剂、胶囊、颗粒或片剂。进一步地，可利用本领域中适当的方法或在雷明顿药物科学(Remington's Pharmaceutical Science，MackPublishingCompany，Easton PA，18th，1990)中记载的方法并根据各种疾病或成分来进行优选的制剂化。
在一实例中，上述药学组合物可以为选自由口服剂型、外用剂、栓剂、灭菌注射用液及喷雾剂组成的组中的一种以上剂型，口服剂型或注射剂型更优选。
在本发明中所使用的术语“给药”是指以任意适当的方法向对象或患者提供规定的物质，可按照期望的方法进行胃肠外给药(例如，适用静脉内、皮下、腹腔内或局部注射剂型)或者口服给药，给药量的范围根据患者的体重、年龄、性别、健康状态、饮食、给药时间、给药方法、排泄率及疾病的重症度等而不同。用于本发明的组合物的口服给药的液态制剂为悬浊剂、内用液剂、乳剂、糖浆剂等，除了作为通常所使用的简单稀释剂的水、液体石蜡之外，还可包含如湿润剂、甜味剂、芳香剂、保存剂等多种赋形剂。用于胃肠外给药的制剂包括灭菌的水溶液、非水性溶剂、悬浊剂、乳剂、冷冻干燥制剂、栓剂等。还可以通过能够将活性物质移动至靶细胞的任意装置给药本发明的药学组合物。优选的给药方式及制剂为静脉注射剂、皮下注射剂、皮内注射剂、肌肉注射剂、点滴注射剂等。可通过生理盐溶液、林格氏液等水性溶剂、植物油、高级脂肪酸乙酯(例如，油酸乙酯等)、醇类(例如，乙醇、苯甲醇、丙二醇、丙三醇等)等非水性溶剂等来制备注射剂，可包含用于防止变质的稳定剂(例如，抗坏血酸、亚硫酸氢钠、焦亚硫酸钠、BHA、生育酚、EDTA等)、乳化剂、用于调节pH的缓冲剂、用于抑制微生物繁殖的保存剂(例如，硝酸苯汞、硫柳汞、苯扎氯铵、苯酚、甲酚、苄醇等)等药学载体。
在本发明中所使用的术语“对象”是指上述癌症发病或者会发病的包括人类在内的猴、牛、马、羊、猪、鸡、火鸡、鹌鹑、猫、狗、小鼠、大鼠、兔或豚鼠等所有动物，“样品”可以为从这些动物中分离的全血、血浆、血清、尿或唾液。
本发明的药学组合物还可以包含药剂学上可接受的添加剂，此时，作为药剂学上可接受的添加剂可使用淀粉、糊化淀粉、微晶纤维素、乳糖、聚维酮、胶态二氧化硅、磷酸氢钙、乳糖、甘露醇、饴糖、阿拉伯树胶、预胶化淀粉、玉米淀粉、粉状纤维素、羟丙基纤维素、欧巴代、羧甲淀粉钠、巴西棕榈蜡、合成硅酸铝、硬脂酸、硬脂酸镁、硬脂酸铝、硬脂酸钙、白糖、葡萄糖、山梨糖醇及滑石粉等。优选地，相对于上述组合物，可包含0.1重量份至90重量份的本发明药剂学上可接受的添加剂，但并不限定于此。
在一实施方式中，本发明涉及使用本发明的病毒或其抗原进行免疫应答来生产的抗体。
上述抗体不仅是全(whole)抗体形态，而且还包含抗体分子的功能性片段。全抗体为具有两个全长的轻链(light chain)及两个全长的重链(heavy chain)的结构，各个轻链通过二硫键(disulfide bond)与重链连接。抗体分子的功能性片段是指具有抗原结合功能的片段，抗体片段例如包括：(i)由轻链的可变区(VL)及重链的可变区(VH)和轻链的恒定区(CL)及重链的第一个恒定区(CH1)组成的Fab片段；(ii)由VH结构域及CH1结构域组成的Fd片段；(iii)由单抗体的VL结构域及VH结构域组成的Fv片段；(iv)由VH结构域组成的dAb片段(Ward ES et al.，Nature 341:544-546(1989)]；(v)分离的CDR区；(vi)包含两个连接的Fab片段的作为二价片段的F(ab')2片段；(vii)通过以使VH结构域及VL结构域形成抗原结合部位的方式结合的肽衔接物结合的单链Fv分子(scFv)；(viii)双特异性单链Fv二聚物(PCT/US92/09965)；以及(ix)通过基因融合制备的作为多价或多特异性片段的双体(diabody)WO94/13804)等。
在一实施方式中，本发明涉及包含发热伴血小板减少综合征病毒或其抗原或针对其的抗体的发热伴血小板减少综合征病毒的诊断试剂盒。
在一实例中，上述试剂盒可包括包含本发明的病毒的病毒试样及上述抗原-抗体复合物检测用试剂。上述抗原-抗体复合物检测用试剂包括放射免疫分析、酶联免疫吸附测定(Enzyme linked immunosorbent assay，ELISA)或免疫荧光分析用试剂。
在一实例中，可利用可简单地通过抗原抗体结合检测到的奥克特洛尼(Ouchterlony)平板、免疫印迹、如Crossed IE、Rocket IE、Fused Rocket IE、Affinity IE等免疫电泳(Immuno Electrophoresis)来实现抗原-抗体复合物的检测。在这种方法中所使用的试剂或物质为公知的，例如，可通过抗原-抗体之间反应、和与抗原特异性结合的底物、核酸或肽适体、与复合物相互作用的受体或配体或辅因子之前的反应来检测，或者可利用质量分析器。可将上述与本发明的抗原-抗体复合物特异性相互作用或结合的试剂或物质与核方式或纳米粒子(nanoparticle)一起使用。上述免疫分析或免疫染色的方法记载于Enzyme Immunoassay，E.T.Maggio，ed.，CRC Press，Boca Raton，Florida，1980；Gaastra，W.,Enzyme-linked immunosorbent assay(ELISA)，in Methods in Molecular Biology，Vol.1，Walker，J.M.ed.,Humana Press，NJ，1984中。可通过分析上述的免疫分析过程的最终信号的强度，即，进行与正常试样之间的信号对照来诊断是否感染。
在一实施方式中，本发明涉及包含发热伴血小板减少综合征病毒或其抗原或针对其的抗体的诊断组合物。
优选地，以能够被检测的方式标记诊断组合物中所使用的本发明的上述化合物。在标记生物分子时可使用的多种方法为本领域的普通技术人员公知的，在本发明的范畴内考虑。上述多种方法记载于Tijssen，'Practice and theory of enzyme immuno assays'，Burden,RHand von Knippenburg(Eds)，Volume 15(1985)，'Basic methods in molecularbiology'；Davis LG，Dibmer MD；Battey Elsevier(1990)，Mayer et al.，(Eds)'Immunochemical methods in cell and molecular biology'Academic Press，London(1987)，or in the series'Methods in Enzymology'，Academic Press，Inc中。
本领域的普通技术人员公知的有标记方法和多种其他标记。可在本发明中使用的标记种类例如有酶、放射性同位素、胶体态金属、荧光化合物、化学发光化合物及生物发光化合物。
通常所使用的标记为荧光物质包括(例如，荧光黄、罗丹明、德克萨斯红等)、酶(例如，辣根过氧化物酶、β-半乳糖苷酶、碱性磷酸酶)、放射性同位素(例如，32P或25I)、生物素、洋地黄毒苷、胶体态金属、化学发光或生物发光化合物(例如，二氧杂环丁烷、鲁米诺或吖啶)。酶或生物素基的共价键合法、碘化法、磷酸化法、生物素法等标记方法为在本领域中公知的。
检测方法为射线自显迹法、荧光显微镜、直接及间接酶反应等，但并不限定于此。通常所使用的检测分析法为放射性同位素或非放射性同位素方法。其中，通常使用免疫印迹、叠加分析法、放射免疫分析(Radioimmuno Assay，RIA)及免疫放射分析(ImmuneRadioimmunometric Assay，IRMA)、酶联免疫分析(Enzyme Immuno Assay，FIA)、酶联免疫吸附分析(Enzyme Linked Immuno Sorbent Assay，ELISA)、荧光免疫分析(FluorescentImmuno Assay，FIA)以及化学发光免疫分析(Chemioluminescent Immune Assay，CLIA)。
在一实施方式中，本发明涉及发热伴血小板减少综合征病毒抗体的检测方法，包括：在可形成抗原-抗体复合物的条件下，使从样品中分离的试样与本发明的病毒或其抗原接触的步骤；以及检测抗原-抗体复合物的形成的步骤。
在一实施方式中，本发明涉及在非人类动物中生产针对发热伴血小板减少综合征病毒的抗血清的方法，包括：向非人类动物给药适于诱导免疫应答的有效量的本发明的病毒或其抗原的步骤；以及收集含有针对上述发热伴血小板减少综合征病毒的抗体的抗血清或血浆的步骤。
在一实施方式中，本发明涉及与发热伴血小板减少综合征的诊断有关的信息的提供方法，包括：通过使从样品中分离的试样与本发明的病毒或其抗原接触来形成抗原-抗体复合物的步骤；以及检测上述抗原-抗体复合物的形成的步骤。
具体实施方式
通过以下实施例更详细地说明本发明。但是，以下实施例仅用于使本发明的内容具体化，而本发明并不限定于此。
实施例1.分离病毒
利用大学附属医院就诊患者中疑似发热伴血小板减少综合征的患者的血液、动物(山羊及遗弃犬)的血液及野生蜱均质物并通过实时荧光定量PCR(real time PCR)、PCR及ELISA分析确认发热伴血小板减少综合征病毒的阳性/阴性。具体地，感染病毒前天，将VeroE6细胞分株于12孔板中后，以大于60％的细胞密度进行培养后，用PBS清洗细胞，将300μL的疑似感染患者的血清(以3000rpm离心分离整个血液20分钟来获得的血清)处理1小时来感染。感染后，去除血清并用PBS清洗后，用含1％的FBS的DMEM培养基更换并培养2周。2周后，通过RT-PCR(逆转录(reverse transcription)后用实时荧光定量PCR确认)及免疫荧光分析法(immuno fluoresence assay)(在实验室，将小鼠(mouse)发热伴血小板减少综合征病毒NP抗体用作第一抗体以及将共轭FITC的抗体用作第二抗体)确认病毒分离与否，在没有分离病毒的情况下，通过将第一次感染过的上清液感染在另一个VeroE6细胞的方式分离病毒。将分离的病毒命名为CB3/2016、CB7/2017及CB6/2016。
实施例2.分析分离的病毒的基因
分别对利用Vero E6细胞分离的病毒CB3/2016、CB7/2017及CB6/2016进行逆转录(Reverse-transcription)、PCR及下一代测序(Next generation sequencing，NGS)来确认各病毒的L、M、S(NP、NS)基因的全长序列。具体地，从各病毒中提取RNA并通过逆转录(Reverse-transcription)PCR来制备cDNA。之后，对各SFTS病毒的L、M、S基因进行PCR来获得各自的全长基因。使用NGS方法进行基因序列分析，使用illumina nextera XT kit并根据由因美纳(illumina)公司提供的协议对各病毒的L、M、S基因进行标签化(tagmentation)及索引PCR(index PCR)。之后，将最终样品利用illimina miniseq测序系统生成Fasta Q文件，利用CLC main workbench program所生成的文件的基因序列分析各自的全长基因序列。将确认到的基因序列与在韩国、中国及日本中分离的以往的病毒的基因整合来进行基因分析，通过其结果确认，在本发明中分离的发热伴血小板减少综合征病毒CB1、CB3及CB4为与目前在中国或韩国分离的病毒(YuXJ et al.,N.Engl.J.Med.2011)及在韩国首次分离的(Gangwon/2012)病毒的基因具有遗传性区别的新型基因型(genotype)的发热伴血小板减少综合征病毒。同时，使用MEGA7.0程序对本发明的病毒与在韩国、中国、日本分离的病毒的L、M、S(NP、NS)基因进行系统学基因分析，通过其结果确认，本发明的病毒接近于韩国分离株所属最多的B组，但是，基因L、M及S(NP及NS)基因中显示与以往的病毒不同之处，细化为至少三个以上组来区分(图1至图4)。对此，将在本发明分离的三种基因型的发热伴血小板减少综合征病毒细化为B-1(CB3/2016)、B-2(CB7/2017)及B-3(CB6/2016)来进行命名。
实施例3.确认各病毒的L、M及S基因氨基酸序列差异
3-1.L基因氨基酸序列差异
以在本发明分离的新型细化基因型B-1、B-2及B-3的病毒的L、M及S基因的可读框(open reading frame，ORF)为基准分析氨基酸序列，其结果，L及M基因具有差异。具体地，B基因型中L基因的ORF(6255bp)编码RdRp，本发明的基因型B-1病毒中，RdRp的第1447位氨基酸为缬氨酸或第1913位氨基酸为赖氨酸，基因型B-2病毒及B-3病毒中，RdRp的第1447位氨基酸为异亮氨酸或第1913位氨基酸为精氨酸(图5的A部分及表1)。
表1
Figure BDA0002810157990000131
3-2.M基因氨基酸序列差异
分析在本发明分离的新型细化基因型B-1、B-2及B-3的病毒的L、M及S基因的氨基酸序列，其结果，L及M基因具有差异。具体地，B基因型中M基因的ORF(3222bp)编码Gn及Gc蛋白，本发明的基因型B-1病毒中，M基因的ORF的第83位氨基酸为酪氨酸、第404位氨基酸为苏氨酸或第904位氨基酸为缬氨酸，基因型B-2病毒中，M基因的ORF的第83位氨基酸为苯丙氨酸、第404位氨基酸为苏氨酸或第904位氨基酸为异亮氨酸，基因型B-3病毒中，M基因的ORF的第83位氨基酸为酪氨酸、第404位氨基酸为丙氨酸或第904位氨基酸为异亮氨酸(图5的B部分及表1)。
实施例4.比较各基因型的基因的同源性
针对包括本发明的细化基因型B-1、B-2及B-3在内的目前在韩国分离的发热伴血小板减少综合征病毒进行基因分析，比较分析了各基因型的L、M及S基因同源性。通过其结果确认，在属于相同基因型的病毒之间的基因同源性(nucleotide level)为约96～100％，与此相反，不同基因型病毒之间的基因同源性较低，为91～97％(表2至表5)。并且，在本发明的基因型B-3组的情况下，相同组中的同源性较低，为约95～100％左右，在B-3组中也可以细化为其他基因型组。
表2
Figure BDA0002810157990000141
比较L基因的同源性
表3
Figure BDA0002810157990000142
比较M基因的同源性
表4
Figure BDA0002810157990000143
比较S(NP)基因的同源性
表5
Figure BDA0002810157990000151
比较S(NS)基因的同源性
实施例5.分析各基因型的交叉免疫原性及确认疫苗效果
5-1.各基因型的交叉免疫原性分析
通过FRNT50(fifty percent of Focus reduction neutralization test)分析各基因型的交叉免疫原性。具体地，使在本发明分离的新型细化基因型B-1、B-2及B-3的病毒大量增殖后，分别添加福尔马林(0.05％)进行灭活后，通过三次的病毒分离(isolation)确认灭活与否。采用20％的蔗糖(sucrose)灭活的上述疫苗(inactivated whole vaccine)进行超离心分离来生产蛋白质后，将其对雪貂进行免疫化。2周后，进一步对雪貂进行免疫化后(两次免疫间隔之间为两周)，采血并分离血清。在56℃的温度下灭活所分离的血清30分钟后，以1/10比例稀释后，进行每次2倍的阶段性稀释。在37℃的温度下，将以200FFU/ml稀释的病毒与阶段性稀释的病毒以1：1的比例进行反应。清洗分株于6孔板中的VeroE6细胞后，用经上述反应的病毒进行感染，1小时后进行清洗后，将含1％的FBS的0.8％的DMEM琼脂糖凝胶倒入细胞中。感染5天后，采用福尔马林固定3小时后，清洗三次后，在室温下各进行5分钟的10％的triton x-100处理。之后，清洗三次并用5％的BSA进行封闭。使用所生产的多克隆NP抗体(polyclonal NP antibody)作为第一抗体来进行培养后清洗三次，用第二抗体使HRP共轭(HRP conjugated)抗体反应1小时并清洗后，用DAB发色来确认结果。应解释为，比仅感染病毒的孔的病灶形成(foucus forming)降低至50％的值为有效。
表6
Figure BDA0002810157990000152
Figure BDA0002810157990000161
确认B-1、B-2及B-3的交叉免疫原性的结果如上述表6所示，针对各病毒显示出最高的血清抵抗。因此，在属于相同的基因型的病毒之间显示出高交叉中和反应性，但在各自不同的基因型之间的病毒之间显示出较低的中和反应性。
5-2.确认疫苗效果
使在本发明分离的新型细化基因型B-1、B-2及B-3的病毒大量增殖后，分别添加福尔马林(0.05％)进行灭活后，通过三次的病毒分离(isolation)确认灭活与否。对各病毒将灭活的上述疫苗(inactivated whole vaccine)以两周为间隔对每五只雪貂进行免疫化两次后，以1×107.6/ml对各病毒进行挑战接种。
通过挑战接种结果确认，对照组动物在10天内都在被挑战病毒感染时死亡，但接种疫苗的组的所有雪貂存活，并在感染2～8天后确认体温上升、体重下降，之后开始恢复(图6)。
概括以上的结果，在发热伴血小板减少综合征病毒中存在具有多种基因的多种基因型的病毒，在属于相同基因型的病毒之间显示出较高基因同源性及低交叉免疫原性，与其他基因型的病毒之间显示出较低基因同源性及低交叉免疫原性，因此，为了产生针对多种基因型的交叉免疫原性，可推断为某个特定基因型的病毒的防御能力是受限的。
因此，可将属于本发明的细化基因型B-1、B-2及B-3的新型病毒CB3/2016、CB7/2017及CB6/2016有用地利用为对基因型B的发热伴血小板减少综合征病毒具有优秀的交叉免疫原性的疫苗。
<110> 鉴定生物株式会社
<120> 新型发热伴血小板减少综合征病毒
<130> PO1903-006
<160> 24
<170> KoPatentIn 3.0
<210> 1
<211> 6255
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 L基因
<400> 1
atggacttgg aagtgctttg tggtaggata aacgtggaga atgggctgtc tcttggagaa 60
ccaggcctgt acgaccaaat ctacgacagg ccagggctgc cagacctaga tgtgactgtc 120
gatgccacag gtgtgacagt ggacataggg gctgtgccag actcagcatc acaactgggc 180
tcatcaatca atgctgggtt gatcacaatc cagctctctg aagcatataa gatcaatcat 240
gacttcacat tttctggcct gtcaaagaca acagaccgac gcctctcaga ggtattcccc 300
attacccatg atggttctga tgggatgacc cctgatgtga tccacaccag attggatgga 360
actattgtgg tggttgaatt ttcaaccact aggagccata acattggggg cctggaggca 420
gcatatagga caaagataga aaaatatagg gacccaatct caaggcgtgt tgatatcatg 480
gagaacccga gagtcttctt tggtgttatt gtagtctcgt caggaggggt tctgtccaac 540
atgcccctga ctcaggatga ggcagaggag ctcatgtaca ggttctgcat agccaatgaa 600
atctacacta aggctagatc tatggatgca gacattgagc tacagaagag tgaagaagag 660
cttgaggcta tcagcagggc actttcattc ttcagtttgt tcgagcctaa cattgaaaga 720
gtggaaggaa cattccccaa ttcagaaatt gagatgctgg aacagtttct ctcaacacca 780
gctgatgttg acttcatcac caagaccctc aaagcaaaag aggtggaggc ctatgctgat 840
ctttgtgaca gccactacct aaagcctgaa aaaaccattc aggagcgtct agagatcaat 900
agatgtgagg ctattgacaa aactcaggac ctcctagctg gcctacatgc aaggagcaac 960
aagcaaacat cattgaatcg agggacagtc aaactcccgc cctggctgcc aaagccatca 1020
agtgagtcaa tagacatcaa gaccgactca ggctttggtt ccttaatgga tcatggcgca 1080
tatggtgagc tatgggcaaa gtgccttcta gatgtctcgt taggcaatgt ggagggggta 1140
gtcagtgacc ctgcaaaaga gcttgacatt gctatctctg atgacccaga aaaagacacc 1200
cccaaagagg caaagataac ctataggcga ttcaagcctg ccttaagttc aagtgcccgg 1260
caagaatttt ctctccaagg agtggagggg aagaagtgga agagaatggc agcaaaccag 1320
aagaaagaga aggagtccca tgagacattg agccctttct tggatgttga agacattggg 1380
gatttcctga cattcaacaa tcttcttgca gattcgaggt atggagatga gtccatccag 1440
agagctgtgt caatcttgtt ggaaaaggca tctgccatgc aggacacaga gctcactcat 1500
gctctcaacg actcattcaa gaggaaccta agcagcaatg tggttcagtg gtccctttgg 1560
gtttcctgtt tggcgcagga gctagctagt gctctgaagc agcactgcag ggctggtgag 1620
ttcatcatca agaagctgaa gttctggcct atctatgtca ttatcaagcc gaccaaatcg 1680
tcatctcaca tcttctacag cttagggatc cgcaaggctg acgtgacaag gaggctcact 1740
ggtagagtct tctctgacac cattgatgca ggggaatggg agctaacaga gttcaaaagc 1800
ctgaagacat gtaagctcac gaaccttgtc aacttaccat gcaccatgct gaactcaata 1860
gctttctgga gagagaagct gggcgtggct ccatggctgg tccggaagcc ttgttcagag 1920
ctcagggagc aggtgggcct gaccttcctg atcagtctgg aggacaagtc taagactgag 1980
gagatcatca ccttgacaag gtacacccag atggagggct ttgtctctcc tcccatgctg 2040
cccaaacccc aaaagatgct agggaaactg gatggacctt tgagaaccaa gctacaggtt 2100
tacctcctca ggaagcatct ggattgcatg gtgcgaattg cttctcagcc attcagccta 2160
atcccaagag aggggagagt agaatgggga ggaacattcc atgccatctc aggccggtcc 2220
acaaatcttg agaatatggt gaacagctgg tacattgggt actacaagaa caaagaggag 2280
tcaacagaac taaatgctct cggagaaatg tataagaaga ttgtggagat ggaagaggac 2340
aagcccagca gccctgagtt tctggggtgg ggggacactg attcccctaa gaagcatgaa 2400
ttctcacgga gcttcctgag agctgcttgc tcatctctgg aaagagaaat tgctcagcga 2460
catggaagac aatggaagca gaaccttgag gagcgagtcc tgagagagat tgggaccaag 2520
aacatcctgg accttgcatc catgaaggct actagcaact tttccaaaga ctgggagctc 2580
tactcagaag tccagaccaa agagtaccat aggtccaaac tgctggagaa gatggccaca 2640
ttgattgaga agggggttat gtggtacatt gatgctgtgg gtcaggcatg gaaggcagtt 2700
ctggatgacg ggtgcatgcg aatctgtctc ttcaaaaaga atcagcatgg tggcctcaga 2760
gagatctacg ttatggatgc aaatgcccgg ctcgtgcagt ttggggttga gaccatggct 2820
aggtgtgtct gtgagctgag cccacatgag actgttgcca accctaggct caagaattcc 2880
atcatagaga accatgggct gaagtcagcc cgtagtcttg gccctggctc tataaacata 2940
aactcatcca atgatgccag gaagtggaat caggggcact acacaacaaa gctagctcta 3000
gttctttgtt ggttcatgcc agccaaattc cacagattca tttgggctgc catttccatg 3060
tttcggagaa aaaagatgat ggtggaccta aggtttttag ctcacctcag ttctaaatct 3120
gagtctaggt catctgatcc atttagggaa gcaatgacag acgccttcca tggcaatagg 3180
gaagtctcat ggatggacaa agggcgaact tacataaaga cagagacagg tatgatgcag 3240
ggtatactgc actttacatc cagcctcctc cactcttgtg ttcagagctt ttacaagtct 3300
tatttcgtct cgaaactcaa ggagggctac atgggagaaa gcatcaatgg ggtggtggat 3360
gtcatagaag gctctgacga ctcagcgatc atgatcagca tacgccccaa gtcagacatg 3420
gatgaagtcc gatcaaggtt ctttgttgct aacttactcc actctgtaaa gttcttgaac 3480
cctttgtttg ggatctactc atcagagaaa tcaacagtga acacagtgta ttgtgtcgag 3540
tataactctg aattccattt ccacaggcac ttggttcgac ccacactgag atggatagca 3600
gcatctcacc aaatctcaga gactgaggcc cttgcaagca ggcaagagga ttattcaaac 3660
cttctaaccc agtgcttgga gggaggggcc tcattctctc ttacctacct catacagtgc 3720
gctcagctcc tgcaccacta catgcttcta ggactatgct tacacccctt gtttggaact 3780
ttcatgggga tgctgatatc agacccagat ccagccctag ggttcttcct catggacaac 3840
cctgcattcg caggaggagc aggatttaga ttcaatctgt ggagagcctg caagactaca 3900
gaccttgggc ggaagtatgc atattatttt aatgagatac agggtaaaac aaagggagat 3960
gaggactaca gagctctgga cgccacatca ggaggaaccc tcagccactc tgttatggtg 4020
tactgggggg acaggaagaa gtatcaggcc ttattgaaca ggatgggcct tcctgaggac 4080
tgggtggagc agatagatga gaatcccggt gtcctttaca ggagagctgc caacaagaag 4140
gaactactct taaaactggc agagaaggtt cattcacctg gtgtgactag cagcctgagt 4200
aaagggcatg tagtgcctcg ggtggtggca gcaggagtat accttctctc acgccattgc 4260
tttcgcttta gctcaagcat ccatggaagg ggctcagcac agaaggctag ccttataaaa 4320
ctgttgatga tgtcttctgt ttctgccatg aagcatgggg gctcactaaa ccctaatcag 4380
gagcgaatgc tcttccctca ggctcaagag tatgacagag tatgcacatt gcttgaggag 4440
gttgaacacc taacagggaa atttgttgtt agggagagga acattgtcag gagccgcata 4500
gacttgttcc aagagccagt ggacttgcgg tgcaaggcag aagatctggt gtcagaggtg 4560
tggtttggcc tgaaaaggac taaacttgga ccccgtctcc tcaaggaaga gtgggacaaa 4620
cttagggcct catttgcatg gctgagcaca gacccatctg aaacattgag ggatggtcct 4680
tttcttagcc atgtgcagtt taggaacttc atagcccacg ttgatgccaa atcaagatca 4740
gtcaggctcc taggtgcccc cgtaaagaag tcaggtgggg tcaccactat aagccaagta 4800
gtcagaatga acttcttccc aggttttagc ctagaagctg agaagagctt agacaatcag 4860
gaaagacttg agagcatctc catcctcaag catgtcttgt tcatggtctt gaatggccca 4920
tacactgagg agtacaagct ggaaatgatc atagaggcct tctctactct tgtgatacct 4980
cagccatcag aggtcatcag gaaatcaagg accatgactt tgtgcctctt atcaaattac 5040
ttgtctagta ggggtgggtc cattctagac cagattgaga gggcacagtc aggcactcta 5100
gggggcttca gcaagcccca gaagactttc attaggccag gaggtggtat cggctacaag 5160
ggaaagggtg tgtggactgg agtgatggag gacacccatg ttcaaattct gatagatgga 5220
gatgggacta gtaactggct tgaggagatc aggctcagta gtgatgccag actttatgat 5280
gtcattgagt ccatccgaag gttatgtgat gacctcggga tcaacaacag ggtggcatct 5340
gcatatagag gccattgcat ggttaggctg agtggattca agatcaagcc agcatcaagg 5400
actgatggct gcccagtcag gattatggaa aggggcttca ggatcaggga actccaaaac 5460
ccagatgagg tcaagatgag agtgagaggt gacatcctca acctctctgt caccattcaa 5520
gaaggaaggg tcatgaacat tctaagctac aggccgagag acactgatat atcagaatca 5580
gccgcagcat atctctggag caatcgagac ctcttctcct ttgggaagaa ggagccatcc 5640
tgcagctgga tctgcttgaa aactcttgac aattgggcct ggtcacatgc ctcagttctc 5700
ctggcaaatg ataggaagac ccaaggcatt gataataagg ctatggggaa cattttcagg 5760
gactgtctcg agggttctct tagaaagcaa gggctgatga ggtcaaagct cacagagatg 5820
gtggagaaga atgtagttcc tttaacaact caagagcttg tcgacatcct ggaggaggac 5880
atagactttt cagatgtcat agctgtggaa ctctcagagg gatcacttga tattgaatcc 5940
atctttgatg gggcacctat cttgtggtct gctgaggtgg aagagtttgg ggaaggagtg 6000
gtggctgtga gctattccag taagtactat catctaaccc tgatggacca agctgccatc 6060
acaatgtgtg cgatcatggg taaggaaggc tgtagagggc tccttactga gaagagatgc 6120
atggcagcca tacgagagca ggtacggcca ttcctcatat tcctgcaaat ccctgaggat 6180
agcatttctt gggtgtctga tcagttctgc gactccaggg gtcttgatga ggagagcacc 6240
attatgtggg gttga 6255
<210> 2
<211> 3222
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 M基因
<400> 2
atgatgaaag tcatctggtt ctcctctctg atctgcttag tcattcaatg cagtggggat 60
acgggtccaa tcatatgcgc agggcccatc cactcaaaca agagtgccaa cataccccac 120
ctgcttggct actctgagaa gatttgtcag atagatcggc tgatacatgt ttcgtcatgg 180
ctgagaaacc attcacaatt tcagggctat gtggggcagc gaggtggacg ctctcaggta 240
agctattacc cagctgaaaa ctcttactca aggtggagtg gacttctaag cccctgtgat 300
gcagattggc ttgggatgct tgttgtgaag aaggccaaag ggtctgatat gatagttcct 360
gggccttcat acaagggaaa agtctttttt gaacggccaa cttttgatgg atacgtaggc 420
tggggctgtg gcagtgggaa gtcaaggaca gagtcagggg agctctgcag ctcagactca 480
gggaccagtt ccggtcttct gccctcagat agggttctct ggataggtga tgttgcttgc 540
cagcctatga cacccatccc tgaggagaca tttctggagc tgaagagttt tagccagagt 600
gaattcccag acatatgcaa aattgatggc attgtgttca accagtgtga gagtgagagt 660
ctacctcaac ccttagatgt tgcgtggatg gatgtaggcc actctcataa aatcatcatg 720
agggagcaca agactaaatg ggtacaagag agctcatcta aggattttgt gtgctacaag 780
gaagggactg ggccatgttc tgaatcagaa gaaaagactt gcaagaccag tggatcatgt 840
aggggggaca tgcagttttg caaggtggca ggttgtgaac atggggaaga agcatctgat 900
gccaagtgta gatgctcact agtgcacaag cccggggaag ttgttgtgtc atatggaggg 960
atgcgtgtca gaccaaagtg ttatggcttc tccagaatga tggcaacact agaggtgaac 1020
ccaccagagc aaaggattgg ccaatgcact ggctgccatc ttgaatgcat aaatgggggt 1080
gtgaggctaa tcactctgac tagtgagctc aagtcagcta ctgtctgtgc ttcccacttt 1140
tgtagttctg ccacaagtgg caagaaaagc acggagattc aatttcactc agggtcatta 1200
gttgggaaaa caacaataca cgtcaaaggg gctttggtgg atggaactga attcacattt 1260
gagggcagtt gcatgttccc agatggttgt gacgcagtgg actgcacatt ctgtcgtgag 1320
tttctaaaaa atcctcagtg ctaccctgca aagaaatggc tgttcatcat tattgtcatc 1380
ctccttggat atgcaggcct catgctactt accaatgtcc ttaaggcaat cggggtttgg 1440
ggatcatggg tcatagctcc agtgaagcta atgtttgcca tcataaagaa actgatgaga 1500
tctgtgagct gcttgatggg gaaattaatg gataggggaa ggcaagtgat ccatgaagaa 1560
ataggggaga atagagaggg caaccaagat gatgttagga tcgagatggc aagacccaga 1620
agggtaaggc attggatgta ctcacctgtc atcctgacta ttctagcaat tgggcttgcc 1680
gagggctgcg atgagatggt ccatgctgac tccaaacttg tttcgtgcaa gcaagggagc 1740
ggaaacatga aggaatgtgt cacaactggg agggcactcc ttcctgcggt gaacccagga 1800
caagaggcat gtctgcactt cacggcacct gggagtccgg actcaaaatg tctcaaaatt 1860
aaggtcaaga ggattaacct aaaatgtaag aagtcatcat catattttgt tcctgatgct 1920
cggtctaggt gtacatctgt gaggagatgt cgctgggcag gagactgcca gtctgggtgc 1980
ccctctcatt tcacgtccaa ctccttctct gatgattggg caggtaaaat ggacagggca 2040
ggtctaggat tcagtgggtg ctctgatgga tgtggaggag cagcctgcgg ctgctttaat 2100
gcagcccctt catgcatctt ttggaggaaa tgggtagaga acccgcatgg gatcatctgg 2160
aaagtatctc catgtgctgc atgggtccca tcagcagtca tagagctaac aatgccctca 2220
ggggaagtga ggacattcca ccccatgagc ggcatcccta cacaagtctt caagggtgtg 2280
agtgtgacgt acttaggctc agatatggag gtgtctggct tgactgacct gtgtgagata 2340
gaagagctca agtccaagaa gctggcatta gccccctgca atcaggctgg catgggggtt 2400
gtaggcaagg ttggagagat acagtgcagt agcgaggaaa gtgcccgtac cataaaaaaa 2460
gatgggtgta tatggaatgc tgaccttgtg ggcatagagc tacgagtgga tgacgctgtg 2520
tgctactcta agatcactag tgtggaggca gttgcaaact actctgccat acccaccact 2580
attggggggc tgaggtttga gagaagccat gacagccagg gtaaaatatc tggtagcccc 2640
ttagatataa cagccataag agggtctttt tcagttaatt atagaggcct tcgactgagc 2700
ctctcagagg ttactgctac ttgcacagga gaggtgacga atgtgagtgg gtgttactct 2760
tgcatgacag gcgccaaagt ctccatcaaa ctgcatagca gcaaaaatag cactgcccat 2820
gtaagatgca aaggggatga gacagcattc agtgtcctag tgggagttca tagctatact 2880
gtcagtctca gctttgacca tgcagtggtc gatgagcagt gccagctgaa ctgtggaggg 2940
catgagagtc aagtgactct aaaaggcaac ctcatcttcc tggatgtccc aaaatttgtg 3000
gatggcagct atatgcagac atatcatagt tctgtgccca caggggccaa catcccaagc 3060
cctacagact ggctgaatgc cttgttcggc aatgggctga gtaggtggat tctgggggta 3120
ataggggttc tactgggggg attggctctc tttttcttaa tcatgtctct gttcaaattg 3180
ggaacaaaac aggtatttcg atcaaggacg aagctggctt aa 3222
<210> 3
<211> 738
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 NP基因
<400> 3
atgtcagagt ggtccaggat tgcagtggag tttggtgagc agcagctcaa tttgacggag 60
cttgaggact tcgcgagaga gctggcctat gaaggccttg atcctgcttt gatcatcaag 120
aagctgaagg agacaggtgg ggatgattgg gtgagggata caaagttcat cattgtcttt 180
gccctgactc gaggcaataa gattgtcaag gcatcaggga aaatgtcaaa ctcagggtct 240
aagaggttga tggcactcca agagaagtat ggactggttg agagggcaga aaccaggctc 300
tcaatcactc ctgtgagggt ggcacagagc ctacccactt ggacatgtgc tgctgcagca 360
gccttaaagg agtatcttcc agttgggcca gctgtcatga acctgaaggt cgagaattat 420
cctccagaga tgatgtgcat ggcctttggg tccctgattc caactgcggg ggtgtcagaa 480
gctacaacga agaccctgat ggaggcctac tctctgtggc aagatgcctt cacaaagact 540
atcaatgtga agatgcgcgg agccagtaag acagaggttt acaactcctt cagggatcct 600
ctccatgctg ctgtgaactt cgtctttttc ccccaagatg ttcgggtgaa gtggctgaag 660
gccaagggaa tccttggccc agatggggtc cccagcagag ctgctgaggt tgctgctgct 720
gcttacagaa acctgtaa 738
<210> 4
<211> 882
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 NS基因
<400> 4
atgtcgctga gcaaatgctc caacgttgac ctcaaatctg tggcaatgaa tgccaacact 60
gtcaggcttg agccatctct aggagagtac cccactctta ggagagacct cgttgaatgc 120
tcttgtagtg tgttgactct atcaatggtt aagaggatgg gcaagatgac caacacagta 180
tggttgtttg gtaacccaaa aaatcctctt caccagcttg agcctggact cgagcagctg 240
ttggacatgt actacaagga catgaggtgc tactcccaga gagagctgag tgctcttagg 300
tggcctagtg ggaagccatc tgtatggttc ctgcaggcag ctcatatgtt cttctccatc 360
aagaacagct gggcaatgga aaccggcaga gagaattggc ggggcctctt ccacaggata 420
acaaaaggca aaaagtatct ttttgaagga gacatgatat tggattctct tgaggccata 480
gagaagcgaa ggcttagact tgggctacct gagatcctaa taactggact atccccgatt 540
ctggatgtgg ccctcctcca gatagagtca cttgcaaggc taagaggcat gagcttgaac 600
caccacttat tcacatcttc ctcattgcgt aagcctttgt tggactgttg ggacttcttt 660
attcctatcc ggaaaaagag gacagatggc tcatacagta tcttggatga ggatgatgaa 720
cttggggtcc ttcaaggtta cccatatctg atggcacact atttgaatag gtgcccattc 780
cacaacctca tcaggtttga tgaagagctg agaactgcag ccctaaacac catctgggga 840
agagattggc cggccattgg tgacctcccg aaggaggtct aa 882
<210> 5
<211> 6255
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 L基因
<400> 5
atgaacttgg aagtgctttg tggtaggata aacgtggaga atgggctgtc tcttggagaa 60
ccaggcctgt acgaccaaat ctacgacagg ccagggctgc cagacctaga tgtgactgtc 120
gatgccacag gtgtgacagt ggacataggg gctgtaccag actcagcatc acaactgggc 180
tcatcaatca atgctgggtt gatcacaatc cagctctctg aagcatataa gatcaatcat 240
gacttcacat tttctggcct gtcaaagaca acagaccgac gcctctcaga ggtattcccc 300
attacccatg atggttcaga tgggatgacc cctgatgtga ttcataccag attggatgga 360
accattgtgg tggttgaatt ttcaaccact aggagccata acattggggg cctggagacg 420
gcatatagaa caaagataga gaaatatagg gacccaatct caaggcgtgt tgatatcatg 480
gagaacccga gggtcttctt tggcgttatt gtagtctcgt caggaggggt tctatccaac 540
atgcccctga ctcaggatga ggcagaggag ctcatgtaca ggttctgcat agccaatgag 600
atctacacca aggctagatc tatggatgca gacattgagc tacagaagag tgaagaagag 660
cttgaggcta ttagcagggc actgtcattc ttcagtttgt ttgagcctaa cattgaaaaa 720
gtggaaggaa cattccccaa ttcagaaatc gagatgctgg aacagtttct ttcaacacca 780
gctgatgttg acttcatcac taagacactc aaagcaaaag aggtggaggc ctatgctgat 840
ctttgtgaca gccactacct aaagcctgaa aaaaccattc aggagcggct agagatcaat 900
agatgtgagg ctattgataa aactcaggac ctcctagcta gcctgcatgc aaggagcaac 960
aaacaaacat cactgaatcg agggacagtc aaactcccgc cctggctacc aaagccatca 1020
agtgagtcaa tagacatcaa gaccgactca ggctttggtt ccttaatgga ccatggcgca 1080
tatggtgagc tgtgggcaaa gtgccttcta gatgtctcgc tgggcaatgt ggagggggta 1140
atcagtgacc ctgcaaaaga acttgacatt gctatctctg atgatccaga aaaagatacc 1200
cccaaagaag caaagataac ctataggcga ttcaagcctg ccttaagttc aagtgcccgt 1260
caggaatttt ctctccaagg agtggaggga aagaagtgga agagaatggc agcaaaccag 1320
aagaaagaga aggagtccca tgaggcattg agccccttct tggatgttga ggacattggg 1380
gatttcctaa cattcaacaa tcttcttgca gattcaaggt atggagatga gtccgtccag 1440
agagctgtgt caatcctgtt ggagaaggca tctgccatgc aaaacacaga gctaactcat 1500
gccctcaatg actcattcaa gaggaaccta agcagtaatg tggttcagtg gtccctctgg 1560
gtctcctgtt tagcacagga gctagctagt gctctgaagc agcactgcag ggctggtgag 1620
ttcatcatca agaagttgaa gttctggcct atctatgtca tcatcaagcc gaccaaatcg 1680
tcttcccata tcttctacag cttagggatc cgcaaggctg atgtgacaag gaggctcact 1740
ggcagagtct tctctgacac cattgatgct ggggaatggg agctaacaga gttcaaaagc 1800
ctgaagacat gcaagctcac gaaccttgtc aacttaccat gcaccatgct gaactcaata 1860
gctttctgga gagagaagct gggcgtggct ccatggctgg ttcggaagcc ttgttcagag 1920
ctcagagagc aggtgggcct gaccttcctg atcagtctgg aggacaagtc taagactgag 1980
gagatcatca ccttgacaag gtacacccag atggagggct ttgtctctcc tcccatgctg 2040
cctaagcccc aaaagatgct agggaaactg gatggacctt tgagaactaa gttacaggta 2100
tacctcctca ggaagcatct ggattgcatg gtgcgaattg cttctcagcc attcagccta 2160
atccctagag aggggagggt agaatgggga ggaacattcc atgccatctc aggccggtcc 2220
acaaaccttg agaatatggt gaacagctgg tacattgggt actacaagaa caaagaggag 2280
tcaacagagc taaatgctct cggagaaatg tataagaaga ttgtagagat ggaagaggac 2340
aagcccagta gccctgagtt tctagggtgg ggggacactg attcccctaa gaagcatgaa 2400
ttctcacgga gcttcctcag agctgcttgc tcatctctgg agagagaaat tgctcagcga 2460
catggaagac aatggaagca gaaccttgag gagcgtgtcc tgagagagat tgggaccaag 2520
aacatcctgg accttgcatc catgaaggct acaagcaact tttccaaaga ctgggagctc 2580
tactcagagg tccagaccaa agagtaccat aggtccaaac tgctggagaa gatggccaca 2640
ttgatagaga agggggttat gtggtacatt gatgctgtgg gccaggcatg gaaggcagtt 2700
ctagatgacg ggtgcatgcg aatctgtctc ttcaaaaaga atcagcatgg tggtctcaga 2760
gagatctacg ttatggatgc aaatgcccgg ctcgtgcagt ttggggttga gaccatggct 2820
aggtgtgtct gtgagttgag cccacatgag actgttgcca accctagact caagaattcc 2880
atcatagaga accatgggct gaagtcagcc cgtagtcttg gtcctggctc tataaacata 2940
aactcatcca atgacgccaa gaagtggaat caggggcact acacaacaaa gctagctcta 3000
gttctttgtt ggttcatgcc agccaaattc cacagattca tttgggccgc catttccatg 3060
tttcggagaa aaaagatgat ggtggaccta aggtttttag ctcacctcag ttctaaatct 3120
gagtctaggt catctgaccc gtttagggaa gcaatgacag acgctttcca tggtaatagg 3180
gaagtctcat ggatggacaa agggcgaact tacataaaga cagagacagg aatgatgcag 3240
ggcatactgc actttacatc cagcctcctt cactcttgtg ttcagagctt ttacaagtct 3300
tatttcgtct cgaagcttaa ggagggctac atgggggaaa gcatcaatgg ggtggtggat 3360
gtcatagaag gctctgacga ctctgcgatc atgatcagca tacgccctaa gtcagacatg 3420
gatgaagtcc gatcaaggtt ctttgttgct aacttgctcc actctgtcaa gttcttgaac 3480
cctttgtttg gtatttactc atcagagaaa tcaacagtga acacagtgta ttgtgttgag 3540
tataactctg aattccactt ccacaggcac ttggtcagac ccacactgag atggatagca 3600
gcgtctcacc aaatctcaga gactgaagcc cttgcaagca ggcaagagga ttactccaac 3660
cttctaaccc agtgcttgga aggaggggcc tcattctctc ttacctacct tatacagtgc 3720
gctcagctcc tgcaccacta catgctccta ggactatgct tacatccctt gtttggaact 3780
ttcatgggga tgctgatatc agacccagat ccagccctag ggttcttcct catggacaac 3840
cctgcattcg cagggggagc aggatttagg ttcaatctgt ggagggcctg caagactaca 3900
gaccttgggc ggaagtatgc atattatttt aatgagatac agggtaaaac aaagggagat 3960
gaggattaca gagctctgga cgccacatcg ggaggaactc tcagccactc tgtcatggtg 4020
tactgggggg acaggaagaa gtatcaggcc ttattgaaca ggatgggcct tcctgaagac 4080
tgggtggagc agatagatga gaatcctgga gtcctttaca ggagagctgc caacaaaaag 4140
gaactactct taaaactggc agagaaggtt cattcaccag gtgtgactag cagcctgagt 4200
aaagggcatg tagtgcctcg ggtggtggca gcaggagtat accttctctc acgccactgc 4260
tttcgcttta gctcaagtat ccatggaagg ggctcagcac agaaggctag tcttataaaa 4320
ctgctgatga tgtcttctat ttctgccatg aagcacgggg gctcactaaa ccctaatcag 4380
gagcgaatgc tcttccctca ggcccaggag tatgacagag tatgcacatt gcttgaggaa 4440
gttgagcacc taacagggaa atttgttgtt agggagagaa acattgtcag gagccgtata 4500
gacttgttcc aagagccagt ggacttgcgg tgcaaggcag aagatctggt gtcagaggtg 4560
tggtttggcc tgaaaaggac taagcttgga ccccgtctcc tcaaggaaga gtgggacaaa 4620
cttagggcct catttgcatg gctgagcaca gacccatctg aaacattgag ggatggccct 4680
tttcttagcc atgtgcagtt tagaaacttc atagcccatg ttgatgccaa atcaagatca 4740
gtcaggctcc taggtgcccc cgtaaagaag tcaggtgggg tcaccactat aagccaagta 4800
gtcaggatga acttcttccc tggttttagc ctagaagctg agaagagctt agacaatcag 4860
gaaagacttg agagcatctc catcctcaag catgtcttgt tcatggtctt gaatggccca 4920
tacactgagg agtacaagct ggaaatgatc atagaggcct tctctactct tgtgatacct 4980
cagccatcag aggtcatcag gaaatcaagg accatgactt tatgcctctt atcgaattac 5040
ttgtctagta ggggtgggtc cattctagac cagattgaga gggcacagtc aggcactcta 5100
gggggcttca gcaagcccca gaagacattc attaggccag gaggtggtat tggctacaag 5160
ggaaaaggtg tgtggactgg agtgatggag gacacccatg ttcaaatctt gatagatgga 5220
gatgggacta gtaactggct tgaggagatc aggctcagta gtgatgccag gctttatgat 5280
gtcattgaat ccatccgaag gttatgtgac gaccttggga tcaataacag ggtggcatct 5340
gcatatagag gtcattgcat ggttaggctg agtgggttca agatcaagcc agcatcaagg 5400
actgacggct gtccagtcag gattatggaa aggggcttca ggatcaggga acttcaaaac 5460
ccagatgagg tcaagatgag agtgaggggt gacatcctca acctttcagt caccatacaa 5520
gaaggaaggg tcatgaacat tctaagctac aggcctagag acactgatat atcagagtca 5580
gccgcagcat acctctggag caatcgagac ctcttctcct ttgggaagaa ggagccatcc 5640
tgcagctgga tctgcttgaa aactcttgac aattgggcct ggtcacatgc ctcagttctc 5700
ctggcaaatg ataggaagac ccaaggcatt gataatagag ccatggggaa cattttcagg 5760
gactgtctcg agggctctct tagaaagcag gggctgatga ggtcaaaact cacagagatg 5820
gtggagaaga atgttgttcc tttaacaact caagagcttg tcgacatctt ggaggaggac 5880
atagactttt cagatgtcat agctgtggag ctctcagagg gatcacttga cattgaatcc 5940
atctttgatg gggcacctat cttgtggtct gctgaggtgg aagagttcgg ggaaggagtg 6000
gtggctgtga gctattccag taagtactat catctaaccc tgatggatca ggctgccatc 6060
acaatgtgtg cgatcatggg taaggaaggc tgtagagggc tccttactga gaagagatgc 6120
atggcagcca tacgagagca ggtacggcca ttcctcatat tcctgcaaat tcctgaggac 6180
agcatttctt gggtatctga tcagttctgt gactccaggg gtcttgatga agagagcacc 6240
attatgtggg gttga 6255
<210> 6
<211> 3222
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 M基因
<400> 6
atgatgaaag tcatctggtt ctcctctctg atctgcttag tcattcaatg cagtggggac 60
acgggcccaa tcatatgcgc agggcccatc cactcaaaca agagtgccga cataccccac 120
ctgcttggtt actctgagaa gatttgtcag atagatcggc tgatacatgt ttcgtcatgg 180
ctgagaaacc attcacaatt tcagggctac gtggggcagc gaggtggacg ctctcaggtg 240
agttacttcc cagctgaaaa ctcttactca aggtggagtg ggcttctaag cccctgtgat 300
gctgattggc ttgggatgct tgtcgtgaag aaggccaagg ggtctgatat gatagttcct 360
gggccttcat acaagggaaa agtctttttt gaacggccaa cttttgatgg atatgttggc 420
tggggctgtg gcagtgggaa gtcaaggact gagtcaggag agctctgcag ctcagactca 480
gggaccagtt ccggtcttct gccctcaaat agggttctct ggataggtga tgttgcttgc 540
cagcctatga cacccatccc tgaagagaca tttctggagc tgaagagttt tagccagagt 600
gaatttccag atatatgcaa aattgatggc attgtgttca accagtgtga gagtgagagc 660
ctacctcagc cctttgatgt tgcttggatg gatgttggcc actctcataa aatcatcatg 720
agggagcaca agaccaaatg ggtacaagag agctcatcta aggattttgt gtgctacaag 780
gaagggactg ggccgtgttc tgaatcagaa gaaaagactt gcaagaccag tggatcatgt 840
aggggggaca tgcagttttg caaggtggca ggttgtgaac atggggaaga gacatctgag 900
gccaaatgca gatgctcact agtgcacaag cccggggaag ttgttgtgtc atatggaggg 960
atgcgtgtca gaccaaaatg ctatggtttc tccagaatga tggcaacact agaggtgaac 1020
ccaccagagc aaaggattgg ccaatgtact ggctgccatc tagaatgcat aaatgggggt 1080
gtgaggataa tcactctaac tagtgagctc aagtcagcta ctgtctgtgc ttcccacttt 1140
tgtagttctg ccacaagtgg caagaaaagc acggagattc aattccactc agggtcatta 1200
gttgggaaaa cagcaattca cgtcaaaggg gcattggtgg atggaactga attcacattt 1260
gaaggcagtt gcatgttccc agatggttgt gacgcagtgg actgcacatt ctgtcgtgag 1320
tttctaaaaa atcctcagtg ctaccctgca aagaaatggt tgttcatcat tattgtcatc 1380
ctccttggat atgcaggcct catgctactc accaatgtcc ttaaggcaat cggggtttgg 1440
gggtcatggg tcatagctcc agtgaagcta atgtttgcca tcataaagaa actgatgaga 1500
tctgtgagct gcttgatggg gaaattgatg gataggggaa ggcaagtgat ccatgaagaa 1560
ataggggaga atagagaggg caaccaagat gatgttagga tcgagatggc aaggcctaga 1620
agggtaaggc actggatgta ctcacctgtc atcctgacta ttctagcaat tgggcttgct 1680
gaggggtgcg atgagatggt ccatgcagat tctaaacttg tttcgtgcaa gcaagggagc 1740
ggaaatatga aggaatgtgt cacaactggg agggcgctcc ttcctgcggt gaacccaggg 1800
caagaggcat gtctgcactt cacagcacca gggagtccgg actcaaaatg tctcaaaatc 1860
aaagttaaga ggatcaacct gaaatgcaag aagtcatcat catatttcgt tcctgatgct 1920
cggtccaggt gtacatctgt gaggagatgc cgctgggcag gagactgtca gtctgggtgc 1980
ccctctcatt tcacgtccaa ctccttttct gacgattggg caggtaaaat ggacagggct 2040
ggtctaggat tcagtgggtg ctctgatgga tgtggaggag cagcctgcgg ctgctttaat 2100
gcggcccctt catgcatctt ctggaggaaa tgggtagaga atccacatgg gatcatctgg 2160
aaagtatctc catgtgctgc atgggtccca tcagcagtca tagagcttac aatgccctcg 2220
ggggaagtga ggacattcca ccccatgagc ggcatcccta ctcaagtctt caagggtgtg 2280
agtgtgactt atttgggctc agatatggag gtatctggct tgactgatct gtgtgaaata 2340
gaagagctca agtccaagaa gctggcatta gctccctgca atcaggctgg catgggggtt 2400
gtaggcaagg ttggagagat acagtgcagt agtgaggaaa gtgcccgtac cataaaaaaa 2460
gatgggtgta tatggaatgc tgacctcgtg ggcatcgagc tacgagtgga tgacgctgtg 2520
tgctactcta agatcactag tgtggaggca gttgcaaact actctgccat acccaccact 2580
attgggggac tgaggtttga gagaagccat gacagccagg gcaaaatatc tggtagcccc 2640
ttggacatca cagccataag agggtctttt tcagttaact atagaggcct tcgactgagc 2700
ctctcagaaa ttactgctac ttgcacaggg gaggtgacaa atgtgagtgg gtgttactct 2760
tgcatgacag gcgccaaagt ctccatcaaa ctgcatagca gcaaaaatag cactgcacat 2820
gtaaggtgca aaggggatga gactgcgttc agtgtcctgg agggagttca tagctatact 2880
gtcagcctca gttttgacca tgcagtggtc gatgagcagt gccagctgaa ctgtgggggg 2940
catgagagcc aagtgactct aaaaggcaac ctcatcttcc tggatgtccc aaaattcgta 3000
gatggcagct acatgcagac atatcatagc tctgtaccca caggagcaaa tatcccaagc 3060
ccaacagact ggctgaatgc cctgtttggc aatgggctga gtaggtggat tctgggggtg 3120
ataggggttc tactgggggg attagctctc tttttcctaa tcatgtcttt gttcaaactg 3180
ggaacaaaac aggtatttcg atcaaggacg aagctggctt ag 3222
<210> 7
<211> 738
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 NP基因
<400> 7
atgtcagagt ggtccaggat tgcagtggag tttggtgagc agcagctcaa tttgactgag 60
cttgaagatt ttgcgagaga gctggcctat gaaggccttg atcctgcatt gatcatcaag 120
aagctgaagg agacaggtgg agatgattgg gtgagggaca caaagttcat cattgtcttt 180
gccctgactc gaggcaacaa gatcgtcaag gcatcaggga aaatgtcaaa ctctgggtct 240
aagaggttga tggcactcca agagaaatat gggctggttg agagggcaga aaccaggctc 300
tcaatcactc ctgtgagggt tgcacagagc cttcccactt ggacatgtgc tgcagcagca 360
gccctaaagg agtatctccc agtggggcca gctgtcatga acctgaaggt cgaaaattat 420
ccccctgaga tgatgtgcat ggcctttggg tccctgattc caactgcagg ggtatctgaa 480
gccacaacga agaccctgat ggaggcctac tctctgtggc aagatgcctt caccaagact 540
atcaatgtaa agatgcgcgg agccagcaag acagaggttt acaactcttt cagggatcct 600
ctccatgctg ctgtgaactc tgtcttcttt cccaatgatg tccgggtgaa gtggctgaag 660
gccaagggaa tccttggccc agatggggtc cccagcagag ctgctgaggt tgctgccgct 720
gcttacagaa acctgtaa 738
<210> 8
<211> 882
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 NS基因
<400> 8
atgtcgctga gcaaatgctc caacgttgac ctcaaatctg ttgcaatgaa tgccaacact 60
gtcaggcttg agccatctct aggagagtac cccactctta ggagagacct cgttgaatgc 120
tcttgtagtg tgttgactct atcaatggtc aagaggatgg gcaagatgac caacacagta 180
tggctatttg gcaacccaaa gaatcctctt caccagcttg agcctggact cgagcagctg 240
ttagacatgt actacaagga catgaggtgc tactcccaga gagagctgag tgctcttagg 300
tggcctagtg ggaagccatc tgtatggttc ctacaggcag ctcacatgtt cttctccatc 360
aagaacagct gggcaatgga aaccggtaga gagaactggc ggggcctctt ccacaggata 420
acaaaaggcc aaaagtatct ttttgaaggg gacatgatat tggattctct tgaggccata 480
gagaagcgaa ggcttagact agggttacct gagatcctaa taactgggct atccccaatt 540
ctggatgtgg ccctcctcca gatagagtca cttgcaaggc taagaggaat gagcttgaac 600
caccacttat tcacttcttc ctcattgcgt aagcctctat tagactgttg ggacttcttt 660
attcccatcc gcaaaaagaa gacagatggc tcatacagtg tcctggatga ggatgatgag 720
cctgggatcc ttcaaggtta tccatatctg atggcacact atttgaatag gtgcccattc 780
cacaacctca tcaggtttga tgaagagctg agaactgcag ccctaaacac catctgggga 840
agagattggc cagccattgg tgacctcccg aaggaggtct aa 882
<210> 9
<211> 6255
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 L基因
<400> 9
atgaacttgg aagtgctttg tggtaggata aacgtggaga atgggctgtc tcttggagaa 60
ccaggcctgt acgaccaaat ctacgacagg ccagggctgc cagacctaga tgtgactgtc 120
gatgccatag gtgtgacagt ggacataggg gctgtgccag actcagcatc acaactgggt 180
tcatcaatca atgctgggtt gatcacaatc cagctctctg aagcatataa gatcaatcat 240
gatttcacgt tttctggcct gtcaaagaca acagaccgac gcctctcaga ggtattcccc 300
attacacatg atggttctga tgggatgacc cctgatgtga tccacaccag attggatgga 360
accattgtgg tggttgaatt ttcaactact aggagccata acattggggg tctggaggca 420
gcatacagga caaagataga aaaatatagg gaccctatct caaggcgtgt tgatatcatg 480
gagaacccga gggtcttctt tggcgtcatt gtggtctcgt cagggggagt tctgtccaac 540
atgcccctga ctcaggatga ggcagaggag ctcatgtaca ggttctgcat agccaatgag 600
atctacacta aggctaggtc tatggatgca gacattgagc tgcagaagag cgaagaagag 660
cttgaggcta ttagcagggc actatcattc ttcagtttgt ttgagccaaa cattgaaaga 720
gtggaaggaa cattccctaa ttcggaaatc gagatgctgg aacagtttct ctcaactcca 780
gctgatgttg acttcatcac caagaccctc aaagcaaaag aggtggaggc ctatgctgat 840
ctttgtgaca gccactatct aaagcctgaa aaaaccattc aggagcggct agagatcaat 900
agatgtgagg ctattgacaa gactcaggac ctcctagcta gcctgcatgc aaggagcaac 960
aagcaaacat cattgaatcg agggacagtc aagctcccgc cctggctacc aaagccatca 1020
agtgagtcaa tagacatcaa gactgactca ggctttggtt ccttaatgga tcatggcaca 1080
tatggagagc tgtgggcaaa gtgcctccta gatgtctcgc tgggcaatgt ggagggggta 1140
gtcagtgacc ctgcaaaaga acttgacatt gctatctctg atgatccaga aaaagatacc 1200
cccaaagagg caaagataac ctataggcgg ttcaagcctg ccttgagctc aagtgcccgt 1260
caagaatttt ctctccaagg agtggagggg aagaagtgga agagaatggc agcaaaccag 1320
aagaaagaga aggagtccca tgagacattg agccctttct tggatgttga agacattggg 1380
gatttcctaa cattcaacaa tcttctcgca gattcgaggt atggagatga gtccgtccag 1440
agagctgtgt caatcttgtt ggaaaaggca tctgccatgc aagacacaga gctcactcat 1500
gccctcaacg actcattcaa gaggaaccta agcagcaatg tggttcagtg gtccctttgg 1560
gtctcctgtc tagcacaaga gctagctagt gctctgaagc agcactgcag ggctggtgag 1620
ttcatcatca agaagctgaa gttctggcct atctatgtca ttatcaagcc gaccaaatcg 1680
tcatcccata tcttctacag cttagggatc cgcaaggctg atgtgacaag gaggctcact 1740
ggcagagtct tctctgacac cattgatgct ggggaatggg agctaacaga gttcaagagc 1800
ctgaagacat gcaagctcac caaccttgtc aacttgccat gcaccatgct gaactcaata 1860
gctttctgga gagagaagct gggcgtggct ccatggctgg ttcggaagcc ttgttcagag 1920
ctcagagagc aggtgggcct gaccttcttg atcagtttgg aggacaagtc taagactgag 1980
gagatcatca ccttgacaag gtacactcaa atggagggct tcgtctctcc tcctatgctg 2040
cctaagcccc aaaagatgct agggaaactg gatgggcctt tgagaactaa gctacaggta 2100
tacctcctca ggaagcatct ggattgcatg gtgcgaattg cttcccagcc attcagcctg 2160
atccctagag aggggagggt agaatgggga gggacattcc atgccatctc aggccggtcc 2220
acaaaccttg agaatatggt gaacagctgg tacattgggt actacaagaa caaagaggag 2280
tcaacagagc taaatgctct tggagaaatg tataagaaga ttgtggagat ggaagaggac 2340
aagcccagca gccctaagtt tctagggtgg ggggacactg attcccctaa gaagcatgaa 2400
ttctcacgga gcttcctcag agctgcttgc tcatctctgg agagagaaat tgctcagcga 2460
catggaagac aatggaagca gaaccttgag gagcgtgtcc tgagagagat tggaaccaag 2520
aacatcctag accttgcatc catgaaggct acaagcaact tttccaaaga ctgggagctc 2580
tactcagaag tccagaccaa agagtaccat aggtccaaat tgctggagaa gatggccaca 2640
ttgattgaga agggggttat gtggtacatt gatgctgtgg gccaggcttg gaaggcagtt 2700
ctagatgacg ggtgcatgcg aatctgtctc ttcaaaaaga atcagcatgg tggcctcaga 2760
gagatctacg ttatggatgc aaatgcccgg ctcgtgcagt ttggggttga gaccatggct 2820
aggtgtgtct gtgagctgag cccacatgag actgttgcca atcctaggct taagaattcc 2880
atcatagaga accatgggct gaagtcagcc cgtagccttg gccctggctc tataaacata 2940
aactcatcca atgatgccaa gaagtggaat caggggcact acacaacaaa gctagctcta 3000
gttctttgtt ggttcatgcc agccaaattc cacagattca tttgggctgc catttccatg 3060
tttcggagaa aaaagatgat ggtggaccta aggtttttag ctcacctcag ttctaaatct 3120
gagtccaggt catctgatcc atttagggaa gcaatgacag acgcattcca tggaaatagg 3180
gaagtctcat ggatggacaa ggggcgaact tacataaaga cagagacagg gatgatgcag 3240
ggcatactgc actttacatc cagcctcctc cactcttgtg ttcagagttt ttacaagtct 3300
tatttcgtct cgaagctcaa ggagggctac atgggggaaa gcatcagtgg ggtggtggat 3360
gtcatagaag gttctgacga ctcagcgatc atgatcagca tacgccctaa gtcagatatg 3420
gatgaagtcc gatcaaggtt ttttgttgct aacctgctcc actctgtcaa attcttgaac 3480
cctttgtttg ggatttactc atcagagaag tcaacagtga acacagtgta ttgtgtcgag 3540
tataactctg aattccattt ccacaggcac ttggttagac ccacactgag atggatagca 3600
gcgtctcacc aaatctcaga gactgaagcc cttgcaagca ggcaagagga ttactccaac 3660
cttctaaccc agtgcttgga aggaggggcc tcattctctc ttacctacct catacagtgc 3720
gctcagctcc tacaccacta catgcttcta ggactatgct tgcatccctt gtttggaacc 3780
ttcatgggga tgctgatatc agacccagat cctgccctag gattcttcct catggacaac 3840
cctgcattcg caggaggagc aggatttaga ttcaatctgt ggagagcctg caagaccaca 3900
gaccttgggc ggaagtatgc atattacttc aatgagatac agggtaaaac aaagggagat 3960
gaggactaca gagctctgga cgccacatcg ggaggaactc tcagccactc tgttatggtg 4020
tactgggggg acaggaagaa gtatcaggcc ttattgaaca ggatgggcct tcctgaagac 4080
tgggtggagc agatagatga gaatcctgga gtcctttaca ggagagctgc caacaagaag 4140
gaactactct taaaactggc agagaaggtt cattcacctg gtgtgactag cagcctgagt 4200
aaagggcatg tagtgcctcg ggtggtggca gcaggagtat accttctctc acgccactgc 4260
tttcgcttta gctcaagcat ccatggaagg ggctcagcac agaaggctag tctcataaaa 4320
ctgctgatga tgtcttctat ttctgccatg aaacacgggg gctcattaaa ccccaatcag 4380
gagcgaatgc tcttccctca ggctcaagag tatgatagag tatgcacatt gcttgaggaa 4440
gttgaacacc taacagggaa atttgttgtt agggagagaa acattgtcag gagccgcata 4500
gacttgttcc aagagccagt tgacttgcgg tgtaaggcag aagatctggt gtcagaggtg 4560
tggtttggcc tgaaaaggac taagcttgga ccccgtctcc tcaaggaaga gtgggacaaa 4620
cttagggcct catttgcatg gctgagcaca gacccatctg aaacattgag ggatggtcct 4680
tttcttagcc atgtgcagtt taggaacttc atagcccacg ttgatgccaa atcaagatca 4740
gtcaggctcc taggtgcccc cgtgaagaag tcaggtgggg taaccaccat aagccaagta 4800
gtcagaatga acttcttccc tggttttagc ctagaagctg agaagagctt agacaatcag 4860
gagagacttg agagcatctc catcctcaag catgtcttgt tcatggtctt gaatggccca 4920
tacactgagg agtacaagct ggacatgatc atagaggcct tctctactct tgtgatacct 4980
cagccatcag aggtcatcag gaaatcaagg accatgactt tatgcctctt atcgaattac 5040
ttgtctagta ggggtgggtc cattctagac cagattgaga gggcacagtc aggcactcta 5100
gggggattca gcaagcccca gaagacattc atcaggccag gaggtggtat tggctacaag 5160
ggaaaaggtg tgtggactgg agtgatggag gacacccatg ttcaaattct gatagatgga 5220
gatgggacta gcaactggct tgaggagatc aggctcagta gtgatgccag gctttatgat 5280
gtcattgaat ccatccggag gttatgtgat gaccttggga tcaacaacag ggtggcatcg 5340
gcatataggg gtcattgcat ggttagactg agtggattca agatcaagcc agcatcaagg 5400
actgacggct gtccagttag gattatggaa aggggcttca ggatcagaga gcttcaaaac 5460
ccagatgagg tcaagatgag agtgaggggt gacattctca acctctctgt taccatacaa 5520
gaaggaagag tcatgaacat tctgagctac aggccgagag acactgatat atcagagtca 5580
gcagcagcat acctatggag caatcgagac ctcttctcct ttgggaagaa ggagccatcc 5640
tgcagctgga tctgcttgaa aactcttgac aattgggcct ggtcacatgc ctcagttctc 5700
ctggcaaatg ataggaagac ccaaggcatt gataatagag ctatggggaa cattttcagg 5760
gactgtctcg agggttccct cagaaagcaa gggctgatga ggtcaaagct cactgagatg 5820
gtggagaaga atgtggttcc tttaacaact caagagcttg tcgatatcct ggaggaggat 5880
atagactttt cagatgtcat agctgtggag ctctcagagg gatcacttga cattgagtcc 5940
atctttgatg gagcacctat cttgtggtct gctgaggtgg aagagtttgg agaaggagtg 6000
gtagctgtga gctattccag taagtactat catctaaccc tgatggacca agctgccatc 6060
acaatgtgtg cgatcatggg taaggagggc tgtagagggc tcctcactga gaagagatgc 6120
atggcagcca tacgagagca ggtaaggcca ttcctcatat tcctgcaaat ccctgaggac 6180
agcatttctt gggtgtctga tcagttctgc gactccaggg gtcttgatga agagagcacc 6240
attatgtggg gttaa 6255
<210> 10
<211> 3222
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 M基因
<400> 10
atgatgaaag tcatctggtt ctcctctctg atctgcttag tcattcaatg cagtggggat 60
acgggcccaa tcatatgcgc tgggcccatc cactcaaaca agagcgccaa cataccccac 120
ctgcttggtt actctgagaa aatttgtcag atagatcggc ttatacatgt ttcgtcatgg 180
ctgagaaacc attcacaatt tcagggctac gtggggcagc gaggtggacg ctctcaggtg 240
agttactacc cagctgaaaa ctcttactca aggtggagtg gacttctaag cccctgtgat 300
gctgattggc ttgggatgct tgtcgtgaag aaggccaagg ggtctgatat gatagttcct 360
gggccttcat acaaagggaa agtcttcttt gaacggccaa cttttgatgg atatgtgggc 420
tggggctgtg gtagtgggaa gtcaaggaca gagtcaggtg agctctgcag ctcagactca 480
gggaccagtt ctggtctact gccctcaaat agggttctct ggataggtga tgttgcttgc 540
cagcctatga cacccatccc tgaggagaca tttctggagc tgaagagttt tagccagagt 600
gaattcccag acatatgcaa agttgatggc attgtgttca accagtgtga gagtgagagt 660
ctacctcagc cctttgatgt tgcatggatg gatgtaggcc actctcataa aatcatcatg 720
agggagcaca agaccaaatg ggtacaagag agctcatcta aggattttgt gtgctacaag 780
gaagggactg ggccgtgttc tgaatcagaa gaaaagactt gcaagaccag tggatcatgc 840
aggggggaca tgcagttttg caaggtagca ggttgtgaac atggggaaga ggcatctgaa 900
gccaaatgta gatgctcact agtgcacaag cccggggaag ttgttgtgtc atatggaggg 960
atgcgtgtca gaccaaagtg ttatggtttc tccagaatga tggcaacact agaggtgaac 1020
ccaccagagc aaagaattgg ccaatgcact ggctgccatc tagaatgcat aaatgggggt 1080
gtgaggctaa ttactctaac tagtgagctc aagtcagcta ctgtctgtgc ttcccacttt 1140
tgtagttctg ctacaagtgg caagaaaagc acggagattc aattccactc agggtcatta 1200
gttgggaaag cagcaattca cgtcaaaggg actttggtgg atggaactga attcacattt 1260
gagggcagtt gcatgttccc agatggttgt gacgcagtgg actgcacatt ctgtcgcgag 1320
ttcctaaaaa atcctcagtg ctaccctgca aagaaatggt tgttcataat tattgccatc 1380
ctccttggat atgcaggcct catgctgctc accaatgttc ttaaggcaat cggggtttgg 1440
ggatcatggg tcatagctcc agtgaagctg atgtttgcca tcataaagaa actgatgaga 1500
tctgtgagct gcttgatggg gaaattaatg gataggggaa ggcaagtgat tcatgaagaa 1560
ataggggaga atagagaggg caaccaagaa gatgttagaa ttgagattgc aagacccaga 1620
agggtgaggc attggatgta ctcacctgtc atcctggcta ttctagcaat tgggcttgct 1680
gagggctgcg atgagatggt ccatgcagat tcaaaacttg tttcgtgcag gcaagggagc 1740
ggaaatatga aggaatgtgt cacaactggg agggcgcttc ttcctgcggt gaacccagga 1800
caagaggcat gtctgcactt cacggcacct ggaagtccgg actcaaaatg tctcaagatc 1860
aaggttaaga ggatcaacct aaaatgtaag aagtcatcat catattttgt tcctgatgct 1920
cggtccagat gtacgtctgt gaggagatgt cgctgggcag gagactgtca gtctgggtgc 1980
ccctctcatt tcacgtccaa ctccttctct gatgattggg caggtaaaat ggacagggct 2040
ggtctaggat tcagtgggtg ctctgatgga tgtggaggag cagcctgcgg ctgctttaat 2100
gcggcccctt catgcatctt ttggaggaaa tgggtagaga atccacatgg gatcatctgg 2160
aaagtatctc catgtgctgc atgggtccct tcaacagtca tagagctaac aatgccctcg 2220
ggggaagtga ggacattcca ccccatgagc ggcatcccca cacaagtctt caagggtgtg 2280
agtgtgactt acttaggctc agatatggag gtgtctggcc tgactgacct gtgtgagata 2340
gaagagctca agtccaagaa gctggcatta gctccctgca atcaggctgg catgggagtt 2400
gtgggcaagg ttggagagat acagtgcagt agcgaggaaa gcgcccgttc cataaagaaa 2460
gatgggtgta tatggaatgc tgaccttgtg ggcatagagc tacgagtgga tgacgcagtg 2520
tgctattcta agatcactag tgtggaggca gttgcaaact actctgccat acccaccact 2580
attggggggt tgaggtttga gagaagccat gacagccagg gtaaaatatc tggtagcccc 2640
ctagacatta cagccataag agggtctttt tccgttaatt atagaggcct tcgactgagc 2700
ctctcagaaa tcactgctac ttgcacagga gaggtgacga atgtgagtgg gtgttactct 2760
tgcatgacag gcgccaaagt ctccatcaaa ctgcatagca gcaaaaatag cactgcccat 2820
gtaagatgca aaggggatga gaccgcattc agtgtcctgg agggagttca tagctatact 2880
gtcagtctta gctttgacca tgcagtggtc gatgagcagt gccagctgaa ctgtgggggg 2940
catgagagtc aagtgactct aaaaggcaac ctcatcttcc tggatgtccc aaaatttgta 3000
gatggcagct atatgcagac atatcatagt tctgtgccca caggggctaa tatcccaagc 3060
cctacagact ggctgaatgc cttgtttggc aatgggctga gtaggtggat tcttggggta 3120
ataggggttc tactgggggg attggctctc ttcttcttaa ttatgtcctt gttcaaactg 3180
ggaacaaaac agatattccg atcaaggacg aagctggctt ag 3222
<210> 11
<211> 738
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 NP基因
<400> 11
atgtcagagt ggtccaggat tgcagtggag tttggtgagc agcagctcaa tttgactgag 60
cttgaggatt tcgcgagaga gctagcctat gaaggccttg atcctgcctt gataatcaag 120
aagctgaagg agacaggtgg agatgattgg gtgagagata caaagttcat cattgtcttt 180
gccctgaccc gaggcaacaa gatcgtcaag gcatcaggga aaatgtcaaa ctcagggtct 240
aagaggttga tggcacttca agagaaatat ggactggttg agagggcaga aaccaggctc 300
tcaatcactc ctgtgagggt agcacagagc cttcccactt ggacgtgcgc tgcagcagca 360
gccttaaagg agtatctccc agtgggccca gctgtcatga acctgaaggt cgaaaattac 420
cccccagaga tgatgtgcat ggcctttggg tctctgattc caactgcagg ggtatcagaa 480
gccacaacga agaccctgat ggaggcctac tctctgtggc aagatgcctt caccaagact 540
attaatgtga agatgcgtgg agccagcaag acagaggttt acaactcctt cagagatccc 600
ctccatgctg ctgtgaactc tgtcttcttt cccaatgatg ttcgggtgaa gtggctgaag 660
gccaagggaa tcctaggccc agatggggtc cccagcagag ctgctgaggt tgctgctgct 720
gcttacagaa acctgtaa 738
<210> 12
<211> 882
<212> DNA
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 NS基因
<400> 12
atgtcgctga gcaaatgctc caacgttgac ctcaaatctg tagcaatgaa tgccaacact 60
gttaggcttg aaccatctct aggagagtac cccactctta ggaaagacct cgttgaatgc 120
tcttgtagtg tgttgactct atcaatggtc aagaggatgg gcaagatgac caacacagta 180
tggttatttg gcaacccaaa aaatcctctt caccagcttg agcctggact tgagcagctg 240
ttggatatgt actacaagga catgaggtgc tactcccaga gagagctgag tgccctcagg 300
tggcctagtg ggaagccttc tgtatggttc ctacaggcag ctcacatgtt cttttccatc 360
aagaacagct gggcaatgga aaccggtaga gagaactggc ggggcctctt ccacaggata 420
acaaaaggca aaaagtatct ttttgaaggg gacatgatat tggattctct tgaagccata 480
gagaagcgaa ggctcagact tgggttacct gagatcctaa taactggact atccccaatt 540
ctggatgtgg ccctcctcca gatagagtca cttgcaaggc taagaggcat gagcttgaac 600
caccacttat tcacttcttc ctcactgcgt aagcctctgt tagattgttg ggacttcttt 660
attcctatcc gcaaaaagaa gacagatggc tcatacagtg ttttggatga ggatgatgag 720
cctggggtcc ttcaaggtta cccatatctg atggcacact atctgaacag gtgcccattc 780
cacaacctca tcagatttga tgaagaactg agaactgcag ccctgaacac catctgggga 840
agagattggc cggccattgg tgacctcccg aaggaggtct aa 882
<210> 13
<211> 2085
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 L
<400> 13
Met Asp Leu Glu Val Leu Cys Gly Arg Ile Asn Val Glu Asn Gly Leu
1 5 10 15
Ser Leu Gly Glu Pro Gly Leu Tyr Asp Gln Ile Tyr Asp Arg Pro Gly
20 25 30
Leu Pro Asp Leu Asp Val Thr Val Asp Ala Thr Gly Val Thr Val Asp
35 40 45
Ile Gly Ala Val Pro Asp Ser Ala Ser Gln Leu Gly Ser Ser Ile Asn
50 55 60
Ala Gly Leu Ile Thr Ile Gln Leu Ser Glu Ala Tyr Lys Ile Asn His
65 70 75 80
Asp Phe Thr Phe Ser Gly Leu Ser Lys Thr Thr Asp Arg Arg Leu Ser
85 90 95
Glu Val Phe Pro Ile Thr His Asp Gly Ser Asp Gly Met Thr Pro Asp
100 105 110
Val Ile His Thr Arg Leu Asp Gly Thr Ile Val Val Val Glu Phe Ser
115 120 125
Thr Thr Arg Ser His Asn Ile Gly Gly Leu Glu Ala Ala Tyr Arg Thr
130 135 140
Lys Ile Glu Lys Tyr Arg Asp Pro Ile Ser Arg Arg Val Asp Ile Met
145 150 155 160
Glu Asn Pro Arg Val Phe Phe Gly Val Ile Val Val Ser Ser Gly Gly
165 170 175
Val Leu Ser Asn Met Pro Leu Thr Gln Asp Glu Ala Glu Glu Leu Met
180 185 190
Tyr Arg Phe Cys Ile Ala Asn Glu Ile Tyr Thr Lys Ala Arg Ser Met
195 200 205
Asp Ala Asp Ile Glu Leu Gln Lys Ser Glu Glu Glu Leu Glu Ala Ile
210 215 220
Ser Arg Ala Leu Ser Phe Phe Ser Leu Phe Glu Pro Asn Ile Glu Arg
225 230 235 240
Val Glu Gly Thr Phe Pro Asn Ser Glu Ile Glu Met Leu Glu Gln Phe
245 250 255
Leu Ser Thr Pro Ala Asp Val Asp Phe Ile Thr Lys Thr Leu Lys Ala
260 265 270
Lys Glu Val Glu Ala Tyr Ala Asp Leu Cys Asp Ser His Tyr Leu Lys
275 280 285
Pro Glu Lys Thr Ile Gln Glu Arg Leu Glu Ile Asn Arg Cys Glu Ala
290 295 300
Ile Asp Lys Thr Gln Asp Leu Leu Ala Gly Leu His Ala Arg Ser Asn
305 310 315 320
Lys Gln Thr Ser Leu Asn Arg Gly Thr Val Lys Leu Pro Pro Trp Leu
325 330 335
Pro Lys Pro Ser Ser Glu Ser Ile Asp Ile Lys Thr Asp Ser Gly Phe
340 345 350
Gly Ser Leu Met Asp His Gly Ala Tyr Gly Glu Leu Trp Ala Lys Cys
355 360 365
Leu Leu Asp Val Ser Leu Gly Asn Val Glu Gly Val Val Ser Asp Pro
370 375 380
Ala Lys Glu Leu Asp Ile Ala Ile Ser Asp Asp Pro Glu Lys Asp Thr
385 390 395 400
Pro Lys Glu Ala Lys Ile Thr Tyr Arg Arg Phe Lys Pro Ala Leu Ser
405 410 415
Ser Ser Ala Arg Gln Glu Phe Ser Leu Gln Gly Val Glu Gly Lys Lys
420 425 430
Trp Lys Arg Met Ala Ala Asn Gln Lys Lys Glu Lys Glu Ser His Glu
435 440 445
Thr Leu Ser Pro Phe Leu Asp Val Glu Asp Ile Gly Asp Phe Leu Thr
450 455 460
Phe Asn Asn Leu Leu Ala Asp Ser Arg Tyr Gly Asp Glu Ser Ile Gln
465 470 475 480
Arg Ala Val Ser Ile Leu Leu Glu Lys Ala Ser Ala Met Gln Asp Thr
485 490 495
Glu Leu Thr His Ala Leu Asn Asp Ser Phe Lys Arg Asn Leu Ser Ser
500 505 510
Asn Val Val Gln Trp Ser Leu Trp Val Ser Cys Leu Ala Gln Glu Leu
515 520 525
Ala Ser Ala Leu Lys Gln His Cys Arg Ala Gly Glu Phe Ile Ile Lys
530 535 540
Lys Leu Lys Phe Trp Pro Ile Tyr Val Ile Ile Lys Pro Thr Lys Ser
545 550 555 560
Ser Ser His Ile Phe Tyr Ser Leu Gly Ile Arg Lys Ala Asp Val Thr
565 570 575
Arg Arg Leu Thr Gly Arg Val Phe Ser Asp Thr Ile Asp Ala Gly Glu
580 585 590
Trp Glu Leu Thr Glu Phe Lys Ser Leu Lys Thr Cys Lys Leu Thr Asn
595 600 605
Leu Val Asn Leu Pro Cys Thr Met Leu Asn Ser Ile Ala Phe Trp Arg
610 615 620
Glu Lys Leu Gly Val Ala Pro Trp Leu Val Arg Lys Pro Cys Ser Glu
625 630 635 640
Leu Arg Glu Gln Val Gly Leu Thr Phe Leu Ile Ser Leu Glu Asp Lys
645 650 655
Ser Lys Thr Glu Glu Ile Ile Thr Leu Thr Arg Tyr Thr Gln Met Glu
660 665 670
Gly Phe Val Ser Pro Pro Met Leu Pro Lys Pro Gln Lys Met Leu Gly
675 680 685
Lys Leu Asp Gly Pro Leu Arg Thr Lys Leu Gln Val Tyr Leu Leu Arg
690 695 700
Lys His Leu Asp Cys Met Val Arg Ile Ala Ser Gln Pro Phe Ser Leu
705 710 715 720
Ile Pro Arg Glu Gly Arg Val Glu Trp Gly Gly Thr Phe His Ala Ile
725 730 735
Ser Gly Arg Ser Thr Asn Leu Glu Asn Met Val Asn Ser Trp Tyr Ile
740 745 750
Gly Tyr Tyr Lys Asn Lys Glu Glu Ser Thr Glu Leu Asn Ala Leu Gly
755 760 765
Glu Met Tyr Lys Lys Ile Val Glu Met Glu Glu Asp Lys Pro Ser Ser
770 775 780
Pro Glu Phe Leu Gly Trp Gly Asp Thr Asp Ser Pro Lys Lys His Glu
785 790 795 800
Phe Ser Arg Ser Phe Leu Arg Ala Ala Cys Ser Ser Leu Glu Arg Glu
805 810 815
Ile Ala Gln Arg His Gly Arg Gln Trp Lys Gln Asn Leu Glu Glu Arg
820 825 830
Val Leu Arg Glu Ile Gly Thr Lys Asn Ile Leu Asp Leu Ala Ser Met
835 840 845
Lys Ala Thr Ser Asn Phe Ser Lys Asp Trp Glu Leu Tyr Ser Glu Val
850 855 860
Gln Thr Lys Glu Tyr His Arg Ser Lys Leu Leu Glu Lys Met Ala Thr
865 870 875 880
Leu Ile Glu Lys Gly Val Met Trp Tyr Ile Asp Ala Val Gly Gln Ala
885 890 895
Trp Lys Ala Val Leu Asp Asp Gly Cys Met Arg Ile Cys Leu Phe Lys
900 905 910
Lys Asn Gln His Gly Gly Leu Arg Glu Ile Tyr Val Met Asp Ala Asn
915 920 925
Ala Arg Leu Val Gln Phe Gly Val Glu Thr Met Ala Arg Cys Val Cys
930 935 940
Glu Leu Ser Pro His Glu Thr Val Ala Asn Pro Arg Leu Lys Asn Ser
945 950 955 960
Ile Ile Glu Asn His Gly Leu Lys Ser Ala Arg Ser Leu Gly Pro Gly
965 970 975
Ser Ile Asn Ile Asn Ser Ser Asn Asp Ala Arg Lys Trp Asn Gln Gly
980 985 990
His Tyr Thr Thr Lys Leu Ala Leu Val Leu Cys Trp Phe Met Pro Ala
995 1000 1005
Lys Phe His Arg Phe Ile Trp Ala Ala Ile Ser Met Phe Arg Arg Lys
1010 1015 1020
Lys Met Met Val Asp Leu Arg Phe Leu Ala His Leu Ser Ser Lys Ser
1025 1030 1035 1040
Glu Ser Arg Ser Ser Asp Pro Phe Arg Glu Ala Met Thr Asp Ala Phe
1045 1050 1055
His Gly Asn Arg Glu Val Ser Trp Met Asp Lys Gly Arg Thr Tyr Ile
1060 1065 1070
Lys Thr Glu Thr Gly Met Met Gln Gly Ile Leu His Phe Thr Ser Ser
1075 1080 1085
Leu Leu His Ser Cys Val Gln Ser Phe Tyr Lys Ser Tyr Phe Val Ser
1090 1095 1100
Lys Leu Lys Glu Gly Tyr Met Gly Glu Ser Ile Asn Gly Val Val Asp
1105 1110 1115 1120
Val Ile Glu Gly Ser Asp Asp Ser Ala Ile Met Ile Ser Ile Arg Pro
1125 1130 1135
Lys Ser Asp Met Asp Glu Val Arg Ser Arg Phe Phe Val Ala Asn Leu
1140 1145 1150
Leu His Ser Val Lys Phe Leu Asn Pro Leu Phe Gly Ile Tyr Ser Ser
1155 1160 1165
Glu Lys Ser Thr Val Asn Thr Val Tyr Cys Val Glu Tyr Asn Ser Glu
1170 1175 1180
Phe His Phe His Arg His Leu Val Arg Pro Thr Leu Arg Trp Ile Ala
1185 1190 1195 1200
Ala Ser His Gln Ile Ser Glu Thr Glu Ala Leu Ala Ser Arg Gln Glu
1205 1210 1215
Asp Tyr Ser Asn Leu Leu Thr Gln Cys Leu Glu Gly Gly Ala Ser Phe
1220 1225 1230
Ser Leu Thr Tyr Leu Ile Gln Cys Ala Gln Leu Leu His His Tyr Met
1235 1240 1245
Leu Leu Gly Leu Cys Leu His Pro Leu Phe Gly Thr Phe Met Gly Met
1250 1255 1260
Leu Ile Ser Asp Pro Asp Pro Ala Leu Gly Phe Phe Leu Met Asp Asn
1265 1270 1275 1280
Pro Ala Phe Ala Gly Gly Ala Gly Phe Arg Phe Asn Leu Trp Arg Ala
1285 1290 1295
Cys Lys Thr Thr Asp Leu Gly Arg Lys Tyr Ala Tyr Tyr Phe Asn Glu
1300 1305 1310
Ile Gln Gly Lys Thr Lys Gly Asp Glu Asp Tyr Arg Ala Leu Asp Ala
1315 1320 1325
Thr Ser Gly Gly Thr Leu Ser His Ser Val Met Val Tyr Trp Gly Asp
1330 1335 1340
Arg Lys Lys Tyr Gln Ala Leu Leu Asn Arg Met Gly Leu Pro Glu Asp
1345 1350 1355 1360
Trp Val Glu Gln Ile Asp Glu Asn Pro Gly Val Leu Tyr Arg Arg Ala
1365 1370 1375
Ala Asn Lys Lys Glu Leu Leu Leu Lys Leu Ala Glu Lys Val His Ser
1380 1385 1390
Pro Gly Val Thr Ser Ser Leu Ser Lys Gly His Val Val Pro Arg Val
1395 1400 1405
Val Ala Ala Gly Val Tyr Leu Leu Ser Arg His Cys Phe Arg Phe Ser
1410 1415 1420
Ser Ser Ile His Gly Arg Gly Ser Ala Gln Lys Ala Ser Leu Ile Lys
1425 1430 1435 1440
Leu Leu Met Met Ser Ser Val Ser Ala Met Lys His Gly Gly Ser Leu
1445 1450 1455
Asn Pro Asn Gln Glu Arg Met Leu Phe Pro Gln Ala Gln Glu Tyr Asp
1460 1465 1470
Arg Val Cys Thr Leu Leu Glu Glu Val Glu His Leu Thr Gly Lys Phe
1475 1480 1485
Val Val Arg Glu Arg Asn Ile Val Arg Ser Arg Ile Asp Leu Phe Gln
1490 1495 1500
Glu Pro Val Asp Leu Arg Cys Lys Ala Glu Asp Leu Val Ser Glu Val
1505 1510 1515 1520
Trp Phe Gly Leu Lys Arg Thr Lys Leu Gly Pro Arg Leu Leu Lys Glu
1525 1530 1535
Glu Trp Asp Lys Leu Arg Ala Ser Phe Ala Trp Leu Ser Thr Asp Pro
1540 1545 1550
Ser Glu Thr Leu Arg Asp Gly Pro Phe Leu Ser His Val Gln Phe Arg
1555 1560 1565
Asn Phe Ile Ala His Val Asp Ala Lys Ser Arg Ser Val Arg Leu Leu
1570 1575 1580
Gly Ala Pro Val Lys Lys Ser Gly Gly Val Thr Thr Ile Ser Gln Val
1585 1590 1595 1600
Val Arg Met Asn Phe Phe Pro Gly Phe Ser Leu Glu Ala Glu Lys Ser
1605 1610 1615
Leu Asp Asn Gln Glu Arg Leu Glu Ser Ile Ser Ile Leu Lys His Val
1620 1625 1630
Leu Phe Met Val Leu Asn Gly Pro Tyr Thr Glu Glu Tyr Lys Leu Glu
1635 1640 1645
Met Ile Ile Glu Ala Phe Ser Thr Leu Val Ile Pro Gln Pro Ser Glu
1650 1655 1660
Val Ile Arg Lys Ser Arg Thr Met Thr Leu Cys Leu Leu Ser Asn Tyr
1665 1670 1675 1680
Leu Ser Ser Arg Gly Gly Ser Ile Leu Asp Gln Ile Glu Arg Ala Gln
1685 1690 1695
Ser Gly Thr Leu Gly Gly Phe Ser Lys Pro Gln Lys Thr Phe Ile Arg
1700 1705 1710
Pro Gly Gly Gly Ile Gly Tyr Lys Gly Lys Gly Val Trp Thr Gly Val
1715 1720 1725
Met Glu Asp Thr His Val Gln Ile Leu Ile Asp Gly Asp Gly Thr Ser
1730 1735 1740
Asn Trp Leu Glu Glu Ile Arg Leu Ser Ser Asp Ala Arg Leu Tyr Asp
1745 1750 1755 1760
Val Ile Glu Ser Ile Arg Arg Leu Cys Asp Asp Leu Gly Ile Asn Asn
1765 1770 1775
Arg Val Ala Ser Ala Tyr Arg Gly His Cys Met Val Arg Leu Ser Gly
1780 1785 1790
Phe Lys Ile Lys Pro Ala Ser Arg Thr Asp Gly Cys Pro Val Arg Ile
1795 1800 1805
Met Glu Arg Gly Phe Arg Ile Arg Glu Leu Gln Asn Pro Asp Glu Val
1810 1815 1820
Lys Met Arg Val Arg Gly Asp Ile Leu Asn Leu Ser Val Thr Ile Gln
1825 1830 1835 1840
Glu Gly Arg Val Met Asn Ile Leu Ser Tyr Arg Pro Arg Asp Thr Asp
1845 1850 1855
Ile Ser Glu Ser Ala Ala Ala Tyr Leu Trp Ser Asn Arg Asp Leu Phe
1860 1865 1870
Ser Phe Gly Lys Lys Glu Pro Ser Cys Ser Trp Ile Cys Leu Lys Thr
1875 1880 1885
Leu Asp Asn Trp Ala Trp Ser His Ala Ser Val Leu Leu Ala Asn Asp
1890 1895 1900
Arg Lys Thr Gln Gly Ile Asp Asn Lys Ala Met Gly Asn Ile Phe Arg
1905 1910 1915 1920
Asp Cys Leu Glu Gly Ser Leu Arg Lys Gln Gly Leu Met Arg Ser Lys
1925 1930 1935
Leu Thr Glu Met Val Glu Lys Asn Val Val Pro Leu Thr Thr Gln Glu
1940 1945 1950
Leu Val Asp Ile Leu Glu Glu Asp Ile Asp Phe Ser Asp Val Ile Ala
1955 1960 1965
Val Glu Leu Ser Glu Gly Ser Leu Asp Ile Glu Ser Ile Phe Asp Gly
1970 1975 1980
Ala Pro Ile Leu Trp Ser Ala Glu Val Glu Glu Phe Gly Glu Gly Val
1985 1990 1995 2000
Val Ala Val Ser Tyr Ser Ser Lys Tyr Tyr His Leu Thr Leu Met Asp
2005 2010 2015
Gln Ala Ala Ile Thr Met Cys Ala Ile Met Gly Lys Glu Gly Cys Arg
2020 2025 2030
Gly Leu Leu Thr Glu Lys Arg Cys Met Ala Ala Ile Arg Glu Gln Val
2035 2040 2045
Arg Pro Phe Leu Ile Phe Leu Gln Ile Pro Glu Asp Ser Ile Ser Trp
2050 2055 2060
Val Ser Asp Gln Phe Cys Asp Ser Arg Gly Leu Asp Glu Glu Ser Thr
2065 2070 2075 2080
Ile Met Trp Gly ***
2085
<210> 14
<211> 1074
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 M
<400> 14
Met Met Lys Val Ile Trp Phe Ser Ser Leu Ile Cys Leu Val Ile Gln
1 5 10 15
Cys Ser Gly Asp Thr Gly Pro Ile Ile Cys Ala Gly Pro Ile His Ser
20 25 30
Asn Lys Ser Ala Asn Ile Pro His Leu Leu Gly Tyr Ser Glu Lys Ile
35 40 45
Cys Gln Ile Asp Arg Leu Ile His Val Ser Ser Trp Leu Arg Asn His
50 55 60
Ser Gln Phe Gln Gly Tyr Val Gly Gln Arg Gly Gly Arg Ser Gln Val
65 70 75 80
Ser Tyr Tyr Pro Ala Glu Asn Ser Tyr Ser Arg Trp Ser Gly Leu Leu
85 90 95
Ser Pro Cys Asp Ala Asp Trp Leu Gly Met Leu Val Val Lys Lys Ala
100 105 110
Lys Gly Ser Asp Met Ile Val Pro Gly Pro Ser Tyr Lys Gly Lys Val
115 120 125
Phe Phe Glu Arg Pro Thr Phe Asp Gly Tyr Val Gly Trp Gly Cys Gly
130 135 140
Ser Gly Lys Ser Arg Thr Glu Ser Gly Glu Leu Cys Ser Ser Asp Ser
145 150 155 160
Gly Thr Ser Ser Gly Leu Leu Pro Ser Asp Arg Val Leu Trp Ile Gly
165 170 175
Asp Val Ala Cys Gln Pro Met Thr Pro Ile Pro Glu Glu Thr Phe Leu
180 185 190
Glu Leu Lys Ser Phe Ser Gln Ser Glu Phe Pro Asp Ile Cys Lys Ile
195 200 205
Asp Gly Ile Val Phe Asn Gln Cys Glu Ser Glu Ser Leu Pro Gln Pro
210 215 220
Leu Asp Val Ala Trp Met Asp Val Gly His Ser His Lys Ile Ile Met
225 230 235 240
Arg Glu His Lys Thr Lys Trp Val Gln Glu Ser Ser Ser Lys Asp Phe
245 250 255
Val Cys Tyr Lys Glu Gly Thr Gly Pro Cys Ser Glu Ser Glu Glu Lys
260 265 270
Thr Cys Lys Thr Ser Gly Ser Cys Arg Gly Asp Met Gln Phe Cys Lys
275 280 285
Val Ala Gly Cys Glu His Gly Glu Glu Ala Ser Asp Ala Lys Cys Arg
290 295 300
Cys Ser Leu Val His Lys Pro Gly Glu Val Val Val Ser Tyr Gly Gly
305 310 315 320
Met Arg Val Arg Pro Lys Cys Tyr Gly Phe Ser Arg Met Met Ala Thr
325 330 335
Leu Glu Val Asn Pro Pro Glu Gln Arg Ile Gly Gln Cys Thr Gly Cys
340 345 350
His Leu Glu Cys Ile Asn Gly Gly Val Arg Leu Ile Thr Leu Thr Ser
355 360 365
Glu Leu Lys Ser Ala Thr Val Cys Ala Ser His Phe Cys Ser Ser Ala
370 375 380
Thr Ser Gly Lys Lys Ser Thr Glu Ile Gln Phe His Ser Gly Ser Leu
385 390 395 400
Val Gly Lys Thr Thr Ile His Val Lys Gly Ala Leu Val Asp Gly Thr
405 410 415
Glu Phe Thr Phe Glu Gly Ser Cys Met Phe Pro Asp Gly Cys Asp Ala
420 425 430
Val Asp Cys Thr Phe Cys Arg Glu Phe Leu Lys Asn Pro Gln Cys Tyr
435 440 445
Pro Ala Lys Lys Trp Leu Phe Ile Ile Ile Val Ile Leu Leu Gly Tyr
450 455 460
Ala Gly Leu Met Leu Leu Thr Asn Val Leu Lys Ala Ile Gly Val Trp
465 470 475 480
Gly Ser Trp Val Ile Ala Pro Val Lys Leu Met Phe Ala Ile Ile Lys
485 490 495
Lys Leu Met Arg Ser Val Ser Cys Leu Met Gly Lys Leu Met Asp Arg
500 505 510
Gly Arg Gln Val Ile His Glu Glu Ile Gly Glu Asn Arg Glu Gly Asn
515 520 525
Gln Asp Asp Val Arg Ile Glu Met Ala Arg Pro Arg Arg Val Arg His
530 535 540
Trp Met Tyr Ser Pro Val Ile Leu Thr Ile Leu Ala Ile Gly Leu Ala
545 550 555 560
Glu Gly Cys Asp Glu Met Val His Ala Asp Ser Lys Leu Val Ser Cys
565 570 575
Lys Gln Gly Ser Gly Asn Met Lys Glu Cys Val Thr Thr Gly Arg Ala
580 585 590
Leu Leu Pro Ala Val Asn Pro Gly Gln Glu Ala Cys Leu His Phe Thr
595 600 605
Ala Pro Gly Ser Pro Asp Ser Lys Cys Leu Lys Ile Lys Val Lys Arg
610 615 620
Ile Asn Leu Lys Cys Lys Lys Ser Ser Ser Tyr Phe Val Pro Asp Ala
625 630 635 640
Arg Ser Arg Cys Thr Ser Val Arg Arg Cys Arg Trp Ala Gly Asp Cys
645 650 655
Gln Ser Gly Cys Pro Ser His Phe Thr Ser Asn Ser Phe Ser Asp Asp
660 665 670
Trp Ala Gly Lys Met Asp Arg Ala Gly Leu Gly Phe Ser Gly Cys Ser
675 680 685
Asp Gly Cys Gly Gly Ala Ala Cys Gly Cys Phe Asn Ala Ala Pro Ser
690 695 700
Cys Ile Phe Trp Arg Lys Trp Val Glu Asn Pro His Gly Ile Ile Trp
705 710 715 720
Lys Val Ser Pro Cys Ala Ala Trp Val Pro Ser Ala Val Ile Glu Leu
725 730 735
Thr Met Pro Ser Gly Glu Val Arg Thr Phe His Pro Met Ser Gly Ile
740 745 750
Pro Thr Gln Val Phe Lys Gly Val Ser Val Thr Tyr Leu Gly Ser Asp
755 760 765
Met Glu Val Ser Gly Leu Thr Asp Leu Cys Glu Ile Glu Glu Leu Lys
770 775 780
Ser Lys Lys Leu Ala Leu Ala Pro Cys Asn Gln Ala Gly Met Gly Val
785 790 795 800
Val Gly Lys Val Gly Glu Ile Gln Cys Ser Ser Glu Glu Ser Ala Arg
805 810 815
Thr Ile Lys Lys Asp Gly Cys Ile Trp Asn Ala Asp Leu Val Gly Ile
820 825 830
Glu Leu Arg Val Asp Asp Ala Val Cys Tyr Ser Lys Ile Thr Ser Val
835 840 845
Glu Ala Val Ala Asn Tyr Ser Ala Ile Pro Thr Thr Ile Gly Gly Leu
850 855 860
Arg Phe Glu Arg Ser His Asp Ser Gln Gly Lys Ile Ser Gly Ser Pro
865 870 875 880
Leu Asp Ile Thr Ala Ile Arg Gly Ser Phe Ser Val Asn Tyr Arg Gly
885 890 895
Leu Arg Leu Ser Leu Ser Glu Val Thr Ala Thr Cys Thr Gly Glu Val
900 905 910
Thr Asn Val Ser Gly Cys Tyr Ser Cys Met Thr Gly Ala Lys Val Ser
915 920 925
Ile Lys Leu His Ser Ser Lys Asn Ser Thr Ala His Val Arg Cys Lys
930 935 940
Gly Asp Glu Thr Ala Phe Ser Val Leu Val Gly Val His Ser Tyr Thr
945 950 955 960
Val Ser Leu Ser Phe Asp His Ala Val Val Asp Glu Gln Cys Gln Leu
965 970 975
Asn Cys Gly Gly His Glu Ser Gln Val Thr Leu Lys Gly Asn Leu Ile
980 985 990
Phe Leu Asp Val Pro Lys Phe Val Asp Gly Ser Tyr Met Gln Thr Tyr
995 1000 1005
His Ser Ser Val Pro Thr Gly Ala Asn Ile Pro Ser Pro Thr Asp Trp
1010 1015 1020
Leu Asn Ala Leu Phe Gly Asn Gly Leu Ser Arg Trp Ile Leu Gly Val
1025 1030 1035 1040
Ile Gly Val Leu Leu Gly Gly Leu Ala Leu Phe Phe Leu Ile Met Ser
1045 1050 1055
Leu Phe Lys Leu Gly Thr Lys Gln Val Phe Arg Ser Arg Thr Lys Leu
1060 1065 1070
Ala ***
<210> 15
<211> 1074
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 NP
<400> 15
Met Met Lys Val Ile Trp Phe Ser Ser Leu Ile Cys Leu Val Ile Gln
1 5 10 15
Cys Ser Gly Asp Thr Gly Pro Ile Ile Cys Ala Gly Pro Ile His Ser
20 25 30
Asn Lys Ser Ala Asn Ile Pro His Leu Leu Gly Tyr Ser Glu Lys Ile
35 40 45
Cys Gln Ile Asp Arg Leu Ile His Val Ser Ser Trp Leu Arg Asn His
50 55 60
Ser Gln Phe Gln Gly Tyr Val Gly Gln Arg Gly Gly Arg Ser Gln Val
65 70 75 80
Ser Tyr Tyr Pro Ala Glu Asn Ser Tyr Ser Arg Trp Ser Gly Leu Leu
85 90 95
Ser Pro Cys Asp Ala Asp Trp Leu Gly Met Leu Val Val Lys Lys Ala
100 105 110
Lys Gly Ser Asp Met Ile Val Pro Gly Pro Ser Tyr Lys Gly Lys Val
115 120 125
Phe Phe Glu Arg Pro Thr Phe Asp Gly Tyr Val Gly Trp Gly Cys Gly
130 135 140
Ser Gly Lys Ser Arg Thr Glu Ser Gly Glu Leu Cys Ser Ser Asp Ser
145 150 155 160
Gly Thr Ser Ser Gly Leu Leu Pro Ser Asp Arg Val Leu Trp Ile Gly
165 170 175
Asp Val Ala Cys Gln Pro Met Thr Pro Ile Pro Glu Glu Thr Phe Leu
180 185 190
Glu Leu Lys Ser Phe Ser Gln Ser Glu Phe Pro Asp Ile Cys Lys Ile
195 200 205
Asp Gly Ile Val Phe Asn Gln Cys Glu Ser Glu Ser Leu Pro Gln Pro
210 215 220
Leu Asp Val Ala Trp Met Asp Val Gly His Ser His Lys Ile Ile Met
225 230 235 240
Arg Glu His Lys Thr Lys Trp Val Gln Glu Ser Ser Ser Lys Asp Phe
245 250 255
Val Cys Tyr Lys Glu Gly Thr Gly Pro Cys Ser Glu Ser Glu Glu Lys
260 265 270
Thr Cys Lys Thr Ser Gly Ser Cys Arg Gly Asp Met Gln Phe Cys Lys
275 280 285
Val Ala Gly Cys Glu His Gly Glu Glu Ala Ser Asp Ala Lys Cys Arg
290 295 300
Cys Ser Leu Val His Lys Pro Gly Glu Val Val Val Ser Tyr Gly Gly
305 310 315 320
Met Arg Val Arg Pro Lys Cys Tyr Gly Phe Ser Arg Met Met Ala Thr
325 330 335
Leu Glu Val Asn Pro Pro Glu Gln Arg Ile Gly Gln Cys Thr Gly Cys
340 345 350
His Leu Glu Cys Ile Asn Gly Gly Val Arg Leu Ile Thr Leu Thr Ser
355 360 365
Glu Leu Lys Ser Ala Thr Val Cys Ala Ser His Phe Cys Ser Ser Ala
370 375 380
Thr Ser Gly Lys Lys Ser Thr Glu Ile Gln Phe His Ser Gly Ser Leu
385 390 395 400
Val Gly Lys Thr Thr Ile His Val Lys Gly Ala Leu Val Asp Gly Thr
405 410 415
Glu Phe Thr Phe Glu Gly Ser Cys Met Phe Pro Asp Gly Cys Asp Ala
420 425 430
Val Asp Cys Thr Phe Cys Arg Glu Phe Leu Lys Asn Pro Gln Cys Tyr
435 440 445
Pro Ala Lys Lys Trp Leu Phe Ile Ile Ile Val Ile Leu Leu Gly Tyr
450 455 460
Ala Gly Leu Met Leu Leu Thr Asn Val Leu Lys Ala Ile Gly Val Trp
465 470 475 480
Gly Ser Trp Val Ile Ala Pro Val Lys Leu Met Phe Ala Ile Ile Lys
485 490 495
Lys Leu Met Arg Ser Val Ser Cys Leu Met Gly Lys Leu Met Asp Arg
500 505 510
Gly Arg Gln Val Ile His Glu Glu Ile Gly Glu Asn Arg Glu Gly Asn
515 520 525
Gln Asp Asp Val Arg Ile Glu Met Ala Arg Pro Arg Arg Val Arg His
530 535 540
Trp Met Tyr Ser Pro Val Ile Leu Thr Ile Leu Ala Ile Gly Leu Ala
545 550 555 560
Glu Gly Cys Asp Glu Met Val His Ala Asp Ser Lys Leu Val Ser Cys
565 570 575
Lys Gln Gly Ser Gly Asn Met Lys Glu Cys Val Thr Thr Gly Arg Ala
580 585 590
Leu Leu Pro Ala Val Asn Pro Gly Gln Glu Ala Cys Leu His Phe Thr
595 600 605
Ala Pro Gly Ser Pro Asp Ser Lys Cys Leu Lys Ile Lys Val Lys Arg
610 615 620
Ile Asn Leu Lys Cys Lys Lys Ser Ser Ser Tyr Phe Val Pro Asp Ala
625 630 635 640
Arg Ser Arg Cys Thr Ser Val Arg Arg Cys Arg Trp Ala Gly Asp Cys
645 650 655
Gln Ser Gly Cys Pro Ser His Phe Thr Ser Asn Ser Phe Ser Asp Asp
660 665 670
Trp Ala Gly Lys Met Asp Arg Ala Gly Leu Gly Phe Ser Gly Cys Ser
675 680 685
Asp Gly Cys Gly Gly Ala Ala Cys Gly Cys Phe Asn Ala Ala Pro Ser
690 695 700
Cys Ile Phe Trp Arg Lys Trp Val Glu Asn Pro His Gly Ile Ile Trp
705 710 715 720
Lys Val Ser Pro Cys Ala Ala Trp Val Pro Ser Ala Val Ile Glu Leu
725 730 735
Thr Met Pro Ser Gly Glu Val Arg Thr Phe His Pro Met Ser Gly Ile
740 745 750
Pro Thr Gln Val Phe Lys Gly Val Ser Val Thr Tyr Leu Gly Ser Asp
755 760 765
Met Glu Val Ser Gly Leu Thr Asp Leu Cys Glu Ile Glu Glu Leu Lys
770 775 780
Ser Lys Lys Leu Ala Leu Ala Pro Cys Asn Gln Ala Gly Met Gly Val
785 790 795 800
Val Gly Lys Val Gly Glu Ile Gln Cys Ser Ser Glu Glu Ser Ala Arg
805 810 815
Thr Ile Lys Lys Asp Gly Cys Ile Trp Asn Ala Asp Leu Val Gly Ile
820 825 830
Glu Leu Arg Val Asp Asp Ala Val Cys Tyr Ser Lys Ile Thr Ser Val
835 840 845
Glu Ala Val Ala Asn Tyr Ser Ala Ile Pro Thr Thr Ile Gly Gly Leu
850 855 860
Arg Phe Glu Arg Ser His Asp Ser Gln Gly Lys Ile Ser Gly Ser Pro
865 870 875 880
Leu Asp Ile Thr Ala Ile Arg Gly Ser Phe Ser Val Asn Tyr Arg Gly
885 890 895
Leu Arg Leu Ser Leu Ser Glu Val Thr Ala Thr Cys Thr Gly Glu Val
900 905 910
Thr Asn Val Ser Gly Cys Tyr Ser Cys Met Thr Gly Ala Lys Val Ser
915 920 925
Ile Lys Leu His Ser Ser Lys Asn Ser Thr Ala His Val Arg Cys Lys
930 935 940
Gly Asp Glu Thr Ala Phe Ser Val Leu Val Gly Val His Ser Tyr Thr
945 950 955 960
Val Ser Leu Ser Phe Asp His Ala Val Val Asp Glu Gln Cys Gln Leu
965 970 975
Asn Cys Gly Gly His Glu Ser Gln Val Thr Leu Lys Gly Asn Leu Ile
980 985 990
Phe Leu Asp Val Pro Lys Phe Val Asp Gly Ser Tyr Met Gln Thr Tyr
995 1000 1005
His Ser Ser Val Pro Thr Gly Ala Asn Ile Pro Ser Pro Thr Asp Trp
1010 1015 1020
Leu Asn Ala Leu Phe Gly Asn Gly Leu Ser Arg Trp Ile Leu Gly Val
1025 1030 1035 1040
Ile Gly Val Leu Leu Gly Gly Leu Ala Leu Phe Phe Leu Ile Met Ser
1045 1050 1055
Leu Phe Lys Leu Gly Thr Lys Gln Val Phe Arg Ser Arg Thr Lys Leu
1060 1065 1070
Ala ***
<210> 16
<211> 294
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-1 NS
<400> 16
Met Ser Leu Ser Lys Cys Ser Asn Val Asp Leu Lys Ser Val Ala Met
1 5 10 15
Asn Ala Asn Thr Val Arg Leu Glu Pro Ser Leu Gly Glu Tyr Pro Thr
20 25 30
Leu Arg Arg Asp Leu Val Glu Cys Ser Cys Ser Val Leu Thr Leu Ser
35 40 45
Met Val Lys Arg Met Gly Lys Met Thr Asn Thr Val Trp Leu Phe Gly
50 55 60
Asn Pro Lys Asn Pro Leu His Gln Leu Glu Pro Gly Leu Glu Gln Leu
65 70 75 80
Leu Asp Met Tyr Tyr Lys Asp Met Arg Cys Tyr Ser Gln Arg Glu Leu
85 90 95
Ser Ala Leu Arg Trp Pro Ser Gly Lys Pro Ser Val Trp Phe Leu Gln
100 105 110
Ala Ala His Met Phe Phe Ser Ile Lys Asn Ser Trp Ala Met Glu Thr
115 120 125
Gly Arg Glu Asn Trp Arg Gly Leu Phe His Arg Ile Thr Lys Gly Lys
130 135 140
Lys Tyr Leu Phe Glu Gly Asp Met Ile Leu Asp Ser Leu Glu Ala Ile
145 150 155 160
Glu Lys Arg Arg Leu Arg Leu Gly Leu Pro Glu Ile Leu Ile Thr Gly
165 170 175
Leu Ser Pro Ile Leu Asp Val Ala Leu Leu Gln Ile Glu Ser Leu Ala
180 185 190
Arg Leu Arg Gly Met Ser Leu Asn His His Leu Phe Thr Ser Ser Ser
195 200 205
Leu Arg Lys Pro Leu Leu Asp Cys Trp Asp Phe Phe Ile Pro Ile Arg
210 215 220
Lys Lys Arg Thr Asp Gly Ser Tyr Ser Ile Leu Asp Glu Asp Asp Glu
225 230 235 240
Leu Gly Val Leu Gln Gly Tyr Pro Tyr Leu Met Ala His Tyr Leu Asn
245 250 255
Arg Cys Pro Phe His Asn Leu Ile Arg Phe Asp Glu Glu Leu Arg Thr
260 265 270
Ala Ala Leu Asn Thr Ile Trp Gly Arg Asp Trp Pro Ala Ile Gly Asp
275 280 285
Leu Pro Lys Glu Val ***
290
<210> 17
<211> 2085
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 L
<400> 17
Met Asn Leu Glu Val Leu Cys Gly Arg Ile Asn Val Glu Asn Gly Leu
1 5 10 15
Ser Leu Gly Glu Pro Gly Leu Tyr Asp Gln Ile Tyr Asp Arg Pro Gly
20 25 30
Leu Pro Asp Leu Asp Val Thr Val Asp Ala Thr Gly Val Thr Val Asp
35 40 45
Ile Gly Ala Val Pro Asp Ser Ala Ser Gln Leu Gly Ser Ser Ile Asn
50 55 60
Ala Gly Leu Ile Thr Ile Gln Leu Ser Glu Ala Tyr Lys Ile Asn His
65 70 75 80
Asp Phe Thr Phe Ser Gly Leu Ser Lys Thr Thr Asp Arg Arg Leu Ser
85 90 95
Glu Val Phe Pro Ile Thr His Asp Gly Ser Asp Gly Met Thr Pro Asp
100 105 110
Val Ile His Thr Arg Leu Asp Gly Thr Ile Val Val Val Glu Phe Ser
115 120 125
Thr Thr Arg Ser His Asn Ile Gly Gly Leu Glu Thr Ala Tyr Arg Thr
130 135 140
Lys Ile Glu Lys Tyr Arg Asp Pro Ile Ser Arg Arg Val Asp Ile Met
145 150 155 160
Glu Asn Pro Arg Val Phe Phe Gly Val Ile Val Val Ser Ser Gly Gly
165 170 175
Val Leu Ser Asn Met Pro Leu Thr Gln Asp Glu Ala Glu Glu Leu Met
180 185 190
Tyr Arg Phe Cys Ile Ala Asn Glu Ile Tyr Thr Lys Ala Arg Ser Met
195 200 205
Asp Ala Asp Ile Glu Leu Gln Lys Ser Glu Glu Glu Leu Glu Ala Ile
210 215 220
Ser Arg Ala Leu Ser Phe Phe Ser Leu Phe Glu Pro Asn Ile Glu Lys
225 230 235 240
Val Glu Gly Thr Phe Pro Asn Ser Glu Ile Glu Met Leu Glu Gln Phe
245 250 255
Leu Ser Thr Pro Ala Asp Val Asp Phe Ile Thr Lys Thr Leu Lys Ala
260 265 270
Lys Glu Val Glu Ala Tyr Ala Asp Leu Cys Asp Ser His Tyr Leu Lys
275 280 285
Pro Glu Lys Thr Ile Gln Glu Arg Leu Glu Ile Asn Arg Cys Glu Ala
290 295 300
Ile Asp Lys Thr Gln Asp Leu Leu Ala Ser Leu His Ala Arg Ser Asn
305 310 315 320
Lys Gln Thr Ser Leu Asn Arg Gly Thr Val Lys Leu Pro Pro Trp Leu
325 330 335
Pro Lys Pro Ser Ser Glu Ser Ile Asp Ile Lys Thr Asp Ser Gly Phe
340 345 350
Gly Ser Leu Met Asp His Gly Ala Tyr Gly Glu Leu Trp Ala Lys Cys
355 360 365
Leu Leu Asp Val Ser Leu Gly Asn Val Glu Gly Val Ile Ser Asp Pro
370 375 380
Ala Lys Glu Leu Asp Ile Ala Ile Ser Asp Asp Pro Glu Lys Asp Thr
385 390 395 400
Pro Lys Glu Ala Lys Ile Thr Tyr Arg Arg Phe Lys Pro Ala Leu Ser
405 410 415
Ser Ser Ala Arg Gln Glu Phe Ser Leu Gln Gly Val Glu Gly Lys Lys
420 425 430
Trp Lys Arg Met Ala Ala Asn Gln Lys Lys Glu Lys Glu Ser His Glu
435 440 445
Ala Leu Ser Pro Phe Leu Asp Val Glu Asp Ile Gly Asp Phe Leu Thr
450 455 460
Phe Asn Asn Leu Leu Ala Asp Ser Arg Tyr Gly Asp Glu Ser Val Gln
465 470 475 480
Arg Ala Val Ser Ile Leu Leu Glu Lys Ala Ser Ala Met Gln Asn Thr
485 490 495
Glu Leu Thr His Ala Leu Asn Asp Ser Phe Lys Arg Asn Leu Ser Ser
500 505 510
Asn Val Val Gln Trp Ser Leu Trp Val Ser Cys Leu Ala Gln Glu Leu
515 520 525
Ala Ser Ala Leu Lys Gln His Cys Arg Ala Gly Glu Phe Ile Ile Lys
530 535 540
Lys Leu Lys Phe Trp Pro Ile Tyr Val Ile Ile Lys Pro Thr Lys Ser
545 550 555 560
Ser Ser His Ile Phe Tyr Ser Leu Gly Ile Arg Lys Ala Asp Val Thr
565 570 575
Arg Arg Leu Thr Gly Arg Val Phe Ser Asp Thr Ile Asp Ala Gly Glu
580 585 590
Trp Glu Leu Thr Glu Phe Lys Ser Leu Lys Thr Cys Lys Leu Thr Asn
595 600 605
Leu Val Asn Leu Pro Cys Thr Met Leu Asn Ser Ile Ala Phe Trp Arg
610 615 620
Glu Lys Leu Gly Val Ala Pro Trp Leu Val Arg Lys Pro Cys Ser Glu
625 630 635 640
Leu Arg Glu Gln Val Gly Leu Thr Phe Leu Ile Ser Leu Glu Asp Lys
645 650 655
Ser Lys Thr Glu Glu Ile Ile Thr Leu Thr Arg Tyr Thr Gln Met Glu
660 665 670
Gly Phe Val Ser Pro Pro Met Leu Pro Lys Pro Gln Lys Met Leu Gly
675 680 685
Lys Leu Asp Gly Pro Leu Arg Thr Lys Leu Gln Val Tyr Leu Leu Arg
690 695 700
Lys His Leu Asp Cys Met Val Arg Ile Ala Ser Gln Pro Phe Ser Leu
705 710 715 720
Ile Pro Arg Glu Gly Arg Val Glu Trp Gly Gly Thr Phe His Ala Ile
725 730 735
Ser Gly Arg Ser Thr Asn Leu Glu Asn Met Val Asn Ser Trp Tyr Ile
740 745 750
Gly Tyr Tyr Lys Asn Lys Glu Glu Ser Thr Glu Leu Asn Ala Leu Gly
755 760 765
Glu Met Tyr Lys Lys Ile Val Glu Met Glu Glu Asp Lys Pro Ser Ser
770 775 780
Pro Glu Phe Leu Gly Trp Gly Asp Thr Asp Ser Pro Lys Lys His Glu
785 790 795 800
Phe Ser Arg Ser Phe Leu Arg Ala Ala Cys Ser Ser Leu Glu Arg Glu
805 810 815
Ile Ala Gln Arg His Gly Arg Gln Trp Lys Gln Asn Leu Glu Glu Arg
820 825 830
Val Leu Arg Glu Ile Gly Thr Lys Asn Ile Leu Asp Leu Ala Ser Met
835 840 845
Lys Ala Thr Ser Asn Phe Ser Lys Asp Trp Glu Leu Tyr Ser Glu Val
850 855 860
Gln Thr Lys Glu Tyr His Arg Ser Lys Leu Leu Glu Lys Met Ala Thr
865 870 875 880
Leu Ile Glu Lys Gly Val Met Trp Tyr Ile Asp Ala Val Gly Gln Ala
885 890 895
Trp Lys Ala Val Leu Asp Asp Gly Cys Met Arg Ile Cys Leu Phe Lys
900 905 910
Lys Asn Gln His Gly Gly Leu Arg Glu Ile Tyr Val Met Asp Ala Asn
915 920 925
Ala Arg Leu Val Gln Phe Gly Val Glu Thr Met Ala Arg Cys Val Cys
930 935 940
Glu Leu Ser Pro His Glu Thr Val Ala Asn Pro Arg Leu Lys Asn Ser
945 950 955 960
Ile Ile Glu Asn His Gly Leu Lys Ser Ala Arg Ser Leu Gly Pro Gly
965 970 975
Ser Ile Asn Ile Asn Ser Ser Asn Asp Ala Lys Lys Trp Asn Gln Gly
980 985 990
His Tyr Thr Thr Lys Leu Ala Leu Val Leu Cys Trp Phe Met Pro Ala
995 1000 1005
Lys Phe His Arg Phe Ile Trp Ala Ala Ile Ser Met Phe Arg Arg Lys
1010 1015 1020
Lys Met Met Val Asp Leu Arg Phe Leu Ala His Leu Ser Ser Lys Ser
1025 1030 1035 1040
Glu Ser Arg Ser Ser Asp Pro Phe Arg Glu Ala Met Thr Asp Ala Phe
1045 1050 1055
His Gly Asn Arg Glu Val Ser Trp Met Asp Lys Gly Arg Thr Tyr Ile
1060 1065 1070
Lys Thr Glu Thr Gly Met Met Gln Gly Ile Leu His Phe Thr Ser Ser
1075 1080 1085
Leu Leu His Ser Cys Val Gln Ser Phe Tyr Lys Ser Tyr Phe Val Ser
1090 1095 1100
Lys Leu Lys Glu Gly Tyr Met Gly Glu Ser Ile Asn Gly Val Val Asp
1105 1110 1115 1120
Val Ile Glu Gly Ser Asp Asp Ser Ala Ile Met Ile Ser Ile Arg Pro
1125 1130 1135
Lys Ser Asp Met Asp Glu Val Arg Ser Arg Phe Phe Val Ala Asn Leu
1140 1145 1150
Leu His Ser Val Lys Phe Leu Asn Pro Leu Phe Gly Ile Tyr Ser Ser
1155 1160 1165
Glu Lys Ser Thr Val Asn Thr Val Tyr Cys Val Glu Tyr Asn Ser Glu
1170 1175 1180
Phe His Phe His Arg His Leu Val Arg Pro Thr Leu Arg Trp Ile Ala
1185 1190 1195 1200
Ala Ser His Gln Ile Ser Glu Thr Glu Ala Leu Ala Ser Arg Gln Glu
1205 1210 1215
Asp Tyr Ser Asn Leu Leu Thr Gln Cys Leu Glu Gly Gly Ala Ser Phe
1220 1225 1230
Ser Leu Thr Tyr Leu Ile Gln Cys Ala Gln Leu Leu His His Tyr Met
1235 1240 1245
Leu Leu Gly Leu Cys Leu His Pro Leu Phe Gly Thr Phe Met Gly Met
1250 1255 1260
Leu Ile Ser Asp Pro Asp Pro Ala Leu Gly Phe Phe Leu Met Asp Asn
1265 1270 1275 1280
Pro Ala Phe Ala Gly Gly Ala Gly Phe Arg Phe Asn Leu Trp Arg Ala
1285 1290 1295
Cys Lys Thr Thr Asp Leu Gly Arg Lys Tyr Ala Tyr Tyr Phe Asn Glu
1300 1305 1310
Ile Gln Gly Lys Thr Lys Gly Asp Glu Asp Tyr Arg Ala Leu Asp Ala
1315 1320 1325
Thr Ser Gly Gly Thr Leu Ser His Ser Val Met Val Tyr Trp Gly Asp
1330 1335 1340
Arg Lys Lys Tyr Gln Ala Leu Leu Asn Arg Met Gly Leu Pro Glu Asp
1345 1350 1355 1360
Trp Val Glu Gln Ile Asp Glu Asn Pro Gly Val Leu Tyr Arg Arg Ala
1365 1370 1375
Ala Asn Lys Lys Glu Leu Leu Leu Lys Leu Ala Glu Lys Val His Ser
1380 1385 1390
Pro Gly Val Thr Ser Ser Leu Ser Lys Gly His Val Val Pro Arg Val
1395 1400 1405
Val Ala Ala Gly Val Tyr Leu Leu Ser Arg His Cys Phe Arg Phe Ser
1410 1415 1420
Ser Ser Ile His Gly Arg Gly Ser Ala Gln Lys Ala Ser Leu Ile Lys
1425 1430 1435 1440
Leu Leu Met Met Ser Ser Ile Ser Ala Met Lys His Gly Gly Ser Leu
1445 1450 1455
Asn Pro Asn Gln Glu Arg Met Leu Phe Pro Gln Ala Gln Glu Tyr Asp
1460 1465 1470
Arg Val Cys Thr Leu Leu Glu Glu Val Glu His Leu Thr Gly Lys Phe
1475 1480 1485
Val Val Arg Glu Arg Asn Ile Val Arg Ser Arg Ile Asp Leu Phe Gln
1490 1495 1500
Glu Pro Val Asp Leu Arg Cys Lys Ala Glu Asp Leu Val Ser Glu Val
1505 1510 1515 1520
Trp Phe Gly Leu Lys Arg Thr Lys Leu Gly Pro Arg Leu Leu Lys Glu
1525 1530 1535
Glu Trp Asp Lys Leu Arg Ala Ser Phe Ala Trp Leu Ser Thr Asp Pro
1540 1545 1550
Ser Glu Thr Leu Arg Asp Gly Pro Phe Leu Ser His Val Gln Phe Arg
1555 1560 1565
Asn Phe Ile Ala His Val Asp Ala Lys Ser Arg Ser Val Arg Leu Leu
1570 1575 1580
Gly Ala Pro Val Lys Lys Ser Gly Gly Val Thr Thr Ile Ser Gln Val
1585 1590 1595 1600
Val Arg Met Asn Phe Phe Pro Gly Phe Ser Leu Glu Ala Glu Lys Ser
1605 1610 1615
Leu Asp Asn Gln Glu Arg Leu Glu Ser Ile Ser Ile Leu Lys His Val
1620 1625 1630
Leu Phe Met Val Leu Asn Gly Pro Tyr Thr Glu Glu Tyr Lys Leu Glu
1635 1640 1645
Met Ile Ile Glu Ala Phe Ser Thr Leu Val Ile Pro Gln Pro Ser Glu
1650 1655 1660
Val Ile Arg Lys Ser Arg Thr Met Thr Leu Cys Leu Leu Ser Asn Tyr
1665 1670 1675 1680
Leu Ser Ser Arg Gly Gly Ser Ile Leu Asp Gln Ile Glu Arg Ala Gln
1685 1690 1695
Ser Gly Thr Leu Gly Gly Phe Ser Lys Pro Gln Lys Thr Phe Ile Arg
1700 1705 1710
Pro Gly Gly Gly Ile Gly Tyr Lys Gly Lys Gly Val Trp Thr Gly Val
1715 1720 1725
Met Glu Asp Thr His Val Gln Ile Leu Ile Asp Gly Asp Gly Thr Ser
1730 1735 1740
Asn Trp Leu Glu Glu Ile Arg Leu Ser Ser Asp Ala Arg Leu Tyr Asp
1745 1750 1755 1760
Val Ile Glu Ser Ile Arg Arg Leu Cys Asp Asp Leu Gly Ile Asn Asn
1765 1770 1775
Arg Val Ala Ser Ala Tyr Arg Gly His Cys Met Val Arg Leu Ser Gly
1780 1785 1790
Phe Lys Ile Lys Pro Ala Ser Arg Thr Asp Gly Cys Pro Val Arg Ile
1795 1800 1805
Met Glu Arg Gly Phe Arg Ile Arg Glu Leu Gln Asn Pro Asp Glu Val
1810 1815 1820
Lys Met Arg Val Arg Gly Asp Ile Leu Asn Leu Ser Val Thr Ile Gln
1825 1830 1835 1840
Glu Gly Arg Val Met Asn Ile Leu Ser Tyr Arg Pro Arg Asp Thr Asp
1845 1850 1855
Ile Ser Glu Ser Ala Ala Ala Tyr Leu Trp Ser Asn Arg Asp Leu Phe
1860 1865 1870
Ser Phe Gly Lys Lys Glu Pro Ser Cys Ser Trp Ile Cys Leu Lys Thr
1875 1880 1885
Leu Asp Asn Trp Ala Trp Ser His Ala Ser Val Leu Leu Ala Asn Asp
1890 1895 1900
Arg Lys Thr Gln Gly Ile Asp Asn Arg Ala Met Gly Asn Ile Phe Arg
1905 1910 1915 1920
Asp Cys Leu Glu Gly Ser Leu Arg Lys Gln Gly Leu Met Arg Ser Lys
1925 1930 1935
Leu Thr Glu Met Val Glu Lys Asn Val Val Pro Leu Thr Thr Gln Glu
1940 1945 1950
Leu Val Asp Ile Leu Glu Glu Asp Ile Asp Phe Ser Asp Val Ile Ala
1955 1960 1965
Val Glu Leu Ser Glu Gly Ser Leu Asp Ile Glu Ser Ile Phe Asp Gly
1970 1975 1980
Ala Pro Ile Leu Trp Ser Ala Glu Val Glu Glu Phe Gly Glu Gly Val
1985 1990 1995 2000
Val Ala Val Ser Tyr Ser Ser Lys Tyr Tyr His Leu Thr Leu Met Asp
2005 2010 2015
Gln Ala Ala Ile Thr Met Cys Ala Ile Met Gly Lys Glu Gly Cys Arg
2020 2025 2030
Gly Leu Leu Thr Glu Lys Arg Cys Met Ala Ala Ile Arg Glu Gln Val
2035 2040 2045
Arg Pro Phe Leu Ile Phe Leu Gln Ile Pro Glu Asp Ser Ile Ser Trp
2050 2055 2060
Val Ser Asp Gln Phe Cys Asp Ser Arg Gly Leu Asp Glu Glu Ser Thr
2065 2070 2075 2080
Ile Met Trp Gly ***
2085
<210> 18
<211> 1074
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 M
<400> 18
Met Met Lys Val Ile Trp Phe Ser Ser Leu Ile Cys Leu Val Ile Gln
1 5 10 15
Cys Ser Gly Asp Thr Gly Pro Ile Ile Cys Ala Gly Pro Ile His Ser
20 25 30
Asn Lys Ser Ala Asp Ile Pro His Leu Leu Gly Tyr Ser Glu Lys Ile
35 40 45
Cys Gln Ile Asp Arg Leu Ile His Val Ser Ser Trp Leu Arg Asn His
50 55 60
Ser Gln Phe Gln Gly Tyr Val Gly Gln Arg Gly Gly Arg Ser Gln Val
65 70 75 80
Ser Tyr Phe Pro Ala Glu Asn Ser Tyr Ser Arg Trp Ser Gly Leu Leu
85 90 95
Ser Pro Cys Asp Ala Asp Trp Leu Gly Met Leu Val Val Lys Lys Ala
100 105 110
Lys Gly Ser Asp Met Ile Val Pro Gly Pro Ser Tyr Lys Gly Lys Val
115 120 125
Phe Phe Glu Arg Pro Thr Phe Asp Gly Tyr Val Gly Trp Gly Cys Gly
130 135 140
Ser Gly Lys Ser Arg Thr Glu Ser Gly Glu Leu Cys Ser Ser Asp Ser
145 150 155 160
Gly Thr Ser Ser Gly Leu Leu Pro Ser Asn Arg Val Leu Trp Ile Gly
165 170 175
Asp Val Ala Cys Gln Pro Met Thr Pro Ile Pro Glu Glu Thr Phe Leu
180 185 190
Glu Leu Lys Ser Phe Ser Gln Ser Glu Phe Pro Asp Ile Cys Lys Ile
195 200 205
Asp Gly Ile Val Phe Asn Gln Cys Glu Ser Glu Ser Leu Pro Gln Pro
210 215 220
Phe Asp Val Ala Trp Met Asp Val Gly His Ser His Lys Ile Ile Met
225 230 235 240
Arg Glu His Lys Thr Lys Trp Val Gln Glu Ser Ser Ser Lys Asp Phe
245 250 255
Val Cys Tyr Lys Glu Gly Thr Gly Pro Cys Ser Glu Ser Glu Glu Lys
260 265 270
Thr Cys Lys Thr Ser Gly Ser Cys Arg Gly Asp Met Gln Phe Cys Lys
275 280 285
Val Ala Gly Cys Glu His Gly Glu Glu Thr Ser Glu Ala Lys Cys Arg
290 295 300
Cys Ser Leu Val His Lys Pro Gly Glu Val Val Val Ser Tyr Gly Gly
305 310 315 320
Met Arg Val Arg Pro Lys Cys Tyr Gly Phe Ser Arg Met Met Ala Thr
325 330 335
Leu Glu Val Asn Pro Pro Glu Gln Arg Ile Gly Gln Cys Thr Gly Cys
340 345 350
His Leu Glu Cys Ile Asn Gly Gly Val Arg Ile Ile Thr Leu Thr Ser
355 360 365
Glu Leu Lys Ser Ala Thr Val Cys Ala Ser His Phe Cys Ser Ser Ala
370 375 380
Thr Ser Gly Lys Lys Ser Thr Glu Ile Gln Phe His Ser Gly Ser Leu
385 390 395 400
Val Gly Lys Thr Ala Ile His Val Lys Gly Ala Leu Val Asp Gly Thr
405 410 415
Glu Phe Thr Phe Glu Gly Ser Cys Met Phe Pro Asp Gly Cys Asp Ala
420 425 430
Val Asp Cys Thr Phe Cys Arg Glu Phe Leu Lys Asn Pro Gln Cys Tyr
435 440 445
Pro Ala Lys Lys Trp Leu Phe Ile Ile Ile Val Ile Leu Leu Gly Tyr
450 455 460
Ala Gly Leu Met Leu Leu Thr Asn Val Leu Lys Ala Ile Gly Val Trp
465 470 475 480
Gly Ser Trp Val Ile Ala Pro Val Lys Leu Met Phe Ala Ile Ile Lys
485 490 495
Lys Leu Met Arg Ser Val Ser Cys Leu Met Gly Lys Leu Met Asp Arg
500 505 510
Gly Arg Gln Val Ile His Glu Glu Ile Gly Glu Asn Arg Glu Gly Asn
515 520 525
Gln Asp Asp Val Arg Ile Glu Met Ala Arg Pro Arg Arg Val Arg His
530 535 540
Trp Met Tyr Ser Pro Val Ile Leu Thr Ile Leu Ala Ile Gly Leu Ala
545 550 555 560
Glu Gly Cys Asp Glu Met Val His Ala Asp Ser Lys Leu Val Ser Cys
565 570 575
Lys Gln Gly Ser Gly Asn Met Lys Glu Cys Val Thr Thr Gly Arg Ala
580 585 590
Leu Leu Pro Ala Val Asn Pro Gly Gln Glu Ala Cys Leu His Phe Thr
595 600 605
Ala Pro Gly Ser Pro Asp Ser Lys Cys Leu Lys Ile Lys Val Lys Arg
610 615 620
Ile Asn Leu Lys Cys Lys Lys Ser Ser Ser Tyr Phe Val Pro Asp Ala
625 630 635 640
Arg Ser Arg Cys Thr Ser Val Arg Arg Cys Arg Trp Ala Gly Asp Cys
645 650 655
Gln Ser Gly Cys Pro Ser His Phe Thr Ser Asn Ser Phe Ser Asp Asp
660 665 670
Trp Ala Gly Lys Met Asp Arg Ala Gly Leu Gly Phe Ser Gly Cys Ser
675 680 685
Asp Gly Cys Gly Gly Ala Ala Cys Gly Cys Phe Asn Ala Ala Pro Ser
690 695 700
Cys Ile Phe Trp Arg Lys Trp Val Glu Asn Pro His Gly Ile Ile Trp
705 710 715 720
Lys Val Ser Pro Cys Ala Ala Trp Val Pro Ser Ala Val Ile Glu Leu
725 730 735
Thr Met Pro Ser Gly Glu Val Arg Thr Phe His Pro Met Ser Gly Ile
740 745 750
Pro Thr Gln Val Phe Lys Gly Val Ser Val Thr Tyr Leu Gly Ser Asp
755 760 765
Met Glu Val Ser Gly Leu Thr Asp Leu Cys Glu Ile Glu Glu Leu Lys
770 775 780
Ser Lys Lys Leu Ala Leu Ala Pro Cys Asn Gln Ala Gly Met Gly Val
785 790 795 800
Val Gly Lys Val Gly Glu Ile Gln Cys Ser Ser Glu Glu Ser Ala Arg
805 810 815
Thr Ile Lys Lys Asp Gly Cys Ile Trp Asn Ala Asp Leu Val Gly Ile
820 825 830
Glu Leu Arg Val Asp Asp Ala Val Cys Tyr Ser Lys Ile Thr Ser Val
835 840 845
Glu Ala Val Ala Asn Tyr Ser Ala Ile Pro Thr Thr Ile Gly Gly Leu
850 855 860
Arg Phe Glu Arg Ser His Asp Ser Gln Gly Lys Ile Ser Gly Ser Pro
865 870 875 880
Leu Asp Ile Thr Ala Ile Arg Gly Ser Phe Ser Val Asn Tyr Arg Gly
885 890 895
Leu Arg Leu Ser Leu Ser Glu Ile Thr Ala Thr Cys Thr Gly Glu Val
900 905 910
Thr Asn Val Ser Gly Cys Tyr Ser Cys Met Thr Gly Ala Lys Val Ser
915 920 925
Ile Lys Leu His Ser Ser Lys Asn Ser Thr Ala His Val Arg Cys Lys
930 935 940
Gly Asp Glu Thr Ala Phe Ser Val Leu Glu Gly Val His Ser Tyr Thr
945 950 955 960
Val Ser Leu Ser Phe Asp His Ala Val Val Asp Glu Gln Cys Gln Leu
965 970 975
Asn Cys Gly Gly His Glu Ser Gln Val Thr Leu Lys Gly Asn Leu Ile
980 985 990
Phe Leu Asp Val Pro Lys Phe Val Asp Gly Ser Tyr Met Gln Thr Tyr
995 1000 1005
His Ser Ser Val Pro Thr Gly Ala Asn Ile Pro Ser Pro Thr Asp Trp
1010 1015 1020
Leu Asn Ala Leu Phe Gly Asn Gly Leu Ser Arg Trp Ile Leu Gly Val
1025 1030 1035 1040
Ile Gly Val Leu Leu Gly Gly Leu Ala Leu Phe Phe Leu Ile Met Ser
1045 1050 1055
Leu Phe Lys Leu Gly Thr Lys Gln Val Phe Arg Ser Arg Thr Lys Leu
1060 1065 1070
Ala ***
<210> 19
<211> 246
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 NP
<400> 19
Met Ser Glu Trp Ser Arg Ile Ala Val Glu Phe Gly Glu Gln Gln Leu
1 5 10 15
Asn Leu Thr Glu Leu Glu Asp Phe Ala Arg Glu Leu Ala Tyr Glu Gly
20 25 30
Leu Asp Pro Ala Leu Ile Ile Lys Lys Leu Lys Glu Thr Gly Gly Asp
35 40 45
Asp Trp Val Arg Asp Thr Lys Phe Ile Ile Val Phe Ala Leu Thr Arg
50 55 60
Gly Asn Lys Ile Val Lys Ala Ser Gly Lys Met Ser Asn Ser Gly Ser
65 70 75 80
Lys Arg Leu Met Ala Leu Gln Glu Lys Tyr Gly Leu Val Glu Arg Ala
85 90 95
Glu Thr Arg Leu Ser Ile Thr Pro Val Arg Val Ala Gln Ser Leu Pro
100 105 110
Thr Trp Thr Cys Ala Ala Ala Ala Ala Leu Lys Glu Tyr Leu Pro Val
115 120 125
Gly Pro Ala Val Met Asn Leu Lys Val Glu Asn Tyr Pro Pro Glu Met
130 135 140
Met Cys Met Ala Phe Gly Ser Leu Ile Pro Thr Ala Gly Val Ser Glu
145 150 155 160
Ala Thr Thr Lys Thr Leu Met Glu Ala Tyr Ser Leu Trp Gln Asp Ala
165 170 175
Phe Thr Lys Thr Ile Asn Val Lys Met Arg Gly Ala Ser Lys Thr Glu
180 185 190
Val Tyr Asn Ser Phe Arg Asp Pro Leu His Ala Ala Val Asn Ser Val
195 200 205
Phe Phe Pro Asn Asp Val Arg Val Lys Trp Leu Lys Ala Lys Gly Ile
210 215 220
Leu Gly Pro Asp Gly Val Pro Ser Arg Ala Ala Glu Val Ala Ala Ala
225 230 235 240
Ala Tyr Arg Asn Leu ***
245
<210> 20
<211> 294
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-2 NS
<400> 20
Met Ser Leu Ser Lys Cys Ser Asn Val Asp Leu Lys Ser Val Ala Met
1 5 10 15
Asn Ala Asn Thr Val Arg Leu Glu Pro Ser Leu Gly Glu Tyr Pro Thr
20 25 30
Leu Arg Arg Asp Leu Val Glu Cys Ser Cys Ser Val Leu Thr Leu Ser
35 40 45
Met Val Lys Arg Met Gly Lys Met Thr Asn Thr Val Trp Leu Phe Gly
50 55 60
Asn Pro Lys Asn Pro Leu His Gln Leu Glu Pro Gly Leu Glu Gln Leu
65 70 75 80
Leu Asp Met Tyr Tyr Lys Asp Met Arg Cys Tyr Ser Gln Arg Glu Leu
85 90 95
Ser Ala Leu Arg Trp Pro Ser Gly Lys Pro Ser Val Trp Phe Leu Gln
100 105 110
Ala Ala His Met Phe Phe Ser Ile Lys Asn Ser Trp Ala Met Glu Thr
115 120 125
Gly Arg Glu Asn Trp Arg Gly Leu Phe His Arg Ile Thr Lys Gly Gln
130 135 140
Lys Tyr Leu Phe Glu Gly Asp Met Ile Leu Asp Ser Leu Glu Ala Ile
145 150 155 160
Glu Lys Arg Arg Leu Arg Leu Gly Leu Pro Glu Ile Leu Ile Thr Gly
165 170 175
Leu Ser Pro Ile Leu Asp Val Ala Leu Leu Gln Ile Glu Ser Leu Ala
180 185 190
Arg Leu Arg Gly Met Ser Leu Asn His His Leu Phe Thr Ser Ser Ser
195 200 205
Leu Arg Lys Pro Leu Leu Asp Cys Trp Asp Phe Phe Ile Pro Ile Arg
210 215 220
Lys Lys Lys Thr Asp Gly Ser Tyr Ser Val Leu Asp Glu Asp Asp Glu
225 230 235 240
Pro Gly Ile Leu Gln Gly Tyr Pro Tyr Leu Met Ala His Tyr Leu Asn
245 250 255
Arg Cys Pro Phe His Asn Leu Ile Arg Phe Asp Glu Glu Leu Arg Thr
260 265 270
Ala Ala Leu Asn Thr Ile Trp Gly Arg Asp Trp Pro Ala Ile Gly Asp
275 280 285
Leu Pro Lys Glu Val ***
290
<210> 21
<211> 2085
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 L
<400> 21
Met Asn Leu Glu Val Leu Cys Gly Arg Ile Asn Val Glu Asn Gly Leu
1 5 10 15
Ser Leu Gly Glu Pro Gly Leu Tyr Asp Gln Ile Tyr Asp Arg Pro Gly
20 25 30
Leu Pro Asp Leu Asp Val Thr Val Asp Ala Ile Gly Val Thr Val Asp
35 40 45
Ile Gly Ala Val Pro Asp Ser Ala Ser Gln Leu Gly Ser Ser Ile Asn
50 55 60
Ala Gly Leu Ile Thr Ile Gln Leu Ser Glu Ala Tyr Lys Ile Asn His
65 70 75 80
Asp Phe Thr Phe Ser Gly Leu Ser Lys Thr Thr Asp Arg Arg Leu Ser
85 90 95
Glu Val Phe Pro Ile Thr His Asp Gly Ser Asp Gly Met Thr Pro Asp
100 105 110
Val Ile His Thr Arg Leu Asp Gly Thr Ile Val Val Val Glu Phe Ser
115 120 125
Thr Thr Arg Ser His Asn Ile Gly Gly Leu Glu Ala Ala Tyr Arg Thr
130 135 140
Lys Ile Glu Lys Tyr Arg Asp Pro Ile Ser Arg Arg Val Asp Ile Met
145 150 155 160
Glu Asn Pro Arg Val Phe Phe Gly Val Ile Val Val Ser Ser Gly Gly
165 170 175
Val Leu Ser Asn Met Pro Leu Thr Gln Asp Glu Ala Glu Glu Leu Met
180 185 190
Tyr Arg Phe Cys Ile Ala Asn Glu Ile Tyr Thr Lys Ala Arg Ser Met
195 200 205
Asp Ala Asp Ile Glu Leu Gln Lys Ser Glu Glu Glu Leu Glu Ala Ile
210 215 220
Ser Arg Ala Leu Ser Phe Phe Ser Leu Phe Glu Pro Asn Ile Glu Arg
225 230 235 240
Val Glu Gly Thr Phe Pro Asn Ser Glu Ile Glu Met Leu Glu Gln Phe
245 250 255
Leu Ser Thr Pro Ala Asp Val Asp Phe Ile Thr Lys Thr Leu Lys Ala
260 265 270
Lys Glu Val Glu Ala Tyr Ala Asp Leu Cys Asp Ser His Tyr Leu Lys
275 280 285
Pro Glu Lys Thr Ile Gln Glu Arg Leu Glu Ile Asn Arg Cys Glu Ala
290 295 300
Ile Asp Lys Thr Gln Asp Leu Leu Ala Ser Leu His Ala Arg Ser Asn
305 310 315 320
Lys Gln Thr Ser Leu Asn Arg Gly Thr Val Lys Leu Pro Pro Trp Leu
325 330 335
Pro Lys Pro Ser Ser Glu Ser Ile Asp Ile Lys Thr Asp Ser Gly Phe
340 345 350
Gly Ser Leu Met Asp His Gly Thr Tyr Gly Glu Leu Trp Ala Lys Cys
355 360 365
Leu Leu Asp Val Ser Leu Gly Asn Val Glu Gly Val Val Ser Asp Pro
370 375 380
Ala Lys Glu Leu Asp Ile Ala Ile Ser Asp Asp Pro Glu Lys Asp Thr
385 390 395 400
Pro Lys Glu Ala Lys Ile Thr Tyr Arg Arg Phe Lys Pro Ala Leu Ser
405 410 415
Ser Ser Ala Arg Gln Glu Phe Ser Leu Gln Gly Val Glu Gly Lys Lys
420 425 430
Trp Lys Arg Met Ala Ala Asn Gln Lys Lys Glu Lys Glu Ser His Glu
435 440 445
Thr Leu Ser Pro Phe Leu Asp Val Glu Asp Ile Gly Asp Phe Leu Thr
450 455 460
Phe Asn Asn Leu Leu Ala Asp Ser Arg Tyr Gly Asp Glu Ser Val Gln
465 470 475 480
Arg Ala Val Ser Ile Leu Leu Glu Lys Ala Ser Ala Met Gln Asp Thr
485 490 495
Glu Leu Thr His Ala Leu Asn Asp Ser Phe Lys Arg Asn Leu Ser Ser
500 505 510
Asn Val Val Gln Trp Ser Leu Trp Val Ser Cys Leu Ala Gln Glu Leu
515 520 525
Ala Ser Ala Leu Lys Gln His Cys Arg Ala Gly Glu Phe Ile Ile Lys
530 535 540
Lys Leu Lys Phe Trp Pro Ile Tyr Val Ile Ile Lys Pro Thr Lys Ser
545 550 555 560
Ser Ser His Ile Phe Tyr Ser Leu Gly Ile Arg Lys Ala Asp Val Thr
565 570 575
Arg Arg Leu Thr Gly Arg Val Phe Ser Asp Thr Ile Asp Ala Gly Glu
580 585 590
Trp Glu Leu Thr Glu Phe Lys Ser Leu Lys Thr Cys Lys Leu Thr Asn
595 600 605
Leu Val Asn Leu Pro Cys Thr Met Leu Asn Ser Ile Ala Phe Trp Arg
610 615 620
Glu Lys Leu Gly Val Ala Pro Trp Leu Val Arg Lys Pro Cys Ser Glu
625 630 635 640
Leu Arg Glu Gln Val Gly Leu Thr Phe Leu Ile Ser Leu Glu Asp Lys
645 650 655
Ser Lys Thr Glu Glu Ile Ile Thr Leu Thr Arg Tyr Thr Gln Met Glu
660 665 670
Gly Phe Val Ser Pro Pro Met Leu Pro Lys Pro Gln Lys Met Leu Gly
675 680 685
Lys Leu Asp Gly Pro Leu Arg Thr Lys Leu Gln Val Tyr Leu Leu Arg
690 695 700
Lys His Leu Asp Cys Met Val Arg Ile Ala Ser Gln Pro Phe Ser Leu
705 710 715 720
Ile Pro Arg Glu Gly Arg Val Glu Trp Gly Gly Thr Phe His Ala Ile
725 730 735
Ser Gly Arg Ser Thr Asn Leu Glu Asn Met Val Asn Ser Trp Tyr Ile
740 745 750
Gly Tyr Tyr Lys Asn Lys Glu Glu Ser Thr Glu Leu Asn Ala Leu Gly
755 760 765
Glu Met Tyr Lys Lys Ile Val Glu Met Glu Glu Asp Lys Pro Ser Ser
770 775 780
Pro Lys Phe Leu Gly Trp Gly Asp Thr Asp Ser Pro Lys Lys His Glu
785 790 795 800
Phe Ser Arg Ser Phe Leu Arg Ala Ala Cys Ser Ser Leu Glu Arg Glu
805 810 815
Ile Ala Gln Arg His Gly Arg Gln Trp Lys Gln Asn Leu Glu Glu Arg
820 825 830
Val Leu Arg Glu Ile Gly Thr Lys Asn Ile Leu Asp Leu Ala Ser Met
835 840 845
Lys Ala Thr Ser Asn Phe Ser Lys Asp Trp Glu Leu Tyr Ser Glu Val
850 855 860
Gln Thr Lys Glu Tyr His Arg Ser Lys Leu Leu Glu Lys Met Ala Thr
865 870 875 880
Leu Ile Glu Lys Gly Val Met Trp Tyr Ile Asp Ala Val Gly Gln Ala
885 890 895
Trp Lys Ala Val Leu Asp Asp Gly Cys Met Arg Ile Cys Leu Phe Lys
900 905 910
Lys Asn Gln His Gly Gly Leu Arg Glu Ile Tyr Val Met Asp Ala Asn
915 920 925
Ala Arg Leu Val Gln Phe Gly Val Glu Thr Met Ala Arg Cys Val Cys
930 935 940
Glu Leu Ser Pro His Glu Thr Val Ala Asn Pro Arg Leu Lys Asn Ser
945 950 955 960
Ile Ile Glu Asn His Gly Leu Lys Ser Ala Arg Ser Leu Gly Pro Gly
965 970 975
Ser Ile Asn Ile Asn Ser Ser Asn Asp Ala Lys Lys Trp Asn Gln Gly
980 985 990
His Tyr Thr Thr Lys Leu Ala Leu Val Leu Cys Trp Phe Met Pro Ala
995 1000 1005
Lys Phe His Arg Phe Ile Trp Ala Ala Ile Ser Met Phe Arg Arg Lys
1010 1015 1020
Lys Met Met Val Asp Leu Arg Phe Leu Ala His Leu Ser Ser Lys Ser
1025 1030 1035 1040
Glu Ser Arg Ser Ser Asp Pro Phe Arg Glu Ala Met Thr Asp Ala Phe
1045 1050 1055
His Gly Asn Arg Glu Val Ser Trp Met Asp Lys Gly Arg Thr Tyr Ile
1060 1065 1070
Lys Thr Glu Thr Gly Met Met Gln Gly Ile Leu His Phe Thr Ser Ser
1075 1080 1085
Leu Leu His Ser Cys Val Gln Ser Phe Tyr Lys Ser Tyr Phe Val Ser
1090 1095 1100
Lys Leu Lys Glu Gly Tyr Met Gly Glu Ser Ile Ser Gly Val Val Asp
1105 1110 1115 1120
Val Ile Glu Gly Ser Asp Asp Ser Ala Ile Met Ile Ser Ile Arg Pro
1125 1130 1135
Lys Ser Asp Met Asp Glu Val Arg Ser Arg Phe Phe Val Ala Asn Leu
1140 1145 1150
Leu His Ser Val Lys Phe Leu Asn Pro Leu Phe Gly Ile Tyr Ser Ser
1155 1160 1165
Glu Lys Ser Thr Val Asn Thr Val Tyr Cys Val Glu Tyr Asn Ser Glu
1170 1175 1180
Phe His Phe His Arg His Leu Val Arg Pro Thr Leu Arg Trp Ile Ala
1185 1190 1195 1200
Ala Ser His Gln Ile Ser Glu Thr Glu Ala Leu Ala Ser Arg Gln Glu
1205 1210 1215
Asp Tyr Ser Asn Leu Leu Thr Gln Cys Leu Glu Gly Gly Ala Ser Phe
1220 1225 1230
Ser Leu Thr Tyr Leu Ile Gln Cys Ala Gln Leu Leu His His Tyr Met
1235 1240 1245
Leu Leu Gly Leu Cys Leu His Pro Leu Phe Gly Thr Phe Met Gly Met
1250 1255 1260
Leu Ile Ser Asp Pro Asp Pro Ala Leu Gly Phe Phe Leu Met Asp Asn
1265 1270 1275 1280
Pro Ala Phe Ala Gly Gly Ala Gly Phe Arg Phe Asn Leu Trp Arg Ala
1285 1290 1295
Cys Lys Thr Thr Asp Leu Gly Arg Lys Tyr Ala Tyr Tyr Phe Asn Glu
1300 1305 1310
Ile Gln Gly Lys Thr Lys Gly Asp Glu Asp Tyr Arg Ala Leu Asp Ala
1315 1320 1325
Thr Ser Gly Gly Thr Leu Ser His Ser Val Met Val Tyr Trp Gly Asp
1330 1335 1340
Arg Lys Lys Tyr Gln Ala Leu Leu Asn Arg Met Gly Leu Pro Glu Asp
1345 1350 1355 1360
Trp Val Glu Gln Ile Asp Glu Asn Pro Gly Val Leu Tyr Arg Arg Ala
1365 1370 1375
Ala Asn Lys Lys Glu Leu Leu Leu Lys Leu Ala Glu Lys Val His Ser
1380 1385 1390
Pro Gly Val Thr Ser Ser Leu Ser Lys Gly His Val Val Pro Arg Val
1395 1400 1405
Val Ala Ala Gly Val Tyr Leu Leu Ser Arg His Cys Phe Arg Phe Ser
1410 1415 1420
Ser Ser Ile His Gly Arg Gly Ser Ala Gln Lys Ala Ser Leu Ile Lys
1425 1430 1435 1440
Leu Leu Met Met Ser Ser Ile Ser Ala Met Lys His Gly Gly Ser Leu
1445 1450 1455
Asn Pro Asn Gln Glu Arg Met Leu Phe Pro Gln Ala Gln Glu Tyr Asp
1460 1465 1470
Arg Val Cys Thr Leu Leu Glu Glu Val Glu His Leu Thr Gly Lys Phe
1475 1480 1485
Val Val Arg Glu Arg Asn Ile Val Arg Ser Arg Ile Asp Leu Phe Gln
1490 1495 1500
Glu Pro Val Asp Leu Arg Cys Lys Ala Glu Asp Leu Val Ser Glu Val
1505 1510 1515 1520
Trp Phe Gly Leu Lys Arg Thr Lys Leu Gly Pro Arg Leu Leu Lys Glu
1525 1530 1535
Glu Trp Asp Lys Leu Arg Ala Ser Phe Ala Trp Leu Ser Thr Asp Pro
1540 1545 1550
Ser Glu Thr Leu Arg Asp Gly Pro Phe Leu Ser His Val Gln Phe Arg
1555 1560 1565
Asn Phe Ile Ala His Val Asp Ala Lys Ser Arg Ser Val Arg Leu Leu
1570 1575 1580
Gly Ala Pro Val Lys Lys Ser Gly Gly Val Thr Thr Ile Ser Gln Val
1585 1590 1595 1600
Val Arg Met Asn Phe Phe Pro Gly Phe Ser Leu Glu Ala Glu Lys Ser
1605 1610 1615
Leu Asp Asn Gln Glu Arg Leu Glu Ser Ile Ser Ile Leu Lys His Val
1620 1625 1630
Leu Phe Met Val Leu Asn Gly Pro Tyr Thr Glu Glu Tyr Lys Leu Asp
1635 1640 1645
Met Ile Ile Glu Ala Phe Ser Thr Leu Val Ile Pro Gln Pro Ser Glu
1650 1655 1660
Val Ile Arg Lys Ser Arg Thr Met Thr Leu Cys Leu Leu Ser Asn Tyr
1665 1670 1675 1680
Leu Ser Ser Arg Gly Gly Ser Ile Leu Asp Gln Ile Glu Arg Ala Gln
1685 1690 1695
Ser Gly Thr Leu Gly Gly Phe Ser Lys Pro Gln Lys Thr Phe Ile Arg
1700 1705 1710
Pro Gly Gly Gly Ile Gly Tyr Lys Gly Lys Gly Val Trp Thr Gly Val
1715 1720 1725
Met Glu Asp Thr His Val Gln Ile Leu Ile Asp Gly Asp Gly Thr Ser
1730 1735 1740
Asn Trp Leu Glu Glu Ile Arg Leu Ser Ser Asp Ala Arg Leu Tyr Asp
1745 1750 1755 1760
Val Ile Glu Ser Ile Arg Arg Leu Cys Asp Asp Leu Gly Ile Asn Asn
1765 1770 1775
Arg Val Ala Ser Ala Tyr Arg Gly His Cys Met Val Arg Leu Ser Gly
1780 1785 1790
Phe Lys Ile Lys Pro Ala Ser Arg Thr Asp Gly Cys Pro Val Arg Ile
1795 1800 1805
Met Glu Arg Gly Phe Arg Ile Arg Glu Leu Gln Asn Pro Asp Glu Val
1810 1815 1820
Lys Met Arg Val Arg Gly Asp Ile Leu Asn Leu Ser Val Thr Ile Gln
1825 1830 1835 1840
Glu Gly Arg Val Met Asn Ile Leu Ser Tyr Arg Pro Arg Asp Thr Asp
1845 1850 1855
Ile Ser Glu Ser Ala Ala Ala Tyr Leu Trp Ser Asn Arg Asp Leu Phe
1860 1865 1870
Ser Phe Gly Lys Lys Glu Pro Ser Cys Ser Trp Ile Cys Leu Lys Thr
1875 1880 1885
Leu Asp Asn Trp Ala Trp Ser His Ala Ser Val Leu Leu Ala Asn Asp
1890 1895 1900
Arg Lys Thr Gln Gly Ile Asp Asn Arg Ala Met Gly Asn Ile Phe Arg
1905 1910 1915 1920
Asp Cys Leu Glu Gly Ser Leu Arg Lys Gln Gly Leu Met Arg Ser Lys
1925 1930 1935
Leu Thr Glu Met Val Glu Lys Asn Val Val Pro Leu Thr Thr Gln Glu
1940 1945 1950
Leu Val Asp Ile Leu Glu Glu Asp Ile Asp Phe Ser Asp Val Ile Ala
1955 1960 1965
Val Glu Leu Ser Glu Gly Ser Leu Asp Ile Glu Ser Ile Phe Asp Gly
1970 1975 1980
Ala Pro Ile Leu Trp Ser Ala Glu Val Glu Glu Phe Gly Glu Gly Val
1985 1990 1995 2000
Val Ala Val Ser Tyr Ser Ser Lys Tyr Tyr His Leu Thr Leu Met Asp
2005 2010 2015
Gln Ala Ala Ile Thr Met Cys Ala Ile Met Gly Lys Glu Gly Cys Arg
2020 2025 2030
Gly Leu Leu Thr Glu Lys Arg Cys Met Ala Ala Ile Arg Glu Gln Val
2035 2040 2045
Arg Pro Phe Leu Ile Phe Leu Gln Ile Pro Glu Asp Ser Ile Ser Trp
2050 2055 2060
Val Ser Asp Gln Phe Cys Asp Ser Arg Gly Leu Asp Glu Glu Ser Thr
2065 2070 2075 2080
Ile Met Trp Gly ***
2085
<210> 22
<211> 1074
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 M
<400> 22
Met Met Lys Val Ile Trp Phe Ser Ser Leu Ile Cys Leu Val Ile Gln
1 5 10 15
Cys Ser Gly Asp Thr Gly Pro Ile Ile Cys Ala Gly Pro Ile His Ser
20 25 30
Asn Lys Ser Ala Asn Ile Pro His Leu Leu Gly Tyr Ser Glu Lys Ile
35 40 45
Cys Gln Ile Asp Arg Leu Ile His Val Ser Ser Trp Leu Arg Asn His
50 55 60
Ser Gln Phe Gln Gly Tyr Val Gly Gln Arg Gly Gly Arg Ser Gln Val
65 70 75 80
Ser Tyr Tyr Pro Ala Glu Asn Ser Tyr Ser Arg Trp Ser Gly Leu Leu
85 90 95
Ser Pro Cys Asp Ala Asp Trp Leu Gly Met Leu Val Val Lys Lys Ala
100 105 110
Lys Gly Ser Asp Met Ile Val Pro Gly Pro Ser Tyr Lys Gly Lys Val
115 120 125
Phe Phe Glu Arg Pro Thr Phe Asp Gly Tyr Val Gly Trp Gly Cys Gly
130 135 140
Ser Gly Lys Ser Arg Thr Glu Ser Gly Glu Leu Cys Ser Ser Asp Ser
145 150 155 160
Gly Thr Ser Ser Gly Leu Leu Pro Ser Asn Arg Val Leu Trp Ile Gly
165 170 175
Asp Val Ala Cys Gln Pro Met Thr Pro Ile Pro Glu Glu Thr Phe Leu
180 185 190
Glu Leu Lys Ser Phe Ser Gln Ser Glu Phe Pro Asp Ile Cys Lys Val
195 200 205
Asp Gly Ile Val Phe Asn Gln Cys Glu Ser Glu Ser Leu Pro Gln Pro
210 215 220
Phe Asp Val Ala Trp Met Asp Val Gly His Ser His Lys Ile Ile Met
225 230 235 240
Arg Glu His Lys Thr Lys Trp Val Gln Glu Ser Ser Ser Lys Asp Phe
245 250 255
Val Cys Tyr Lys Glu Gly Thr Gly Pro Cys Ser Glu Ser Glu Glu Lys
260 265 270
Thr Cys Lys Thr Ser Gly Ser Cys Arg Gly Asp Met Gln Phe Cys Lys
275 280 285
Val Ala Gly Cys Glu His Gly Glu Glu Ala Ser Glu Ala Lys Cys Arg
290 295 300
Cys Ser Leu Val His Lys Pro Gly Glu Val Val Val Ser Tyr Gly Gly
305 310 315 320
Met Arg Val Arg Pro Lys Cys Tyr Gly Phe Ser Arg Met Met Ala Thr
325 330 335
Leu Glu Val Asn Pro Pro Glu Gln Arg Ile Gly Gln Cys Thr Gly Cys
340 345 350
His Leu Glu Cys Ile Asn Gly Gly Val Arg Leu Ile Thr Leu Thr Ser
355 360 365
Glu Leu Lys Ser Ala Thr Val Cys Ala Ser His Phe Cys Ser Ser Ala
370 375 380
Thr Ser Gly Lys Lys Ser Thr Glu Ile Gln Phe His Ser Gly Ser Leu
385 390 395 400
Val Gly Lys Ala Ala Ile His Val Lys Gly Thr Leu Val Asp Gly Thr
405 410 415
Glu Phe Thr Phe Glu Gly Ser Cys Met Phe Pro Asp Gly Cys Asp Ala
420 425 430
Val Asp Cys Thr Phe Cys Arg Glu Phe Leu Lys Asn Pro Gln Cys Tyr
435 440 445
Pro Ala Lys Lys Trp Leu Phe Ile Ile Ile Ala Ile Leu Leu Gly Tyr
450 455 460
Ala Gly Leu Met Leu Leu Thr Asn Val Leu Lys Ala Ile Gly Val Trp
465 470 475 480
Gly Ser Trp Val Ile Ala Pro Val Lys Leu Met Phe Ala Ile Ile Lys
485 490 495
Lys Leu Met Arg Ser Val Ser Cys Leu Met Gly Lys Leu Met Asp Arg
500 505 510
Gly Arg Gln Val Ile His Glu Glu Ile Gly Glu Asn Arg Glu Gly Asn
515 520 525
Gln Glu Asp Val Arg Ile Glu Ile Ala Arg Pro Arg Arg Val Arg His
530 535 540
Trp Met Tyr Ser Pro Val Ile Leu Ala Ile Leu Ala Ile Gly Leu Ala
545 550 555 560
Glu Gly Cys Asp Glu Met Val His Ala Asp Ser Lys Leu Val Ser Cys
565 570 575
Arg Gln Gly Ser Gly Asn Met Lys Glu Cys Val Thr Thr Gly Arg Ala
580 585 590
Leu Leu Pro Ala Val Asn Pro Gly Gln Glu Ala Cys Leu His Phe Thr
595 600 605
Ala Pro Gly Ser Pro Asp Ser Lys Cys Leu Lys Ile Lys Val Lys Arg
610 615 620
Ile Asn Leu Lys Cys Lys Lys Ser Ser Ser Tyr Phe Val Pro Asp Ala
625 630 635 640
Arg Ser Arg Cys Thr Ser Val Arg Arg Cys Arg Trp Ala Gly Asp Cys
645 650 655
Gln Ser Gly Cys Pro Ser His Phe Thr Ser Asn Ser Phe Ser Asp Asp
660 665 670
Trp Ala Gly Lys Met Asp Arg Ala Gly Leu Gly Phe Ser Gly Cys Ser
675 680 685
Asp Gly Cys Gly Gly Ala Ala Cys Gly Cys Phe Asn Ala Ala Pro Ser
690 695 700
Cys Ile Phe Trp Arg Lys Trp Val Glu Asn Pro His Gly Ile Ile Trp
705 710 715 720
Lys Val Ser Pro Cys Ala Ala Trp Val Pro Ser Thr Val Ile Glu Leu
725 730 735
Thr Met Pro Ser Gly Glu Val Arg Thr Phe His Pro Met Ser Gly Ile
740 745 750
Pro Thr Gln Val Phe Lys Gly Val Ser Val Thr Tyr Leu Gly Ser Asp
755 760 765
Met Glu Val Ser Gly Leu Thr Asp Leu Cys Glu Ile Glu Glu Leu Lys
770 775 780
Ser Lys Lys Leu Ala Leu Ala Pro Cys Asn Gln Ala Gly Met Gly Val
785 790 795 800
Val Gly Lys Val Gly Glu Ile Gln Cys Ser Ser Glu Glu Ser Ala Arg
805 810 815
Ser Ile Lys Lys Asp Gly Cys Ile Trp Asn Ala Asp Leu Val Gly Ile
820 825 830
Glu Leu Arg Val Asp Asp Ala Val Cys Tyr Ser Lys Ile Thr Ser Val
835 840 845
Glu Ala Val Ala Asn Tyr Ser Ala Ile Pro Thr Thr Ile Gly Gly Leu
850 855 860
Arg Phe Glu Arg Ser His Asp Ser Gln Gly Lys Ile Ser Gly Ser Pro
865 870 875 880
Leu Asp Ile Thr Ala Ile Arg Gly Ser Phe Ser Val Asn Tyr Arg Gly
885 890 895
Leu Arg Leu Ser Leu Ser Glu Ile Thr Ala Thr Cys Thr Gly Glu Val
900 905 910
Thr Asn Val Ser Gly Cys Tyr Ser Cys Met Thr Gly Ala Lys Val Ser
915 920 925
Ile Lys Leu His Ser Ser Lys Asn Ser Thr Ala His Val Arg Cys Lys
930 935 940
Gly Asp Glu Thr Ala Phe Ser Val Leu Glu Gly Val His Ser Tyr Thr
945 950 955 960
Val Ser Leu Ser Phe Asp His Ala Val Val Asp Glu Gln Cys Gln Leu
965 970 975
Asn Cys Gly Gly His Glu Ser Gln Val Thr Leu Lys Gly Asn Leu Ile
980 985 990
Phe Leu Asp Val Pro Lys Phe Val Asp Gly Ser Tyr Met Gln Thr Tyr
995 1000 1005
His Ser Ser Val Pro Thr Gly Ala Asn Ile Pro Ser Pro Thr Asp Trp
1010 1015 1020
Leu Asn Ala Leu Phe Gly Asn Gly Leu Ser Arg Trp Ile Leu Gly Val
1025 1030 1035 1040
Ile Gly Val Leu Leu Gly Gly Leu Ala Leu Phe Phe Leu Ile Met Ser
1045 1050 1055
Leu Phe Lys Leu Gly Thr Lys Gln Ile Phe Arg Ser Arg Thr Lys Leu
1060 1065 1070
Ala ***
<210> 23
<211> 246
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 NP
<400> 23
Met Ser Glu Trp Ser Arg Ile Ala Val Glu Phe Gly Glu Gln Gln Leu
1 5 10 15
Asn Leu Thr Glu Leu Glu Asp Phe Ala Arg Glu Leu Ala Tyr Glu Gly
20 25 30
Leu Asp Pro Ala Leu Ile Ile Lys Lys Leu Lys Glu Thr Gly Gly Asp
35 40 45
Asp Trp Val Arg Asp Thr Lys Phe Ile Ile Val Phe Ala Leu Thr Arg
50 55 60
Gly Asn Lys Ile Val Lys Ala Ser Gly Lys Met Ser Asn Ser Gly Ser
65 70 75 80
Lys Arg Leu Met Ala Leu Gln Glu Lys Tyr Gly Leu Val Glu Arg Ala
85 90 95
Glu Thr Arg Leu Ser Ile Thr Pro Val Arg Val Ala Gln Ser Leu Pro
100 105 110
Thr Trp Thr Cys Ala Ala Ala Ala Ala Leu Lys Glu Tyr Leu Pro Val
115 120 125
Gly Pro Ala Val Met Asn Leu Lys Val Glu Asn Tyr Pro Pro Glu Met
130 135 140
Met Cys Met Ala Phe Gly Ser Leu Ile Pro Thr Ala Gly Val Ser Glu
145 150 155 160
Ala Thr Thr Lys Thr Leu Met Glu Ala Tyr Ser Leu Trp Gln Asp Ala
165 170 175
Phe Thr Lys Thr Ile Asn Val Lys Met Arg Gly Ala Ser Lys Thr Glu
180 185 190
Val Tyr Asn Ser Phe Arg Asp Pro Leu His Ala Ala Val Asn Ser Val
195 200 205
Phe Phe Pro Asn Asp Val Arg Val Lys Trp Leu Lys Ala Lys Gly Ile
210 215 220
Leu Gly Pro Asp Gly Val Pro Ser Arg Ala Ala Glu Val Ala Ala Ala
225 230 235 240
Ala Tyr Arg Asn Leu ***
245
<210> 24
<211> 294
<212> PRT
<213> 未知
<220>
<223> 发热伴血小板减少综合征病毒B-3 NS
<400> 24
Met Ser Leu Ser Lys Cys Ser Asn Val Asp Leu Lys Ser Val Ala Met
1 5 10 15
Asn Ala Asn Thr Val Arg Leu Glu Pro Ser Leu Gly Glu Tyr Pro Thr
20 25 30
Leu Arg Lys Asp Leu Val Glu Cys Ser Cys Ser Val Leu Thr Leu Ser
35 40 45
Met Val Lys Arg Met Gly Lys Met Thr Asn Thr Val Trp Leu Phe Gly
50 55 60
Asn Pro Lys Asn Pro Leu His Gln Leu Glu Pro Gly Leu Glu Gln Leu
65 70 75 80
Leu Asp Met Tyr Tyr Lys Asp Met Arg Cys Tyr Ser Gln Arg Glu Leu
85 90 95
Ser Ala Leu Arg Trp Pro Ser Gly Lys Pro Ser Val Trp Phe Leu Gln
100 105 110
Ala Ala His Met Phe Phe Ser Ile Lys Asn Ser Trp Ala Met Glu Thr
115 120 125
Gly Arg Glu Asn Trp Arg Gly Leu Phe His Arg Ile Thr Lys Gly Lys
130 135 140
Lys Tyr Leu Phe Glu Gly Asp Met Ile Leu Asp Ser Leu Glu Ala Ile
145 150 155 160
Glu Lys Arg Arg Leu Arg Leu Gly Leu Pro Glu Ile Leu Ile Thr Gly
165 170 175
Leu Ser Pro Ile Leu Asp Val Ala Leu Leu Gln Ile Glu Ser Leu Ala
180 185 190
Arg Leu Arg Gly Met Ser Leu Asn His His Leu Phe Thr Ser Ser Ser
195 200 205
Leu Arg Lys Pro Leu Leu Asp Cys Trp Asp Phe Phe Ile Pro Ile Arg
210 215 220
Lys Lys Lys Thr Asp Gly Ser Tyr Ser Val Leu Asp Glu Asp Asp Glu
225 230 235 240
Pro Gly Val Leu Gln Gly Tyr Pro Tyr Leu Met Ala His Tyr Leu Asn
245 250 255
Arg Cys Pro Phe His Asn Leu Ile Arg Phe Asp Glu Glu Leu Arg Thr
260 265 270
Ala Ala Leu Asn Thr Ile Trp Gly Arg Asp Trp Pro Ala Ile Gly Asp
275 280 285
Leu Pro Lys Glu Val ***
290

Claims (17)

1.一种发热伴血小板减少综合征病毒，其特征在于，
在L基因的可读框中表达的蛋白质的第1447位氨基酸为缬氨酸或第1913位氨基酸为赖氨酸，在M基因的可读框中表达的蛋白质的第83位氨基酸为酪氨酸、第404位氨基酸为苏氨酸或第904位氨基酸为缬氨酸，
其中，L基因的可读框为6255bp，M基因的可读框为3222bp。
2.根据权利要求1所述的发热伴血小板减少综合征病毒，其特征在于，
包括包含序列1的碱基序列的L基因、包含序列2的碱基序列的M基因、包含序列3的碱基序列的NP基因以及包含序列4的碱基序列的NS基因。
3.一种发热伴血小板减少综合征病毒，其特征在于，
在L基因的可读框中表达的蛋白质的第1447位氨基酸为异亮氨酸或第1913位氨基酸为精氨酸，在M基因的可读框中表达的蛋白质的第83位氨基酸为苯丙氨酸、第404位氨基酸为苏氨酸或第904位氨基酸为异亮氨酸，
其中，L基因的可读框为6255bp，M基因的可读框为3222bp。
4.根据权利要求3所述的发热伴血小板减少综合征病毒，其特征在于，
包括包含序列5的碱基序列的L基因、包含序列6的碱基序列的M基因、包含序列7的碱基序列的NP基因以及包含序列8的碱基序列的NS基因。
5.一种发热伴血小板减少综合征病毒，其特征在于，
在L基因的可读框中表达的蛋白质的第1447位氨基酸为异亮氨酸或第1913位氨基酸为精氨酸，在M基因的可读框中表达的蛋白质的第83位氨基酸为酪氨酸、第404位氨基酸为丙氨酸或第904位氨基酸为异亮氨酸，
其中，L基因的可读框为6255bp，M基因的可读框为3222bp。
6.根据权利要求5所述的发热伴血小板减少综合征病毒，其特征在于，
包括包含序列9的碱基序列的L基因、包含序列10的碱基序列的M基因、包含序列11的碱基序列的NP基因以及包含序列12的碱基序列的NS基因。
7.一种用于预防或治疗发热伴血小板减少综合征的免疫原性组合物，其特征在于，
包含权利要求1至6中任一项所述的发热伴血小板减少综合征病毒或其抗原作为有效成分。
8.根据权利要求7所述的用于预防或治疗发热伴血小板减少综合征的免疫原性组合物，其特征在于，
包含灭活的发热伴血小板减少综合征病毒和药剂学上可接受的载体或佐剂。
9.根据权利要求7所述的用于预防或治疗发热伴血小板减少综合征的免疫原性组合物，其特征在于，
上述免疫原性组合物的形态选自由活疫苗、灭活疫苗、使用弱毒化发热伴血小板减少综合征病毒的基因生产的亚单位疫苗、载体疫苗、嵌合疫苗、DNA疫苗及RNA疫苗组成的组中。
10.根据权利要求7所述的用于预防或治疗发热伴血小板减少综合征的免疫原性组合物，其特征在于，
包含如下的发热伴血小板减少综合征病毒或它们的抗原作为有效成分：
包括包含序列1的碱基序列的L基因、包含序列2的碱基序列的M基因、包含序列3的碱基序列的NP基因以及包含序列4的碱基序列的NS基因的发热伴血小板减少综合征病毒；
包括包含序列5的碱基序列的L基因、包含序列6的碱基序列的M基因、包含序列7的碱基序列的NP基因以及包含序列8的碱基序列的NS基因的发热伴血小板减少综合征病毒；以及
包括包含序列9的碱基序列的L基因、包含序列10的碱基序列的M基因、包含序列11的碱基序列的NP基因以及包含序列12的碱基序列的NS基因的发热伴血小板减少综合征病毒。
11.一种抗体，其特征在于，
使用权利要求1至6中任一项所述的发热伴血小板减少综合征病毒或其抗原进行免疫应答来生产。
12.一种发热伴血小板减少综合征病毒的诊断试剂盒，其特征在于，
包含权利要求1至6中任一项所述的发热伴血小板减少综合征病毒或其抗原。
13.一种发热伴血小板减少综合征病毒抗体的检测方法，其特征在于，包括：
步骤(a)，在能够形成抗原-抗体复合物的条件下，使从样品中分离的试样与权利要求1至6中任一项所述的发热伴血小板减少综合征病毒或其抗原接触；以及
步骤(b)，检测抗原-抗体复合物的形成。
14.一种在非人类动物中生产针对发热伴血小板减少综合征病毒的抗血清的方法，其特征在于，包括：
步骤(a)，向非人类动物给药适于诱导免疫应答的有效量的权利要求1至6中任一项所述的发热伴血小板减少综合征病毒或其抗原；以及
步骤(b)，收集含有针对上述发热伴血小板减少综合征病毒的抗体的抗血清或血浆。
15.一种与发热伴血小板减少综合征的诊断有关的信息的提供方法，其特征在于，包括：
步骤(a)，通过使从样品中分离的试样与权利要求1至6中任一项所述的发热伴血小板减少综合征病毒或其抗原接触来形成抗原-抗体复合物；以及
步骤(b)，检测上述抗原-抗体复合物的形成。
16.一种包含发热伴血小板减少综合征病毒的组合物的发热伴血小板减少综合征的预防或治疗用途。
17.一种包含发热伴血小板减少综合征病毒的组合物的发热伴血小板减少综合征病毒的诊断用途。
CN201980037023.0A 2018-04-25 2019-04-23 新型发热伴血小板减少综合征病毒 Pending CN112236515A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0047865 2018-04-25
KR1020180047865A KR102097994B1 (ko) 2018-04-25 2018-04-25 신규한 중증열성혈소판감소증후군 바이러스
PCT/KR2019/004857 WO2019208995A1 (ko) 2018-04-25 2019-04-23 신규한 중증열성혈소판감소증후군 바이러스

Publications (1)

Publication Number Publication Date
CN112236515A true CN112236515A (zh) 2021-01-15

Family

ID=68294646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037023.0A Pending CN112236515A (zh) 2018-04-25 2019-04-23 新型发热伴血小板减少综合征病毒

Country Status (6)

Country Link
US (2) US11738078B2 (zh)
EP (1) EP3786289A4 (zh)
JP (2) JP7264992B2 (zh)
KR (1) KR102097994B1 (zh)
CN (1) CN112236515A (zh)
WO (1) WO2019208995A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113061168B (zh) * 2021-03-29 2021-11-09 北京诺思兰德生物技术股份有限公司 一种截短的发热伴血小板减少综合征病毒Gn蛋白及其应用
CN113337477A (zh) * 2021-05-31 2021-09-03 李家斌 一种发热伴血小板减少综合征病毒株的分离方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070704A (zh) * 2010-09-17 2011-05-25 中国疾病预防控制中心病毒病预防控制所 发热伴血小板减少综合征病毒的全基因序列及应用
WO2017164678A2 (ko) * 2016-03-23 2017-09-28 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
KR101630499B1 (ko) * 2013-10-11 2016-06-15 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스 및 이를 이용한 sfts 진단 방법 및 키트
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
KR101785290B1 (ko) 2014-11-05 2017-10-18 대한민국 중증 열성 혈소판 감소 증후군 바이러스 감염 진단용 단클론항체, 이를 생산하는 하이브리도마 및 이 단클론항체를 사용하는 중증 열성 혈소판 감소 증후군 바이러스 감염 진단방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070704A (zh) * 2010-09-17 2011-05-25 中国疾病预防控制中心病毒病预防控制所 发热伴血小板减少综合征病毒的全基因序列及应用
WO2017164678A2 (ko) * 2016-03-23 2017-09-28 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARK,S CET AL.: "Severe fever with thrombocytopenia syndrome virus isolate CB3 segment M, complete sequence，GenBank: KY789438.1" *
PARK,S ET AL.: "Severe fever with thrombocytopenia syndrome virus isolate CB3 segment L, complete sequence，GenBank: KY789435.1" *
SEOK-MIN YUN ET AL.: "Molecular genomic characterization of tickand human-derived severe fever with thrombocytopenia syndrome virus isolates from South Korea" *

Also Published As

Publication number Publication date
US11738078B2 (en) 2023-08-29
JP2021519615A (ja) 2021-08-12
KR20190123934A (ko) 2019-11-04
JP2023099009A (ja) 2023-07-11
WO2019208995A1 (ko) 2019-10-31
KR102097994B1 (ko) 2020-04-07
US20230346909A1 (en) 2023-11-02
JP7264992B2 (ja) 2023-04-25
EP3786289A1 (en) 2021-03-03
EP3786289A4 (en) 2022-03-09
US20210121557A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EP2482825B1 (en) Piscine reovirus diagnostic compositions
KR20070028547A (ko) 바이러스에 감염되고 백신접종된 생물의 동정
US6316600B1 (en) Methods for the production of chicken monoclonial antibodies
WO1998022510A9 (en) Methods for the production of chicken monoclonal antibodies
US20230346909A1 (en) Novel severe fever with thrombocytopenia syndrome virus
CN114106164B (zh) 抗新型冠状病毒s蛋白的单克隆抗体及其应用
CN115461364A (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
KR101051986B1 (ko) 인간로타바이러스 및 이를 이용한 백신 조성물
KR102097992B1 (ko) 신규한 중증열성혈소판감소증후군 바이러스
KR102097989B1 (ko) 신규한 중증열성혈소판감소증후군 바이러스
KR101080071B1 (ko) 재조합 ｎ 단백질에 대한 단클론 항체를 이용한 리프트계곡열 경합적 효소결합면역측정법
KR101349413B1 (ko) 비브리오 패혈증균 알티엑스에이원 항원에 결합하는 단일클론항체 제조와 진단 항원을 제공하기 위한 재조합 단백질 발현벡터
CN114174516A (zh) 制备抗原结合单元的方法
WO2012060025A1 (ja) ヒトヘルペスウイルス６ ｇｌｙｃｏｐｒｏｔｅｉｎ Ｑ１に対する中和抗体の作製とその解析
CN107011435B (zh) 抗丙型肝炎病毒的全人单克隆抗体8d6
JP2002020399A (ja) ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
KR101372766B1 (ko) 비브리오 패혈증균 알티엑스에이원 항원에 결합하는 단일클론항체 제조와 진단 항원을 제공하기 위한 재조합 단백질 발현벡터
KR100522086B1 (ko) 아프리카 마역 바이러스의 ｖｐ7 항원 및 그에 대한모노클로날 항체를 이용하는 아프리카 마역의 진단방법
CN1646703A (zh) 诊断和治疗与人转酮酶样－1基因过表达有关的增殖异常的组合物和方法
EP1776481A2 (en) Diagnosis and treatment of kawasaki disease and coronavirus infection
KR20240097988A (ko) 신규한 일본뇌염 바이러스 항원과 일본뇌염 특이 항체 및 이의 용도
CN112661837A (zh) 大肠杆菌偏嗜性可溶性猪pd-1重组蛋白的制备及应用
Aaronson et al. Immunologic approaches toward detection of type C viral expression in man
KR20070052097A (ko) 사스 코로나바이러스의 재조합 뉴클레오캡시드 단백질 및이것의 용도
KR20100060196A (ko) 조류메타뉴모바이러스 재조합 뉴클레오캡시드 단백질, 상기단백질에 반응하는 단클론항체를 생산하는 융합세포주 및 그의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination